Establishment and evaluation of a loop-mediated isothermal assay (LAMP) for the semi-quantitative detection of HIV-1 group M virus in blood and plasma by Odari, Eddy Okoth
Dissertation 
zum Erwerb des Doctor of Philosophy (Ph.D.)
an der Medizinischen Fakultät der
Ludwig-Maximilians-Universität zu München
Doctoral Thesis for the awarding of a Doctor of Philosophy (Ph.D.)
at the Medical Faculty of
Ludwig-Maximilians-Universität, Munich
vorgelegt von
submitted by
____________________________________
aus (Geburtsort)
born in (place of birth)
____________________________________
am (Tag an dem die Dissertation abgeschlossen wurde)
submitted on (day of finalization of the thesis)
__________________
EDDY OKOTH ODARI
KISUMU, KENYA
1st July, 2014
Supervisors LMU: Title, first name, last name
Habilitated Supervisor
Direct Supervisor
3
rd
LMU Supervisor
Supervisor External:
Local Supervisor
______________________________
______________________________
______________________________
______________________________
Reviewing Experts:
1
st
Reviewer
2
nd
Reviewer
___________________________________________
___________________________________________
Dean: Prof. Dr. med. Dr. h. c. M. Reiser, FACR, FRCR
Date of Oral Defence: ___________________________________________
Prof. Dr. Dr. h.c. Ulrich Koszinowski
Dr. Hans Nitschko
Prof. Dr. Josef Eberle
Prof. Dr. Dr. Lutz Gürtler
Prof. Dr. Lutz Gürtler
Dr. Hans Nitschko
18th March, 2015
ESTABLISHMENT AND EVALUATION OF A LOOP-MEDIATED ISOTHERMAL
AMPLIFICATION ASSAY (LAMP) FOR THE SEMI-QUANTITATIVE
DETECTION OF HIV-1 GROUP M VIRUS IN BLOOD AND PLASMA
Affidavit
Surname, first name 
Street
Zip code, town
Country
I hereby declare, that the submitted thesis entitled
Thesis Title
Thesis Title (cont.)
Thesis Title (cont.)
is my own work. I have only used the sources indicated and have not made 
unauthorised use of services of a third party. Where the work of others has been 
quoted or reproduced, the source is always given. 
The submitted thesis or parts thereof have not been presented as part of an 
examination degree to any other university. 
I further declare that the electronic version of the submitted thesis is congruent with 
the printed version both in content and format. 
Place, Date Signature PhD Student
ODARI EDDY OKOTH
Moosacher Strasse 81/611
80809 München
Germany
ESTABLISHMENT AND EVALUATION OF A LOOP-MEDIATED ISOTHERMAL
AMPLIFICATION ASSAY (LAMP) FOR THE SEMI-QUANTITATIVE
DETECTION OF HIV-1 GROUP M VIRUS IN BLOOD AND PLASMA
Munich, 19th March, 2015
i 
 
Abstract 
The past decade has witnessed a dramatic increase of anti-retroviral treatment of Human 
Immunodeficiency Virus (HIV) infected patients in many African countries. Due to costs and 
sophistication of currently available commercial viral load assays, little attention has been paid to 
therapy monitoring through measurement of plasma viral load, a challenge that could reverse 
achievements already made against HIV/AIDS infection. Loop-mediated isothermal amplification 
(LAMP) has been shown to be simple, rapid and cost-effective, characteristics which make this assay 
ideal for viral load monitoring in resource limited settings. 
The aim of this study was to establish and evaluate LAMP for quantitative detection of HIV-1 group 
M virus in blood and plasma.  
Cell culture supernatants of HIV-1 subtype B (IIIB and MVP899-87) viruses were used to optimize 
reaction conditions and to test primer suitability. Together with HIV-1 M non-B subtypes, HIV-1 
group O and HIV-2, the cell culture supernatants were used to evaluate the performance of LAMP, to 
generate a model for viral load estimation and to establish the limits of the assay. A panel of 467 
clinical samples was analyzed (282 plasmas and 121 dry blood spots from Kenya and 112 plasmas 
from Germany) and the results obtained by LAMP were compared to those generated by the Abbott 
Real Time HIV-1 assay, an established commercial viral load quantification test. A linear regression 
equation was generated from time to detection values and used to estimate the viral loads of the 
samples by the LAMP assay. Kenyan samples were tested in Nairobi and Munich. 
LAMP primers targeting the integrase of the pol gene were found to be the most suitable compared to 
further 3 primer sets tested. Lower limit of detection (LLOD) of 1,200 copies/mL and lower limit of 
quantification (LLOQ) of 9,800 copies/mL were determined as suitable thresholds for quantitative 
estimations of the LAMP viral loads. Sensitivities of 82 and 86% (Kenyan samples) and 93% 
(German samples) and specificities of 99 and 100% were realized with plasma samples. The study 
also realized a sensitivity of 76% and specificity of 77% with dry blood spot samples from Kenya.  
In conclusion, LAMP assay shows obvious potential for diagnostic application in semi-quantification 
of HIV-1 group M viral load in resource limited countries. However there is a need for further 
improvement of primers in respect to detection of HIV-1 non-B viruses and evaluation of dry blood 
spot samples to ensure that more reliable results are obtained.  
Key words: LAMP assay, HIV integrase primer, semi-quantitative, viral load, Kenya.  
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Chapter 1 
1 Introduction, justification and objectives of the study 
1.1 Introduction 
The identification of the first patients with Acquired Immunodeficiency Syndrome (AIDS) in   1981, 
and the subsequent proof of Human Immunodeficiency Virus (HIV) as the causative agent of AIDS 
by the Medical Scientific Community in 1984, marked the beginning of the fight against the spread of 
HIV/AIDS. The identification of HIV and its roots of infection thus became the first step in the 
process of eliminating transmission of the virus through sexual contacts, transfusion of blood and 
blood products, creating rational policies for control and prevention of infection by the different 
means of transmission, and designing efficient anti-retroviral therapies (Gallo and Montagnier, 2003). 
Since the introduction of Highly Active Anti-Retroviral Therapy (HAART) for treatment of 
HIV/AIDS infection in 1995, millions of lives have been saved globally. Patients receiving this 
combination therapy continue to report decreased viral loads and increased CD4 T-lymphocyte 
counts. Thus the life expectancy among  patients who start treatment at an early stage has moved 
closer to the general mortality rate of HIV negative persons (Johnson et al., 2013). 
Despite the challenges at the beginning, a gradual increase in political commitment has been shown 
within the past 10 years by many governments in Sub-Saharan Africa, the continent with the highest 
burden of HIV/AIDS infection. Coupled with an increase in international funding within the same 
period, the increased level of political commitment has led to the rise in access to HIV/AIDS 
treatment in this region. Currently the number of people on anti-retroviral therapy  (ART) stands at 
7.1 million up from 1 million which was recorded in 2005 (UNAIDS, 2013). More than half of this 
number includes those patients who are in immediate need of treatment. However, despite this 
success, little attention has been paid to the possibility of the emergence and spread of drug resistant 
HIV strains and their implications to the public health systems. 
As opposed to the developed world where management of combination therapy depends on: specialist 
care for individual patients (which includes drug resistance testing to guide on the choice of drug 
regimen), frequent monitoring of plasma viral load for prompt detection of treatment success or 
failure and a wide range of treatment regimens and options to choose from (Department for Health 
and Human Services, 2011), the developing world still has  major limitations.  Resource limited 
countries depend mainly on the public health approaches which include a decentralized service 
delivery, empirical first and second line anti-retroviral combination therapy and clinical or 
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immunological definitions of treatment failure in settings where plasma viral loads cannot be 
ascertained (Hamers et al., 2012a; World Health Organization, 2010a).  
Reliance on immunological capacity through CD4 cell count, although successful, is not sufficient 
since CD4 cell count is a slowly changing parameter that gives insight into the function of the 
immune system. It is an assay which measures residual immune fitness and not viral replication in 
response to ART. Viral load measurement on the other hand, is a sensitive parameter mainly 
influenced by clearance of HIV from plasma by the immune system, efficiency of ART and drug 
combinations, compliance of the patient to drug regimen, and other conditions such as other 
infections or malnutrition which affect the competence of the immune response to control HIV. 
With a constant reduction in international funding, African national health systems are likely to be 
faced with a lot of limitations which could lead to development of drug resistance. The current 
limitations include widespread use of low cost drugs which in some cases are of sub-optimal quality 
e.g. sometimes the use of nevirapine monotherapy in HIV prevention of mother-to-child transmission 
(PMTCT) and stavudine as part of first line treatment (Wainberg et al., 2011). Other limitations 
include limited access to monitoring of plasma viral load (Hosseinipour et al., 2009; Sigaloff et al., 
2011), treatment interruptions when drug supplies run out (Oyugi et al., 2007; Pasquet et al., 2010), 
sub-optimal or non-adherence to treatment (Sethi et al., 2003) and frequent drug to drug interactions 
such as nevirapine and rifampicin in HIV patients co-infected with tuberculosis (Boulle et al., 2008) 
undergoing treatment. 
Benefits of routine blood plasma viral load monitoring, which include avoiding unnecessary ART 
switches hence avoiding accumulation of drug resistant strains are increasingly being accepted by 
many stakeholders. The high costs of implementation and sustainability however remain a major 
point of concern, since any resources allocated to laboratory monitoring could divert funds away from 
expanding access to treatment thereby impinging on healthcare delivery. It is therefore important to 
develop and establish assays for viral load monitoring that are simple and cost effective for use in 
resource limited countries. This study investigates the performance of a loop-mediated isothermal 
amplification (LAMP) assay as a simple and cost effective assay that could potentially be used for 
quantitative determination of HIV plasma viral load in patients within resource limited settings. 
1.2 Justification of the study 
Studies estimate that between 10-24% (Barth et al., 2010; Hamers et al., 2012c) of HIV infected 
patients have detectable plasma viral load during first line therapy. However, switching rates to the 
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next line therapy is still low (Onyedum et al., 2013; World Health Organization, 2011) in resource 
limited settings, partly due to poor sensitivities of clinical and immunological criteria for detection of 
treatment failure (Sigaloff et al., 2011). It is also estimated that poor specificity of these criteria could 
lead to more than 50% of the switches being unnecessary (Sigaloff et. al., 2011). Unnecessary 
switching (from first line treatment) will rapidly exhaust the drug combination options available and 
unnecessarily increase the cost of treatment, since the cost of second line treatment is more than 
double that of the first line treatment (Clinton HIV AIDS Initiative, 2009). Increased cost would 
therefore mean that for every treatment of a wrongful switch to the second line treatment, one to two 
patients would go without treatment due to lack of drugs as a result of a limited budget (Clinton HIV 
AIDS Initiative, 2009). Therefore proper monitoring of plasma viral load could potentially save 
developing countries up to 15 – 30% of the costs of long term HIV treatment by mitigating high costs 
associated with unnecessary switching to second line regimen (Hamers et al., 2012b). 
Apart from avoiding unnecessary switches, benefits of plasma viral load monitoring include 
supporting adherence surveillance (since lapses in treatment can quickly be identified) and identifying 
patients with accumulating drug resistant strains (Cohen et al., 2011; Wilson et al., 2009).  Although 
these benefits are accepted, debate on high costs of implementation and sustenance by the resource 
limited countries still persists and in many cases favor clinical and immunological parameters, mainly 
CD4 cell count.  CD4 cell count, as already discussed in page 2, only measures immune fitness and 
not viral replication in response to ART. Furthermore, studies carried out in the developed world have 
shown that measurement of CD4 cells have limited benefits in patients with suppressed viral loads 
(Ledergerber et al., 2004; Phillips et al., 2002).  
Scientific advancements so far, such as use of dried blood spots (DBS) for sample storage and 
transportation, development of relatively simple assays for HIV detection continue to provide an 
opportunity for improvement and development of assays which would further reduce the costs 
associated with plasma viral load monitoring. 
Therefore the threat of an emergence of drug resistant strains and high cost of monitoring treatment 
which could potentially reverse the gains made in the fight against HIV/AIDS, justifies the need for a 
simple, cost effective and readily available assay for use in monitoring plasma viral load in resource 
limited settings. 
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This study thus evaluated  whether LAMP assay, regarded as simple and cost effective, would have 
the potential for use in quantitative detection of HIV-1 viral load in patients undergoing treatment 
within resource limited settings. 
1.3 Objectives of the study 
1.3.1 Broad objective 
To establish and evaluate a LAMP assay for quantitative detection of HIV-1 group M virus RNA in 
blood and plasma. 
1.3.2 Specific objectives 
1. To compare the performance of primers designed to amplify 4 regions of the HIV genome, 
namely LTR, p24 in the gag gene, integrase in the pol gene and N-terminus of gp41 in the 
env gene. 
2. To refine primers and cycling conditions during LAMP adaptation process. 
3. To analyse performance characteristics of LAMP using cell culture supernatants of HIV-1 
viruses from patients of different African regions and whole blood, plasma samples and dry 
blood spots (DBS) from Munich and Nairobi. 
4. To evaluate the LAMP assay under field conditions in Kenya for HIV detection and viral load 
measurements 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Chapter 2 
2 Literature review 
2.1 Human Immunodeficiency Virus (HIV)  
2.1.1 Historical perspective 
Human Immunodeficiency Virus, the virus that causes AIDS, was first discovered in 1983 (Barre-
Sinoussi et al., 1983; Broder and Gallo, 1984; Gallo et al., 1983) and identified as lymphadenopathy-
associated virus (LAV) by Montagnier’s group and as human T-lymphotropic virus (HTLV-III) by 
Gallo’s group. Montagnier’s group in their virus characterization showed that this new virus had core 
proteins which were immunologically different from those of HTLV-1 (Basavapathruni and 
Anderson, 2007). Another research group in San Francisco in 1984 reported the isolation of a similar 
virus within symptomatic and asymptomatic patients from AIDS risk groups. They named this virus 
AIDS-associated retrovirus (ARV) (Levy et al., 1984). In 1986, the International Committee of Viral 
Taxonomy (ICVT) renamed all the three different viral isolates Human Immunodeficiency Virus 
(HIV-1) (Coffin et al., 1986), after it was demonstrated by nucleic acid sequence analysis of HTLV-
III, LAV-1 and ARV that all three belonged to the same virus family  (Ratner et al., 1985; Sanchez-
Pescador et al., 1985; Wain-Hobson et al., 1985). 
2.1.2 Virus classification and genome morphology 
2.1.2.1 Classification 
Human Immunodeficiency Virus belongs to the family Retroviridae (Fauquet and Fargette, 2005) and 
as such is a RNA virus which codes for the enzyme reverse transcriptase. This enzyme transcribes the 
viral genomic RNA into DNA which then integrates into the genome of the host cell (Fauci, 1988) 
during the HIV life cycle.  
Within the Retroviridae family, the virus is a member of the genus lentivirus (Fauquet and Fargette, 
2005). Lentiviruses have a long incubation period between infection and the occurrence of disease 
(Levy, 1993). Lentiviruses are also known to cause immunodeficiency in their hosts in addition to 
slow progressive wasting disorders, neurodegeneration and death (Haase, 1986; Haase et al., 1990). 
These viruses include feline immunodeficiency virus infecting cats, visna virus infecting sheep, 
caprine arthritis-encephalitis virus infecting goats and simian immunodeficiency viruses infecting 
non-human primates (Gonda et al., 1985; Haase, 1986; Stowring et al., 1979; Temin, 1988; Temin, 
1989). 
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Figure 1. HIV genome structure.  Structural genes gag, pol and env, regulatory genes tat, rev, nef , auxiliary 
genes vif, vpr, vpu  and their positions within the HIV-1 genome of HXB2 strain (the whole genome consists 
of 9719 bp). Adapted from http://www.hiv.lanl.gov/content/sequence/HIV/MAP/landmark.html 
2.1.2.2 Genome structure 
Lentiviruses are distinguished from other members of the Retroviridae family by the complexity of 
their genome. HIV, like other lentiviruses contains three main structural genes, gag, pol and env 
(Figure 1). These genes contain information needed to code for the necessary structural proteins and 
enzymes (Los Alamos National Laboratory, 2008a). Apart from the three essential structural genes, 
HIV further contains complex regulatory genes tat, rev, nef, whose function is to regulate synthesis of 
proteins which control the ability of HIV to infect cells (infection), produce progeny viruses 
(replication), or cause disease (pathogenicity) (Los Alamos National Laboratory, 2008a). Other 
auxiliary genes include vif, vpr and vpu (or vpx in case of HIV-2) (Greene, 1991; Los Alamos 
National Laboratory, 2008a), and have also been referred to as accessory proteins. Although the latter 
have not been absolutely necessary for virus propagation in tissue culture, these accessory proteins 
have been shown to be conserved in the different isolates suggesting that their role in vivo is 
important. Their functional importance has been shown in pathogenicity (Kluge et al., 2013; Sharp 
and Hahn, 2011). The Long Terminal Repeats (LTRs) are found at the 5’ and 3’ ends and serve as a 
DNA sequence flanking the genome of integrated proviruses. The LTR contains important regulatory 
regions, especially those for transcription initiation and polyadenylation (Krebs et al., 2001).  
 
 
 
 
 
 
 
 
2.1.3 Epidemiology 
2.1.3.1 Distribution of HIV types 
Based on genetic variability (Robertson et al., 1995), two types of human immunodeficiency viruses 
(HIV-1 and HIV-2) have been identified. Both can be transmitted by seminal or vaginal secretions 
through sexual intercourse (Ho et al., 1984; Zagury et al., 1984), through transfusion of blood or 
blood products (Jones et al., 1992; Selik et al., 1993; Shrestha, 1996) sharing needles as seen in 
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intravenous drug use or through tattooing and scarification. Perinatal or vertical transmission from 
HIV-positive mother to the child (World Health Organization, 2010c) is another route and occurs 
during pregnancy, vaginal childbirth or through breastfeeding. HIV-2 is less easily transmitted and is 
characterized by a longer period between infection and progression to AIDS (Kanki et al., 1999; 
Marlink et al., 1994; Whittle et al., 1994) compared to HIV-1. 
Although HIV-1 M with its subtypes has a global distribution, HIV-2 is mainly restricted to west 
Africa and India with some cases reported in Angola, Mozambique and Brazil (Marx et al., 2001; 
Santiago et al., 2005). 
2.1.3.2 Global distribution of HIV-1 groups and subtypes 
Four groups have been identified and are currently used to classify HIV-1 virus: group M “Major”, O 
“outlier”, N “Non M, non O” (Charneau et al., 1994; De Leys et al., 1990; Gurtler et al., 1994; Simon 
et al., 1998) and group P (Plantier et al., 2009; Vallari et al., 2011). 
Groups O, N and P virus strains are more restricted to west and central African equatorial regions (the 
Congo basin), while group M is distributed world wide. Different studies have however shown 
sporadic cases of group O and N outside west and central Africa (Delaugerre et al., 2011; Gurtler et 
al., 1996; Rayfield et al., 1996; Sullivan et al., 2000) possibly caused by viral migration in man, since 
the majority of the cases had contact with west-central Africans (Delaugerre et al., 2011; Quinones-
Mateu et al., 2000). 
Group M therefore accounts for the large majority of HIV infections worldwide. This group is further 
divided into nine genetically distinct subtypes: A, B, C, D, F, G, H, J and K (Janssens et al., 1994a; 
Janssens et al., 1994b; Janssens et al., 1994c; Janssens et al., 1994d; Kostrikis et al., 1995; Leitner et 
al., 1995; Louwagie et al., 1995; Louwagie et al., 1993; Myers et al., 1992). When two viruses of 
different subtypes interchange their genetic material in the process of recombination, a new hybrid 
virus may result (Burke, 1997). When a hybrid (recombinant) virus infects more than one person, it is 
defined as a circulating recombinant form (CRF) (Burke, 1997). These CRFs have frequently been 
documented in HIV infected populations (Carr et al., 1996; Gao et al., 1996; Li et al., 2013; Murphy 
et al., 1993; Wei et al., 2014). Subtypes initially named E and I were subsequently grouped as CRFs 
(Los Alamos National Laboratory, 2008b). 
Global estimates of HIV-1 group M virus subtypes show that subtype C accounts  for approximately  
50% of all infections worldwide followed by subtypes A, B, D and G accounting  for 12%, 10%, 3% 
and 6%, respectively. Subtypes F, H, J and K combined together account for only 1% of infections 
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among the 9 major subtypes identified. Some studies have reported that pure subtypes account for 
82% whereas the CRFs account for the remaining 18% (Hemelaar et al., 2006) of HIV-1 infections. 
Circulating recombinant forms CRF01_AE and CRF02_AG each are estimated to account for 5% of 
infections while CRF03_AB accounts for 0.1%. All other remaining recombinants account for the 
final 8% of infections (Hemelaar et al., 2006). A total of 65 major CRFs have been published to date 
(Los Alamos National Laboratory, 2013; Wei et al., 2014) and one inter-circulating recombinant form 
(Inter-CRF) designated CRF61_BC (composed of CRF07_BC and CRF08_BC) has already been 
identified in China (Li et al., 2013).  
2.1.3.3 HIV-1 group M subtypes and disease progression 
In a study done among female sex workers in Senegal infected with subtypes A, C, D and G  (Kanki 
et al., 1999), it was realized that women infected with a non-A subtype were eight  times more likely 
to develop AIDS than those infected with subtype A. This study therefore suggested a possible 
difference in pathogenicity and the rate of progression to AIDS for the different HIV-1 group M 
subtypes.  
Other studies have shown that infection by specific subtypes influences the rate of disease 
progression and eventual death. In a study in Uganda, it was realized that persons infected with HIV-
1 subtype D or recombinant strains incorporating subtype D developed AIDS sooner than those 
infected with subtype A, and in the absence of ART  these patients also died earlier (Kiwanuka et al., 
2008). This Ugandan study associated the virulence of subtype D to its more effective binding to the 
immune cells.  A similar study among Kenyan women also showed that those  infected with subtype 
D had more than twice the risk of death over six years compared to those infected with subtype A 
(Baeten et al., 2007), despite similarity in their plasma viral loads. A study done to evaluate the 
survival patterns of adults in Thailand 8-14 years after HIV-1 subtype E (CRF01_AE) infection 
(Nelson et al., 2007) showed a similar survival pattern of these individuals comparable to those 
individuals infected with HIV-1 group M subtype D in Africa. In their findings, Nelson and 
colleagues also reported that CRF01_AE had a higher rate of disease progression compared to 
subtype B. The latter finding could probably point towards the effect of increasing pathogenicity and 
recombination of an infecting virus on the time to disease and AIDS-related death, since B and D are 
grouped as sub-subtypes with very closely related genetic patterns (Robertson et al., 1999). This 
faster progression to AIDS and AIDS-related death has also been reported in patients from Guinea-
Bissau  infected with a circulating recombinant form A3/A2 (Palm et al., 2014). The latter study has 
so far reported the fastest rate of progression from HIV infection to disease and AIDS-related death. 
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2.1.3.4 HIV-1 group M subtypes and transmission of infection 
Until now the association between HIV subtype and the transmission route of infection has not 
conclusively been evaluated. However, some studies (van Harmelen et al., 1997) have reported that 
subtype B is mainly transmitted among homosexual men compared to subtype C which is mainly 
found in the heterosexual setting. This assertion could be strengthened by the global subtype 
distribution where subtype B is predominantly common in the western world within the gay 
communities. Among the Thai population, it has also been reported that CRF01_AE is transmitted 
more easily in heterosexual relationships compared to subtype B. Whether any biological factors 
influence these observations has continuously been a subject of debate (Bhoopat et al., 2001; Dittmar 
et al., 1997; Essex, 1996; Pope et al., 1997).  
It is also not clear as yet whether infection by a specific HIV subtype influences the rate of vertical 
transmission from mother to child). A matched case-control study addressing whether viruses with 
different long terminal repeat (LTR) subtypes were transmitted equally vertically among a Tanzanian 
population (Blackard et al., 2001) reported a higher rate of mother to child transmission of subtype C 
compared to subtypes A and  D. In this study, the rate of subtype A transmission was 3.2 times higher 
than that of subtype D. However a study done in western Kenya among 414 women (Yang et al., 
2003) identified higher rates of mother to child transmission among women infected with subtype D 
compared to those infected with subtype A. Another study carried out in a Tanzanian population 
targeting the env gene (Renjifo et al., 2004) also identified a higher rate of transmission of subtype C 
compared to a combined rate of subtype A and D. Other studies have however shown no significant 
association between HIV subtype and the rate of mother to child transmission (Martinez et al., 2006; 
Murray et al., 2000; Tapia et al., 2003). 
2.1.3.5 HIV-1 group M subtypes and response to anti-retroviral therapy  
Although different studies have attempted to address this issue, several challenges have been fronted 
with the results obtained from various studies. In their study on response to therapy among 113 
children infected with seven different subtypes (A (15%), B (41%), C (16%), D (9%), F (5%), G 
(2%), H (1%)), CRF01_AE (5%) and CRF02_AG (6%), the Pediatric European Network for 
Treatment of AIDS (PENTA 5 trial) observed no significant difference after 48 weeks of treatment  
(Pillay et al., 2002). This PENTA 5 study however presented with a challenge of low statistical power 
and thus a difficulty in ruling out minor differences between subtypes. It is also worth noting that 
only four different sets of drugs, zidovudine, lamivudine, abacavir, and nelfinavir were used. In 
another study evaluating the virological response to treatment in Europeans infected with subtype B 
and Africans infected with non-B subtype (Frater et al., 2002), there was no difference in time to 
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undetectable viral load as well as recovery of the CD4 cells. However, a significant difference was 
observed with viral load over time where the African group exhibited a continuous increase in viral 
load over the 9 months period, which suggested a higher therapy failure. Although the authors 
concluded the difference to be mainly due to poor adherence among the African group, a number of 
limitations could be cited from this study. Subtype was mainly presumed from the ethnic and 
epidemiological data, after a confirmation of only 60% of the 97 Africans and 30% of the 265 
Europeans. Hence in depth conclusion of subtype responsibility in the treatment failure could not 
substantially be ascertained. Furthermore, there was an imbalance in the two groups, including the 
types of regimen used, transmission risk groups, CD4 cell counts and gender (Pillay et al., 2002). 
2.1.3.6 HIV-1 group M subtypes and resistance to anti-retroviral therapy  
The majority of drug resistance testing has been performed on subtype B virus, however it is 
estimated that more than 90% of resistances occur in the RT within the non-B subtypes (Lessells et 
al., 2012). K65R (mutation of lysine to arginine in position 65) induced resistance to TDF and NRTI 
is an example of a clinically relevant mutation that emerges more frequently and more rapidly in 
subtype C virus compared to subtype B (Lessells et al., 2012). Further, possibilities of genetic 
differences among subtypes exist which may yield differential patterns in the mutations that 
aggravate resistance in response to ART pressure. HIV-1 subtype genetic variations have been 
estimated at 35% and in some regions of the genome, e.g. the env gene, these variations have been 
reported as high as 40%, whereas in the regions such as the gag and the pol (IN) genes these 
variations have been reported as low as 8 to 10% (Brenner, 2007). Since changes in codon sequences 
at positions associated with drug resistance mutations could predispose viral isolates from different 
subtypes to encode different amino acid substitutions, it is thus possible that genetic diversity in HIV-
1 could influence the type of resistance mutations (Brenner, 2007; Kantor, 2006). Brenner and 
colleagues also assert that this diversity may affect the degree of cross resistance to ARTs of the same 
drug class, with a potential impact on clinical outcome, preservation of immunological 
responsiveness and virologic failure (Brenner, 2007). 
A clinical trial among pregnant women taking a single dose nevirapine for PMTCT showed an overall 
resistance of 69% to nevirapine with subtype C virus while subtypes D, A and CRF02_AG showed 
36%, 19% and 21% resistance mutations respectively in various studies (Chaix et al., 2006; Eshleman 
et al., 2005; Toni et al., 2005). Several studies have also shown variations in levels of resistance for 
the different known subtypes. The recombinant form CRF02_AG has been shown to be more 
susceptible to the action of nelfinavir and ritonavir than subtypes C and F whereas subtype G was 
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shown to be more sensitive to tipranavir and lopinavir than other subtypes (Marcelin et al., 2008). 
Subtype C on the other hand was shown in different studies to have an increased risk of developing 
resistance to tenofovir (at K65R) than other subtypes (Brenner et al., 2006; Doualla-Bell et al., 2006; 
Miller et al., 2007). 
Mutational variations in the HIV genome are the major factors considered in assigning different 
subtypes and identifying resistant or emerging strains. These variations therefore continue to play a 
major role in the HIV pandemic, and knowledge of HIV subtype distribution coupled with the 
continuous global molecular epidemiology surveillance on emerging strains or imported strains 
remain fundamental.. 
2.1.3.7 HIV infection in Sub-Saharan Africa 
Although still a home to 70% of all HIV new infections globally, Sub-Saharan Africa has seen a 
steady decline, with annual numbers of new infections among adults declining by up to  34% since 
2001 (UNAIDS, 2013). The high level of political commitment currently seen in this African region 
and the substantial amount of international funding have both led to a drastic scale up in access to 
HIV treatment (World Health Organization, 2011). But even with this success, there is still a major 
challenge of a potential spread of drug resistant mutants since little attention has been paid to the 
emergence of drug mutant strains and their implication to public health.  
2.1.4 HIV treatment  
2.1.4.1 Classes of HIV drugs  
Currently there is still no drug available for complete cure of HIV infection (thus eliminating the 
virus from all cells of the body) (Passaes and Saez-Cirion, 2014), a fact that could remain for the next 
decade. The aim of treatment is therefore to reduce the amount of viral particles to undetectable levels 
in order to help the body restore the weakened immune system. The final result is that an individual 
leads a normal life even with low amounts of virus in circulation. Currently these drugs are 
categorized into six different classes with various drugs in each category already approved by the U.S 
Food and Drug Administration (Food and Drug Administration (FDA), 2013). These classes include 
(1) Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) (2) Non-Nucleoside Reverse 
Transcriptase Inhibitors (NNRTIs) (3) Protease Inhibitors (PIs) (4) Fusion Inhibitors (5) Entry 
Inhibitors (CCR5 co-receptor antagonist) and (6) HIV Integrase Inhibitors. Each of these classes of 
drugs is designed to target a specific stage in the HIV replication cycle (NIAD/NIH, 2012).  
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Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTIs) were the first class of drugs to be approved 
by the FDA (Young, 1988). These drugs inhibit the synthesis of viral DNA by the action of reverse 
transcriptase, the viral enzyme that copies viral RNA into DNA. They are mainly nucleoside 
analogues which bear structural resemblance to the natural nucleoside components of DNA 
(adenosine (A) and guanosine (G), thymidine (T) and cytosine (C)). These dideoxy-analogues are 
triphosphorylated within the cell.  During the replication process, reverse transcriptase enzyme fails 
to distinguish between the phosphorylated nucleosides and their natural counterparts hence using the 
drugs, instead of the nucleosides, in the synthesis of DNA. The drugs are therefore incorporated into 
the newly synthesized strand thereby preventing addition of further nucleotides 
(http://hivinsite.ucsf.edu/InSite?page =ar-drugs-about). Presently used drugs include: lamivudine 
(3TC), zidovudine (AZT), emtricitabine (FTC), abacavir (ABC), dideoxyinosine (ddI), stavudine 
(d4T) and the nucleotide analogue tenofovir disoproxil fumarate (TDF). 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) also inhibit the synthesis of viral DNA. 
As opposed to NRTIs which act as nucleoside analogues (false nucleosides) NNRTIs bind to reverse 
transcriptase hence inhibiting the enzyme’s activities. Unlike the NRTIs this class of drugs does not 
inhibit the RT of related retroviruses such as HIV-1 group O and P, HIV-2 and simian 
immunodeficiency virus (SIV) (Kohlstaedt and Steitz, 1992; Witvrouw et al., 1999). These NNRTI 
include: rilpivirine (RPV), etravirine (ETV), delavirdine (DLV), efavirenz (EFV) and nevirapine 
(NVP). 
Protease inhibitors (PIs) bind to the active site of the protease enzyme hence preventing the 
processing of viral proteins into functional size and conformation. HIV-1 protease is the enzyme 
which cleaves gag-pol polyprotein, gag and pol precursors during maturation of the virion (Miller, 
2001; Park and Morrow, 1993). Although the viral particles are still produced even when the protease 
enzyme is inhibited, these particles cannot infect new cells. Protease inhibitors include: tipranavir 
(TPV), indinavir (IDV), saquinavir mesylate (SQV), lopinavir (LPV), ritonavir (RTV), fosamprenavir 
(fAPV), darunavir (DRV), atazanavir (ATV) and nelfinavir (NFV). 
Fusion Inhibitors prevent the virus from entering target cells. The drug binds to the viral gp41 
envelope protein known for its involvement during entry of the virus into the cell. The drug thus 
blocks interactions between neighboring regions of the gp41 molecule. It eventually interferes with 
the conformational change (folding) of the envelope molecule required for fusion with the target cell 
membrane. Only one peptide-based drug known as enfuvirtide (T-20) currently represents this class. 
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Entry Inhibitors (CCR5 co-receptor antagonist) or chemokine co-receptor antagonists prevent viral 
entry into the target cells. They bind to co-receptors (either CCR5 or CCR2) on the surface of T-
helper CD4 cells hence blocking entry. As opposed to other classes of drugs which target the virus, 
this class of drugs targets a human cell-surface protein. They include maraviroc (MVC) and 
cenicriviroc (CVC), the latter is currently under clinical evaluation. 
Integrase inhibitors (INIs) mainly target the strand transfer reaction hence have also been known as 
integrase strand transfer inhibitors (InSTIs) (Espeseth et al., 2000; Hazuda et al., 2004; McColl and 
Chen, 2010). The drugs bind to the integrase enzyme thus interfering with incorporation of the 
already reverse-transcribed pro-viral DNA into the chromosomes of the host cell. INIs include 
raltegravir (RGV), recently approved dolutegravir (DTG) and elvitegravir (EGV) (Messiaen et al., 
2013). 
2.1.4.2 Highly Active Anti-retroviral Therapy (HAART) 
HAART describes the parallel use of a combination of three or more anti-HIV drugs in the treatment 
of HIV infection. Use of a combination therapy reduces the risk of development of resistance to the 
drugs as opposed to single drug therapy, making treatment effective in the long run. Guidelines for 
HAART have been actualized (World Health Organization, 2013b) where stavudine (d4T) which had 
initially been used together with lamivudine (3TC) and nevirapine (NVP) mainly due to its low cost 
(Gilks et al., 2006), is currently replaced by tenofovir (TDF) in the first line therapy. First line therapy 
which traditionally consists of 1 non-nucleoside reverse transcriptase inhibitor (NNRTI) and 2 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), thus consists, for example, of a fixed-
dose combination of tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV) as a single pill 
(World Health Organization, 2013b). First line therapy is usually initiated at the beginning of 
treatment of HIV infection. However, due to different factors including the side effects and the 
development of resistance to first line therapy, a second line treatment module is recommended. 
Second line therapy mainly consists of a ritonavir-boosted protease inhibitor and two NRTIs. The 
choice of drugs used in each category will depend on different factors including, availability and the 
costs of the drug, number of pills to be taken daily, the side effects of the drugs and the type of 
laboratory monitoring.  
Third line therapy is also known as the salvage or rescue therapy. This term describes treatment 
regimens for people who have very few or limited anti-HIV drug options due to resistance. They 
include patients recording failure in at least two previous anti-HIV regimens, or those patients proved 
to mount HIV drug resistance to at least one drug in each of the three major classes, mainly the 
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NRTIs, NNRTIs and PIs. True salvage or deep salvage is a term used to describe treatment of a 
person who has literally no treatment options. Most third line regimens consist of four or more drugs. 
It has been suggested that third line regimens should include new drugs likely to have anti-HIV 
activity, such as integrase inhibitors and second-generation NNRTIs and PIs (World Health 
Organization, 2010a). However it is important to note that in 2010 the World Health Organization 
made three major recommendations regarding management of multiple treatment failures, which 
included: national programs to develop policies for third-line therapy that consider funding, 
sustainability and the provision of equitable access to ART; third-line regimens to include new drugs 
likely to have anti-HIV activity, such as integrase inhibitors and second-generation NNRTIs and PIs 
and finally patients on a failing second-line regimen with no new ART options to continue with a 
regimen that is tolerated (World Health Organization, 2010a). 
2.1.4.3 HIV treatment in Sub-Saharan Africa 
As opposed to the developed economies where treatment and management of HIV infection is based 
on individualized specialist care, the resource limited countries mainly follow the World Health 
Organization (World Health Organization, 2010c) public health approach. Individualized specialist 
care in the developed world includes frequent monitoring of plasma viral loads for early detection of 
treatment failures, drug resistance testing which guide on the most appropriate regimen and a wider 
range of anti-retroviral drugs to choose from (Department for Health and Human Services, 2011). On 
the other hand, the WHO public health approach is based on a decentralized service delivery, 
empirical first and second line therapies, and empirical clinical or immunological definitions of 
treatment failure in the absence of information on plasma viral load (World Health Organization, 
2010c). 
Since roll-out of ART in Sub-Saharan Africa more than 15 years ago several countries have 
continued to use triple therapy in treatment of HIV infection. These countries however continue to 
meet various challenges which if not checked, have likelihood to aggravate the problem of drug 
resistance. As already mentioned, some of these challenges include continued use of low cost, 
substandard drug regimen. For example, until recently, stavudine has been used together with 
nevirapine as part of the first line regimen in HIV PMTCT (Wainberg et al., 2011). Other challenges 
have included treatment interruptions when stock or supply run out (Oyugi et al., 2007; Pasquet et al., 
2010), restricted or no access to plasma viral load monitoring of treatment failures (Hosseinipour et 
al., 2009; Sigaloff et al., 2011), sub-optimal adherence to therapy due to various factors (Sethi et al., 
2003) and frequent drug – drug interactions especially among patients co-infected with tuberculosis 
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undergoing treatment (Boulle et al., 2008). All these factors have a potential to necessitate the 
development of drug resistant strains in Sub-Saharan Africa.  
2.1.4.4 HIV drug resistance 
During replication, HIV, like any other retrovirus, uses the enzyme reverse transcriptase in the 
synthesis of viral DNA from the RNA genome (Freeman, 2007). Reverse transcriptase however, lacks 
proof reading capabilities and as such is unable to correct errors made during the replication process. 
This leads to mutations occurring within the viral genome (Freeman, 2007). High mutation rates have 
been recorded with HIV (Boyer and Hughes, 2000; Lewis et al., 1999; Mansky, 1996; Mansky and 
Temin, 1995; Rezende and Prasad, 2004; Roberts et al., 1988; Stuke et al., 1997; Svarovskaia et al., 
2003) with a retroviral average of 1.5×10−5 mutations/bp/cycle (Mansky and Temin, 1994; Mansky 
and Temin, 1995; Parthasarathi et al., 1995; Pathak and Temin, 1990a; Pathak and Temin, 1990b). 
These mutations then result in circulating mutant strains, which in most cases would be destroyed by 
the immune system. Those that escape immune recognition continue to replicate and accumulate into 
quasi-species as a result of an increased probability of a virion developing an evolutionary selective 
advantage over other virions (Freeman, 2007). The quasi-species within HIV infected can easily 
adapt to their host (Domingo et al., 1997; Goodenow et al., 1989; Lemey et al., 2006; Vignuzzi et al., 
2006; Wolinsky et al., 1996; Yamaguchi and Gojobori, 1997; Zhang et al., 1997) partly due to 
variations in the replicative fitness which enables a faster growth (Domingo et al., 1997; Tebit et al., 
2007). Due to natural selection, virions with higher fitness are then selected while others are cleared 
by drug treatment and immune actions (Kozal, 2009). The virions that are able to escape the harmful 
effects of the drug then create an entirely new, drug resistant population. These virions replicate in the 
patient to a high load similar to that level of the viruses which circulatedin the patient before 
treatment. The patient thus experiences a decline in the effectiveness of treatment as the virus 
develops resistance leading to an increased amount of resistant variants. This process is known as 
acquired resistance. 
The drug resistant variants selected during treatment failure thus have the potential to resist 
subsequent treatments with the same drugs, and therefore constitute a reservoir for onward 
transmission to newly infected persons (Hamers et al., 2012a) in a process known as transmitted 
resistance. 
Without prompt identification, resistant strains will therefore be transmitted within a population, 
restricting treatment options and increasing the costs of treatment, as a large number of patients will 
have to be switched to the second line of treatment from the beginning. Scaling up of HIV treatment 
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in many African countries has also come with its equal share of increase in drug resistance 
(Aghokeng et al., 2011; Hamers et al., 2011; Price et al., 2011), mainly to NNRTIs (World Health 
Organization, 2010a; World Health Organization, 2010c) which constitute the first line treatment 
regimens. Hamers and colleagues in their study in six African countries (Hamers et al., 2011) 
estimated the rate of transmitted drug resistance to increase at 38% per year after the roll-out of ART, 
with pre-treatment failure found to double the failure to first line drugs and further acquisition of 
resistant variants within the first year of treatment. It is therefore important to monitor any emergence 
of HIV resistance within a population. 
2.1.4.5 Viral load and CD4 Cells 
Although WHO has established clinical and immunological parameters of monitoring treatment 
within the resource limited settings, an important challenge to many anti-retroviral programs is how 
to identify those patients with treatment failure and promptly switch them to second line therapy. As 
already mentioned, an estimated 10% to 24% of patients report detectable plasma viral loads during 
the first line treatment in Sub-Saharan Africa (Barth et al., 2010; Hamers et al., 2012c), however very 
low switching rates have been reported (World Health Organization, 2011), mainly due to poor 
sensitivity of these (clinical or immunological) parameters. Poor specificity of the parameters would 
also lead to unnecessary switches, putting a burden to the cost of treatment and exhaustion of 
available regimen. These two factors of poor sensitivity and specificity of the WHO established 
parameters would literally impinge on the successes achieved in Africa within the last decade. 
One main challenge of HIV/AIDS treatment in Sub-Saharan Africa is adherence (Wilson et al., 2009) 
which is partly attributed to the high level of poverty and the life-style of some groups within the 
populations. Hence the concept of treatment monitoring becomes apparent as lapses potentially due to 
poor treatment adherence would quickly become apparent and patients at risk of developing 
resistance promptly identified (Cohen et al., 2011). 
In the long run it is anticipated that treatment monitoring through plasma viral load and CD4 cell 
count in resource limited settings has a cumulative effect of saving 15-30% of the cost of treatment 
which would otherwise occur as a result of unnecessary switching to second line therapy (Hamers et 
al., 2012b). 
2.1.4.5.1 CD4 cell count/measurement 
High costs associated with current viral load assays have impinged on many African governments 
initiating viral load monitoring programs in the public health sector. With the support of international 
donor funding, e.g. Bill and Melinda Gates foundation, many African HIV programs currently rely on 
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CD4 cell counts. CD4 cell count, however, is an indirect parameter which mainly gives an insight 
into the residual function of the immune system and not viral replication in response to ART (see 
pages 2 and 3). The level of CD4 cells in the body is affected by other factors such as nutrition status 
and a variety of body conditions including the presence of other infections. CD4 cell count therefore 
has its limitations, such as failure to promptly detect patients failing treatment due to factors such as 
adherence or resistance. Besides, CD4 cell count has been reported to have limited benefits in patients 
with suppressed viral load (Ledergerber et al., 2004; Phillips et al., 2002).  
2.1.4.5.2 Viral load monitoring 
Several challenges still exist with the current nucleic acid based techniques in use. These challenges 
include among others the fact that these techniques still remain special techniques available only to 
particular facilities and laboratories because of the use of possibly toxic and unstable fluorescent dyes 
or due to the need to use special equipment for amplification and detection.  
Polymerase Chain Reaction (PCR), which has a wide usage, has got intrinsic disadvantages of 
complex and multiple processes requiring a thermal cycler for the reaction and a time consuming 
post-PCR analysis, which potentially increases the risk of laboratory contamination as seen with 
nested PCR. The development of quantitative real-time PCR (qPCR) (Bustin et al., 2009; Gibson et 
al., 1996; Heid et al., 1996) has brought in several advantages over conventional PCR methods, 
including, rapidity, quantitative measurements, lower contamination rate, higher sensitivity, higher 
specificity and easy standardization (Mackay et al., 2002). Real-time qPCR however has 
disadvantages of complexity since the system requires an instrumentation platform consisting of a 
thermal cycler, computer, optics for fluorescence excitation and emission as well as data collection 
and analysis software, hence the need for high expertise and state of the art equipped laboratories. 
The machines are also very expensive and not within the purchasing powers of many laboratories in 
the developing or resource limited countries. Therefore even with the availability of commercial 
nucleic acid based tests, their use is limited to selected laboratory settings as they are expensive.  For 
example, as at 2007, the kits ranged from U.S $ 50 to 100 per test (Dineva et al., 2007; Fiscus et al., 
2006), which is comparable to a subsidized monthly HIV treatment cost of the same amount in Sub-
Saharan Africa. These disadvantages related to cost, test performance time, computer capacity, 
extensive training and complex or dedicated laboratories for sample preparation and amplification, 
are an indication that the needs of test users are difficult to fulfill for viral load monitoring in resource 
limited settings. In these settings, cost and assay time pose considerable constraints for most testing 
and management strategies for HIV infected patients. 
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Figure 2a. LAMP primer targets. Schematic representation of  loop-mediated isothermal amplification 
(LAMP) primers showing; inner primers FIP (F1c and F2) and BIP (B1c and B2) and the outer primers, 
designed at the region of F3 and B3. The loop primers Loop F and Loop B are designed to target between 
the regions F1c - F2c and B1c – B2c respectively (adapted from Mori and Notomi, 2009). 
With these high costs, long time consumption and other disadvantages associated with the currently 
available nucleic acid techniques and viral load assays, it is important to develop more cost effective 
and easy to use assays for use in detecting HIV and monitoring viral load in patients undergoing 
treatment in resource limited settings. This is one way to ensure that the achievements made so far in 
the fight against HIV/AIDS in Sub-Saharan Africa will be maintained and improved. 
2.2 Loop-mediated isothermal amplification (LAMP) 
2.2.1  Test principle and LAMP primers  
The LAMP assay was developed about 14 years ago (Notomi et al., 2000) and is currently evaluated 
and established for a variety of infectious agents. LAMP exhibits characteristics that are ideal for the 
development of a rapid, cost-effective nucleic acid-based test for detection of many infectious agents 
(Mori and Notomi, 2009). It is a one step isothermal amplification reaction that amplifies a target 
nucleic acid sequence utilizing a DNA polymerase with strand displacement activity, along with two 
inner primers, forward inner primer (FIP) and backward inner primer (BIP), and two outer primers 
forward 3 (F3) and Backward 3 (B3). These primers are specially designed for six specific regions 
within the target sequence. Two additional primers, loop forward (LF) and loop backward (LB) have 
been developed for enhanced specificity and reaction efficiency (Nagamine et al., 2002) and to 
accelerate LAMP reaction. A scheme of the primer targets in the DNA is shown in Figure 2a.  
 
 
 
 
 
 
 
 
 
 
Isothermal reaction in LAMP starts with the displacement of the double strands of DNA by the 
polymerase enzyme and undergoes 8 important steps to form a “dumb-bell” structure which then 
undergoes a cyclic amplification process (Refer. http://loopamp.eiken.co.jp/e/lamp/principle.html). 
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Figure 2b. Schematic representation of the cyclic step in the LAMP amplification process. Steps 9-11 start 
from the dumb-bell shaped stem loop generated in step 8, then undergo exponential amplification using 
inner primers (FIP and BIP); this leads to the formation of differently sized structures consisting of 
alternately inverted repeats of the target sequence on the same strand, resulting in cauliflower-like 
(shown at the upper left and lower right corners) structures. (Copyright ©, 2005, Einken Chemical Co. ltd, 
Japan). 
The cyclic amplification is a complex (Figure 2b) process involving an exponential amplification of 
the original dumb-bell shaped stem-loop DNA by use of the inner primers (FIP and BIP). As a result 
of this process, various sized structures consisting of alternately inverted repeats of the target 
sequence on the same strand are formed. 
 
 
 
 
 
 
 
 
 
2.2.2 Advantages of LAMP assay and its adaptation to detection of viruses 
The LAMP technology has also been adapted for the detection of RNA viruses using reverse 
transcription loop-mediated isothermal amplification (rt-LAMP), simply through the addition of a 
heat stable reverse transcriptase enzyme (Hong et al., 2004; Kurosaki et al., 2007; Soliman and El-
Matbouli, 2006; Yoshida et al., 2007), making it an ideal assay for HIV nucleic acid detection. A 
major asset of this procedure is that it is carried out under isothermal conditions. Operation and 
control of this assay does neither require sophisticated machinery nor highly equipped laboratory 
facilities, as the amplification reaction can be carried out in a heating block or a water bath, obviating 
the need for a thermal cycler. The whole procedure is also very simple and rapid. The amplification 
can be completed in less than one hour by incubating all the reagents in a single tube. Gene 
amplification products can be detected by agarose gel electrophoresis as well as by real-time 
monitoring in an inexpensive turbidimeter measuring the amount of magnesium pyrophosphate 
deposits. Gene copy number can also be quantified with the help of a standard curve generated from 
different concentrations of gene copy numbers plotted against time to positive signal with the help of 
a real-time turbidimeter (Parida et al., 2008). 
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This technology has been developed into commercially available detection kits for a variety of 
pathogens including bacteria and viruses (Mori and Notomi, 2009). In comparison to rt-PCR which is 
currently used for genome amplification of infectious agents in the developed world, this procedure 
has shown great similarities, giving a concordance of 85% on Japanese encephalitis virus detection 
(Parida et al., 2006). Different studies have successfully evaluated this assay for its adaptation in 
nucleic acid detection of HIV-1 group M viruses (Curtis et al., 2008; Hosaka et al., 2009). However, 
not until recently has rt-LAMP been shown to have potential for semi-quantitative analysis of Loa loa 
samples (Drame et al., 2014). Promising results have been published by rt-LAMP for quantification 
of HIV-1 strains circulating within a Chinese population (Zeng et al., 2014) and in HIV-2 viruses 
(Curtis et al., 2014). 
Considering the advantages of rapid amplification, simple operation and easy detection, LAMP has 
potential applications for clinical diagnosis and management of HIV infection in developing countries 
without requiring sophisticated equipment or personnel with special training. Thus there is confidence 
that this assay, once established in a robust form, will work for detection of HIV-RNA and for the 
determination of viral load in HIV-1 patients in Africa, and further lend itself as a refined parameter 
for the proper monitoring of ART treated patients in the sub-urban regions of African countries. 
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Chapter 3 
3 Materials and methods 
3.1 Sample materials 
3.1.1 Cell culture supernatants 
Purified RNA from HIV-1 propagated in cell cultures at the Max von Pettenkofer-Institute was used 
during the optimization of the LAMP assay. Serial dilutions of IIIB and MVP899-87, representing 
HIV-1 group M subtype B, formed a panel that was initially used for the optimization process of the 
primers and the assay system. Other cell culture supernatants representing various HIV types, groups 
and subtypes included: 2 HIV-2 samples MVP11971-87 and MVP438-01; and 6 HIV-1 group O 
samples, MVP2000-01, MVP2901-94, MVP2549-95, MVP5267-95, FLI5066-03 and MVP 5180-91. 
HIV-1 group M non-B subtypes included: MVP8268A-98 (HIV M: A), V0715163B (HIV-1 M: A1), 
3 samples MVP3777-97, MVP5739-98 and FLI810B2-07 (HIV M: C), MVP9619-94 (HIV-1 M:D), 
FLI4334A-99 (HIV M:CRF01_AE), V0634505 (HIV-1 M: F1), MVP7854F-94 (HIV-1 M:F2) and 
V1216136B (HIV-1 M:G). The HIV-1 groups N and P were not represented since these viruses are 
very rare and samples of the two groups were not available.  
3.1.2 Clinical samples 
Clinical samples were obtained either from HIV infected patients who were undergoing treatment at 
the time of the study or from HIV positive plasma samples archived in Nairobi and in Munich. 
Samples were categorized into whole blood samples, plasma samples and dry blood/plasma spot 
(DBS/DPS) samples. Part of the samples obtained from Kenyan patients in Nairobi was transported to 
the Max von Pettenkofer-Institute for further analysis. 
Using a standard formula recommended by WHO/TDR (Banoo et al., 2010) a minimum total of 140 
samples had been calculated to be sufficient for the study. However for a statistically suitable data set 
a total of 467 samples, including both HIV positive and negative were analyzed during the study. 
These samples included 234 HIV positive plasma samples from Kenya of which 87 were analyzed in 
Nairobi while 99 were analyzed in Munich. Others from Kenya included 121 HIV positive dry blood 
spot samples which were shipped to and analyzed in Munich and 48 HIV antibody negative samples 
obtained and analyzed in Nairobi. The HIV antibody negative samples were obtained from healthy 
patients attending or whose blood samples were sent to the Kenya Medical Research Institute 
(KEMRI) for routine medical checks for food borne infections. The final group of samples was a 
panel of 112 plasmas including HIV positive and negative samples obtained from patients undergoing 
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treatment and from persons undergoing routine testing in Munich. The permission to use these 
samples was obtained from the respective institutions.  
3.2 Laboratory procedures   
3.2.1 Optimization of LAMP assay using cell culture supernatants 
3.2.1.1 Viral strains and reagents 
Cell culture supernatant in-house positive controls (IIIB and MVP899-87) for HIV-1 group M 
subtype B, and MVP5180-91 representing HIV-1 group O formed a panel that was initially used for 
the optimization process of the primers and the assay system. Cell culture supernatants MVP11971-
87 and MVP438-01 representing HIV-2 were used to test the specificity of the assay, whereas ultra 
pure water (H2O) and 0.9% sodium chloride (NaCl) were used as negative controls. Total RNA was 
extracted from these cell culture supernatants using an automated system, Roche MagNAPure 
(Roche Diagnostics, Mannheim, Germany), according to manufacturer’s instructions. Ten fold 
dilutions were made from the extracted RNA materials which formed a quantification panel ranging 
from 2.1x101 to 2.1 x 106 copies/mL. Loopamp® RNA Amplification kit and Loopamp® 
fluorescence detection dye (Eiken Chemical Co., Ltd, Tochigi, Japan) and MAST Isoplex™ RNA 
Amplification kit (Mast Diagnostica, Reinfeld, Germany) were used for LAMP amplifications and 
detections. Restriction enzymes (New England Biolabs Inc. Frankfurt, Germany), Biozym LE 
agarose (Biozym Scientific, Oldendorf, Germany) and DNA marker VIII (Roche Diagnostics, 
Mannheim, Germany) were used for amplification product characterization. 
3.2.1.2 Design and synthesis of LAMP primers 
Four sets of primers required for the LAMP reaction were designed recognizing six arbitrary regions 
of the target sequences of the gag-p24 gene of HIV-1 BaL sequence, Gene Bank accession number 
AY713409 (Curtis et al., 2008) and the pol-integrase gene, accession number K02013 (Hosaka et al., 
2009), further the U3 start sequence of the LTR and the N-terminal of gp-41 of the env gene both 
from the HXB2 reference genome sequence. Loop primers (LF and LB) were included to accelerate 
the LAMP reaction. The new primers were designed using PrimerExplorer V3 software (Eiken 
Chemical Co. Ltd. website (http://primerexplorer.jp/e/)) and LAMP designer (Premier biosoft.com). 
All primers were synthesized by Ella Biotech, Munich, Germany. 
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Table 1. List of primers and their target positions within the HIV genome. Hip set of primers are designed to 
target the protein (p24) of the gag gene. HiInteg primers target the integrase of the pol gene. HiLtr is 
designed from the U3 start region of the long terminal repeat (LTR) and HiGp was designed to target the N-
terminal part of the glycoprotein (gp41) of the env gene. Reverse complement primers (RC -in red color). 
FIP and BIP sequences combine 2 sequences (F1c+F2 and B2+B1c). F3 – Forward primer; B3 – Backward 
primer; FIP – Forward Inner Primer; BIP – Backward Inner Primer; LF – Loop Forward; LB – Loop Backward. 
Primer set Primer name                   Sequence (5´to 3´) 
HiP  F3    (1311-1329) ATTATCAGAAGGAGCCACC      
 
B3   (1515   1535)RC 
CATCCTATTTGTTCCTGAAGG  
    
 FIP 
                 (1340   1361)
RC                      
                                (1393-1417) 
CAGCTTCCTCATTGATGGTTTCTTT - TTAACACCATGCTAAACACAGT  
 
BIP 
                  (1455-1478)                                                 (1494   1514)
RC 
TGTTGCACCAGGCCAGATAATTTT - GTACTGGTAGTTCCTGCTATG  
 
LF (1370   1394)RC TTTAACATTTGCATGGCTGCTTGAT  
   
 
LB (1475-1493) GAGATCCAAGGGGAAGTGA 
    HiInteg  F3  (4721-4743) GGTAAGAGATCAGGCTGAACATC  
    B3 (4926   4945)
RC GCTGGTCCTTTCCAAAGTGG  
    
 
FIP              (4747   4766)RC                                                    (4787-4806) 
CCCCAATCCCCCCTTTTCTT -  AGACAGCAGTACAAATGGCA 
 
BIP 
                  (4812-4835)                                         (4900   4921)
RC 
AGTGCAGGGGAAAGAATAGTAGAC - CTGCTGTCCCTGTAATAAACCC  
 
LF TTAAAATTGTGGATGAAT  
    
 
LB GCAACAGACATACAAACTAAAG 
   HiLtr F3     (29-50) ACAAGATATCCTTGATCTGTGG  
   
 
B3   (319   337)RC CGATGTCAGCAGTTCTTGT  
    
 
FIP 
               (158   179)RC                                                    (106-126) 
GGCTTCTTCTAACTTCTCTGGC – GGATCAGATATCCACTGACCT 
 
BIP 
                  (190-210)                                     (245   264)
RC 
AGAACACCAGCTTGTTACACCA - CCTCCACTCTAACACTTCT  
 
 
LF   (127   147)RC CTAGCTTGAAGCACCATCCAA  
    
 
LB  (215-232) GAGCCTGCATGGAATGGA  
    HiGp F3   (8740-8755) GAG CTA TTC GCC ACA TAC C  
     B3  (8964   8979)
RC CTC TTG TGC TTC TAG CCA G  
    
 FIP 
      (8846    8866)RC                                              (8786-8805) 
CAGCTCGTCTCATTCTTTCCC – TTTGCTATAAGATGGGTGGC 
 
 
BIP 
            (8874-8891)                                     (8920   8941)
RC 
AGCAGATAGGGTGGGAGC – CTGTATTGCTACTTGTGATTGC 
 
 
LF  (8819    8835)RC AGG CCA TCC AAT CAC ACT AC  
   
 
LB  (8895-8909) AGC ATC TCG AGA CCT GGA 
       
 
 
 
 
3.2.1.3 Testing of primers 
Binding stringency of LAMP primers was tested on both normal rt-PCR using F3 and B3 primers 
and rt-LAMP assay.   
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3.2.1.3.1 rt-PCR 
Reverse transcription of HIV template RNA was done before PCR amplification using 2 µL B3 
primers (10 µM each), 4 µL 5x buffer (100 µM Tris-HCL, 250 µM KCL, pH 8.4), 2 µL dithiothreitol 
(DTT) (0.1 M), 2 µL desoxynucleotide triphosphates (dNTP) (5 mM) and 40U reverse transcriptase 
enzyme (cat. no. 18064-014, Life Technologies, Germany). 10 µL of the mix was incubated with 10 
µL of the samples at 45ºC for one hour. PCR was performed with 2U Taq polymerase enzyme (cat. 
no. N 808-0152, Life Technologies, Germany) in a master mix of dH2O, dNTP (5 mM), 10x buffer 
(200 mM Tris-HCL (pH 8.4), 500 µL KCL), Primer 1 (F3) and Primer 2 (B3) each 10 µM. 43 µL of 
the master mix was incubated with 7 µL of cDNA template and run in the first PCR amplification. 
The second PCR was performed with 2U Taq polymerase enzyme (cat. no. 10342-020, Life 
technologies, Darmstadt, Germany) in a master mix containing dH2O, dNTP (5 mM), 10x Taq 
polymerase buffer (200 mM Tris-HCl pH 8.4, 500 mM KCl), Primer 3 (FIP) and Primer 4 (BIP). A 
total of 48 µL of the master mix was incubated and run in the second PCR amplification after 2 µL of 
the amplification product (amplicon) of the first PCR was added. 
3.2.1.3.2 rt-LAMP amplification 
The rt-LAMP reaction was carried out using the MAST Isoplex™ RNA Amplification kit (Mast 
Diagnostica, Reinfeld, Germany) containing 8 U/µL Bst polymerase and 20 U/µL reverse 
transcriptase enzymes, 3 mM hydroxynaphthol blue (HNB) dye, a fluorescence dye (V13), water and 
an already constituted 2x  reaction mix (RM). The reaction mix contained dNTPs (2.8 mM), KCl (20 
mM), (NH4)2SO4 (20 mM), Tris buffer (40 mM, pH 8.8), betaine (1600 mM) and MgSO4 (16 mM). 
Briefly, 12.5 µL of the reaction mix, 1 µL of the fluorescence or colour detection dye, 1 µL of Bst 
polymerase enzyme, 0.5 µL reverse transcriptase, water and different concentrations and volumes of 
primers were mixed together in a 25 µL reaction. This was then set at an optimal temperature of 63°C 
for 1 hour. For visualization under UV light, 1 µL of SYBR green fluorescence detection dye (Eiken 
Chemical Co., Ltd, Tochigi, Japan) was used instead of the detection dyes supplied in the 
amplification kit. Sample volume added was dependent on the concentration and the volumes of the 
primers during this initial stage. 
3.2.1.4 Optimization of rt-LAMP reaction conditions 
Primers were first evaluated and tested for selection of the best suitable primers. Varying 
concentrations and volumes of the primers and templates of the cell culture dilution panels were 
tested and time to detection recorded. The primer concentrations included; FIP (40 pmol and 50 
pmol), BIP (40 pmol and 50 pmol), F3 (5 pmol), B3 (5 pmol), LF (20 pmol and 25 pmol), LB (20 
pmol and 25 pmol). The primer volumes also varied between 2 μL and 3 μL. The amount of the target 
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RNA template ranged between 3 μL to 5 μL. The reaction mixture was incubated at 63°C for 60 min 
in a LoopAmp real-time turbidimeter (LA-200m; Teramecs, Kyoto, Japan). The turbidimeter 
measures the amount of turbidity as a result of magnesium pyrophosphate (Mg2P2O7) deposits 
generated during the amplification process. With the aid of a special fluorescence dye (V13) a real 
time measurement was obtained, where a threshold value (Abs) equivalent of an optical density above 
0.1 indicated a positive detection (Figure 3 (3e)). To assess the specificity of non specific products, 
the amplicons from rt-LAMP were run on a 2% agarose gel electrophoresis (Biozym Scientific, 
Oldendorf, Germany). The visual inspection of the processed amplification was also ascertained using 
HNB detection dye, through inspection of visual turbidity due to magnesium pyrophosphate 
(Mg2P2O7) deposits or under UV light using a fluorescent detection SYBR green intercalating dye 
(Eiken Chemical Co., Ltd, Tochigi, Japan). 
3.2.1.5 Analytical sensitivity and specificity of the rt-LAMP 
3.2.1.5.1 Sensitivity 
Serial dilutions of cell culture supernatant panels of IIIB and MVP899-87 viruses ranging from 
0.12x101 to 2.9x106 copies/mL (Figure 12) were tested between 4 to 18 times for individual samples 
in the assay and the results recorded. An in-house software (CERES) developed by the Virus 
Diagnostic Department of the Max von Pettenkofer-Institute was used to calculate the lower limit of 
detection (LLOD) and the lower limit of quantification for the LAMP assay. Viral loads were 
compared to those of an established Abbott Real Time HIV-1 commercial assay (Abbott m2000rt 
system) for HIV-1 nucleic acid amplification and quantification.  
3.2.1.5.2 Specificity 
Purified RNA templates from cell culture supernatants, MVP11971-87 and MVP438-01 representing 
HIV-2 were each tested 14 times and the results recorded. LAMP amplicons that showed unspecific 
amplification (“smear”) by gel electrophoresis were digested in a Restriction Fragment Length 
Polymorphism (RFLP) assay using a set of restriction enzymes. Based on sequence alignment of 
HXB2 (IIIB virus), restriction enzymes were designed by online restriction tools (RestrictionMapper 
version 3.0; http://www.restrictionmapper.org/  and NEBcutter Version 2.0; New England Biolabs 
Inc.). The following restriction enzymes were selected and tested. 
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Figure 3.  Summary scheme of laboratory  procedures. In (A) the samples were processed for nucleic acid 
extraction  (1) directly from whole blood samples and incubated for amplification. In (B) plasma was 
obtained from whole blood then either nucleic acid extracted before amplification (Bi) or the plasma was 
amplified directly after pre-heating at 100°C for 5 minutes or treatment with lysis buffer (Bii). In (C) whole 
blood was spotted on FTA cards (Ci) then dried (Cii) and packaged in special envelopes with desiccants (Ciii) 
and stored either at ambient temperature or at -80°C for 4 to 6 months before shipment. The time duration 
from  extraction to final results was estimated at 2 hours and the results were read as shown in 3a, 3b, 3c, 
3d and 3e. 
Table 2.  Restriction enzymes and their target primer sets. The list shows restriction enzymes for 
amplicons of p24 (HiP) – BsmAI and integrase (HiInteg) – BsrGI target primers and lengths for their target 
products.  
Enzyme          Restriction sequence 
Restriction 
product length 
LAMP 
product length  
Catalogue 
number 
Primer 
set 
BsmAI 5’... G T  C T C  N  NNNN…..3’        205 bp  225 bp R 0529S HiP 
 
3’… C  A G A G N  NNNN  .....5’      
BsrGI 5’…. T  G T A C  A.…..3’        193 bp  203 bp R0575 HiInteg 
 3’…. A  C A T G  T…...5’    
  
  
 
3.2.2 Processing and testing of clinical samples by LAMP assay 
Clinical samples were received either as whole blood in EDTA or as plasma samples (mainly for 
archived samples) and processed as described in Figure 3. Upon reception, nucleic acid was either 
extracted directly from whole blood (A) or whole blood was centrifuged to separate plasma (B) from 
which the nucleic acid was extracted before the LAMP analysis (Bi). Non-processed samples were 
also analyzed directly by the LAMP assay after pre-heating at 100°C for 5 minutes or after treatment 
with lysis buffer (Bii). Dry blood or dry plasma spots were  processed and stored at -80°C (C).   
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3.2.2.1  Preparation of dry blood spot or dry plasma samples 
As shown in C (Figure 3) DBS samples were prepared by spotting 70 µL of whole blood or plasma 
onto each of the 5 half-inch circles on the Whatman 903 neonatal blood FTA collection cards (Lot. 
6273207/51, GE Healthcare Europe, Freiburg Germany). The blood spots were then left to dry on a 
Whatman card drying rack overnight, before the cards were packed into gas impermeable bags with 
desiccant packs and humidity indicator cards. The dry spots were stored at ambient temperature or at 
-80°C if long storage of more than 6 months was anticipated. 
3.2.2.2 Procedures for sample manipulation 
The following steps as already shown in Figure 3 were applied during the laboratory procedures. 
3.2.2.2.1 Manual extraction of nucleic acid  
3.2.2.2.1.1 Extraction from whole blood and plasma 
Manual extraction (Figure 3, step 1) was done on all samples using the High Pure Viral Nucleic Acid 
Kit (cat. no. 11858874001) from Roche Diagnostics (Roche Diagnostics, Mannheim, Germany) 
according to the instructions of the manufacturer. Briefly, a volume of 200 µL of each sample was 
mixed with 200 µL binding buffer supplemented with poly (A) and 50 µL (50 mg/µL) of proteinase 
K and incubated at 72°C for 10 minutes. After incubation, a further volume of 100 µL of the binding 
buffer was added to each sample, mixed, and the sample pipetted to High Pure Filter tubes, connected 
to the connection tube. This complex was then centrifuged at 8,000g for 1 minute, before a volume of 
500 µL of the inhibitor removal buffer was added to the filter tubes and centrifuged for 1 minute at 
8,000g. Two steps of washing were done using 450 µL wash buffer in each case followed by 
centrifugations at 8,000g and 13,500g for 1 minute and 30 seconds respectively in the first and second 
washing steps. This procedure was then followed by an elution step, where RNA was eluted in 50 µL 
elution buffer. 
3.2.2.2.1.2 Extraction from dry blood spots 
One spot was punched out from the cards and incubated in 1,000 µL lysis buffer obtained from the 
Abbott sample preparation system kit (Promega, Madison, U.S.A). The incubation was done at 55°C 
for 10 minutes shaking at 550 rpm in a thermomixer heating block. The sample material was 
centrifuged at 8,000g for 3 minutes, before the supernatant was transferred into a new tube. Nucleic 
acid extraction was performed using the High Pure Viral Nucleic Acid extraction kit as described 
above. 
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3.2.2.2.2 RNA linearization 
Before amplification HIV RNA was linearized by heating the isolated RNA suspension to 72°C for 
10 minutes. This process was followed by immediate cooling on ice for at least 5 minutes before the 
samples were processed for amplification. Alternatively, the linearized RNA was stored at -20°C if 
delayed nucleic acid amplification process was anticipated. 
3.2.2.2.3 Treatment of samples of various categories 
i. Nucleic acid extracted plasmas: Samples were treated as described in chapter 3.2.2.2.1.1 
and then used for comparisons during evaluations in steps iii and iv. 
ii. Nucleic acid extracted DBS: Samples were treated as described in chapter 3.2.2.2.1.2 and 
used for comparisons during evaluations in steps iii and iv. 
iii. Heated non-extracted plasma samples: These samples were first mixed with RNAse free 
water in the ratio of 1:3 to avoid clotting and then subjected to 99°C for 7 minutes on a heating block, 
thereafter 5.5 µL and 9.5 µL were separately used in the LAMP reaction. 
iv. non-extracted plasma samples treated with a lysis buffer: These samples were first diluted 
in a lysis buffer supplied for extraction in the ratio 1:3 to make a starting volume of 200 µL. 
Subsequently a volume of  5.5 µL of the mixture was used in LAMP assay evaluation. 
3.2.2.2.4 rt-LAMP amplification process 
As shown in step 2 (Figure 3), amplification of the linearized products was done using the MAST 
Isoplex™ RNA Amplification kit (Mast Diagnostica, Reinfeld, Germany). Briefly, the final reaction 
volume of 25 µL contained: a primer solution of 0.2 µM of F3 and B3, 1.6 µM FIP and BIP and 0.8 
µM of LF and LB primers; 12.5 µL reaction mix containing dNTPs (2.8 mM), KCl (20 mM), 
(NH4)2SO4 (20 mM), Tris buffer (40 mM, pH 8.8), betaine (1600 mM) and MgSO4 (16 mM); 1 µL of 
3 mM HNB or fluorescent (V13) detection dyes; 8 U of Bst polymerase; 10 U of reverse transcriptase 
and 2.5 µL of water. These components were mixed with 5 µL of the templates, incubated at 63°C for 
1 hour in a real time turbidimeter (LA-200m; Teramecs, Kyoto, Japan) and the time to threshold 
detection recorded. The time to threshold detection was later used to calculate the estimation 
algorithm for viral load. Incubation was also done on a heating block set at 63°C for 1 hour and 
results observed visually by turbidity or visual colour change. 
3.2.2.2.5 Detection of LAMP products and generation of results 
The products generated after rt-LAMP amplification process were detected as desribed in step 3 
(Figure 3) by visual examination of turbidity (3a), colour change due to HNB dye (3b), fluorescence 
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detection by SYBR green dye (3c), gel electrophoresis (3d), and real time detection using the LAMP 
turbidimeter (3e). 
3.2.3 Automated extraction and quantification of viral load by Abbott Real Time HIV-1 assay  
Processing and quantification of samples was first done by the Abbott Real Time HIV-1 assay as 
described by the manufacturer http://www.abbottmolecular.com/static/cms_workspace/pdfs/US/51-
602146R6.pdf. Abbott Real Time HIV-1 is a complete assay which utilizes an automatic extraction of 
samples by use of Abbott (m2000sp) systems followed by amplification and quantification using 
Abbott (m2000rt).  The starting sample volume for automatic nucleic acid extraction was 1,000 µL 
and where the appropriate volume could not be attained, samples were first diluted in 0.9% NaCl and 
then used for analysis. 
3.2.4 Nucleic acid sequencing 
The sequencing process involved 3 main phases and was performed according to manufacturer´s 
protocol.https://www.beckmancoulter.com/wsrportal/bibliography?docname=Protocol_000387v001.pd
f.  (Agencourt Bioscience Corporation, Beverly, MA, United States). This sequencing method is 
based on the technique developed by Sanger (Sanger et al., 1977), also known as Sanger sequencing. 
It mainly involves selective incorporation of chain-terminating di-deoxynucleotides by DNA 
polymerase enzyme during in vitro DNA replication. The di-deoxynucleotide-triphosphates (ddNTPs) 
are responsible for terminating the strand synthesis. 
3.2.4.1 Purification of PCR products 
This phase was performed using the Agencourt® AMPure® XP PCR purification system which 
utilizes a solid-phase paramagnetic bead technology for high-throughput purification of PCR 
amplicons. By using an optimized buffer, PCR amplification products of 100 bp or larger are 
selectively bound to paramagnetic beads. Excess primers, nucleotides, salts, and enzymes are then 
removed through a washing step, resulting in purified PCR products.  
 
In summary, products of PCR amplification were bound to magnetic beads by adding and mixing 72 
µL of AMPure and 40 µL PCR reaction products followed by incubation for 7 minutes, and separated 
on a magnetic plate (SPRIPlate 96R). The beads were then washed  using 200 µL of freshly prepared 
70% ethanol to remove excess primers, nucleotides, salts, enzymes other contaminants before the 
products were finally eluted in 40 µL elution solution (dH2O). 
Quantity of recovered products was estimated reading the optical signals generated by the DNA using 
PicoGreen® intercalating dye (Cat.P11496, Life Technologies, Darmstadt, Germany) 
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3.2.4.2 Pre-sequencing product preparation and sequencing  
Before product preparation and sequencing, a sequence reaction mixture was prepared in which 
eluted DNA aliquots were diluted in dH2O to set up 5.5 µL of the mixture. A sequence reaction 
consisting of 5.5 µL reaction mixture, 0.5 µL of 10 pmol/µL primer (targeting the integrase gene) and 
4.0 µL of Quick Start Master was then set to a 30 cycle sequence reaction PCR.   
Pre-sequencing product preparation and sequencing was then performed using the CleanSEQ® Dye-
Terminator Removal method as described by Agencourt®. This is a 3-step Solid Phase Reversible 
Immobilization (SPRI) magnetic bead-based sequencing purification system which is flexible, simple 
and can be performed directly in the thermal cycling plate without centrifugation or filtration. 
In the first step 10 µL of CleanSEQ and 45 µL of  85% freshly prepared ethanol were added to the 
sequencing extension products generated during the cycle sequencing, mixed and incubated on a 
magnetic plate in order to bind the products to the magnetic beads. The bound products were then 
washed using 100 µL of 70% ethanol to remove unincorporated dyes, nucleotides, salts, and other 
contaminants. The products were then eluted in 40 µL aqueous SLS elution buffer, before a drop of 
oil was added to the wells and the plate loaded into a CEQ 8,800 Beckman device for sequencing.  
3.2.4.3 Editing of sequences and HIV subtyping 
The nucleic acid sequence results generated were edited and finally aligned using a Bioedit software 
(Hall, 1999) (Ibis Biosciences -  Carlsbad, CA,USA). Sequences were  subtyped and assigned using 
Context based modelling for expeditious typing (COMET HIV-1), an online subtyping tool 
(http://comet.retrovirology.lu/).   
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Gel 1b shows amplification product by rt-PCR 
at position 186 bp for HiGP set of primers on 
culture supernatant of MVP899-87 M: 
molecular weight marker, 1: positive sample, 
2: negative control (water)  
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Gel 1a shows amplification products by rt-PCR for HiP, 
HiLtr and HiInteg sets of primers respectively using culture 
supernatants of MVP899-87 viruses. M: molecular weight 
marker VIII, 1: HiP primers, 2: HiLtr 3: HiInteg primers, 4: 
In-house (integrase target primer) positive control.  
Figure 4. Products of rt-PCR amplification generated by LAMP designed primers as detected by agarose 
gel electrophoresis in the presence of ethidium bromide. Results show clear bands at the calculated 
fragment legnths for each primer set. There was no background band formation despite intensive 
staining which indicates high efficiency with the primers. The primers were selected to target 4 
conserved regions of the HIV genome, namely the LTR, gag, pol, and the env. The results show that the 
primers were suitable for use in rt-PCR. 
Chapter 4 
4 Results 
4.1 Testing efficacy of primers 
4.1.1 rt-PCR 
4.1.1.1 Testing primers by rt-PCR 
The four sets (HiP, HiLtr, HiInteg and HiGp) of primers designed, as described in chapter 3, were 
first subjected to conventional rt-PCR using F3, B3, FIP and BIP pairs in each case. The results 
obtained showed amplification of the expected targets at the calculated fragment lengths of 225 bp 
(HiP), 175 bp (HiLtr), 203 bp (HiInteg) and 186 bp (HiGp) as shown in gel electrophoresis photos of 
analyzed PCR products (Figure 4).  
 
 
 
 
 
 
 
 
 
  
 
 
4.1.2 rT-LAMP 
4.1.2.1 Optimization of primers and reaction conditions 
Optimization of primers and reaction conditions was performed for three (HiP, HiInteg and HiLtr) of 
the total four sets of primers. Variations in concentrations and volumes were done to compare and 
select favorable attributes of performance of the LAMP assay. Incubations were done on a real time 
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turbidimeter and a manual heating block  and  detections were performed using detection dyes, 
(fluorochrome dye (FD) – for turbidimetry and HNB for visual colour change) both supplied by Mast 
diagnostics (Mast Diagnostica, Reinfeld, Germany).  
Real-time monitoring of LAMP amplification is mainly achieved through spectrophotometric signals 
measured by real-time turbidimetry. The turbidimeter records the turbidity in the form of optical 
density (OD) values recorded every 6 seconds at 400 nm (Parida et al., 2008). LAMP reaction results 
in the production of large amounts of pyrophosphate by-products which react with magnesium ions 
leading to the formation of a white precipitate of magnesium pyrophosphate. 
The effect of variation of volumes from a stock solution comprising of 0.2 μM F3 and B3, 1.6 μM 
FIP and BIP, 0.8 μM LF and LB primer concentrations was evaluated. When a volume of 2 μL of 
primer was used in a 25 μL total reaction volume, 2 samples of high virus concentrations were not 
detected by HiP set of primers either by turbidimetry, visual turbidity or visual colour change, 
whereas HiInteg and HiLtr detected these 2 samples using the same primer volume by all the 
mentioned detection methods (Table 3). Gel electrophoresis results however showed “smears” for the 
2 samples tested by HiP set of primers (Figure not shown).  
When a volume of 2.5 μL was used, HiP set of primers showed positive detection (27 – 35 minutes) 
by turbidimetry, for the viral load of 2.1x105 copies/mL. Viral concentration approximately 2.1x102 
copies/mL recorded late detection (> 45 minutes) by the same set of primers. The HiInteg primer set 
recorded early detections (26 - 33 minutes), with the same primer volume, while the HiLtr primer set 
showed late detections (34 - 39 minutes) for virus concentration of 2.1x105 copies/mL tested in 
triplicates. The lowest virus concentration detected by the HiInteg set of primers was 2.1x102 
copies/mL compared to that detected by HiLtr (2.1x104 copies/mL).  
There was however lack of consistency in results generated by the HiInteg and HiLtr sets of primers 
when the volume of primers was increased to 3 μL as shown in test 3  and 4 (Table 3). An increased 
concentration of the inner primers (FIP and BIP) and the loop primers (LF and LB) did not yield any 
significant improvement of detection for HiP and HiInteg set of primers as shown in test 4 (dotted 
square) in Table 3.  Although the results shown in Table 3 were each generated with a sample volume 
of 5 µL in a 25 µL total reaction, it was realized that similar results were obtained when 3 µL of the 
samples were used. However, when 3 µL was used, only samples of viral loads >2.1x103 copies/mL 
were easily detected by the HiP set of primers whereas HiInteg produced inconsistent results which 
were considered unreliable. 
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Table 3. Optimization of the primer concentration for LAMP analysis. The table shows a summary of the effects of variation of primer volume from a 
stock of 0.2 μM (F3 and B3), 1.6 μM (FIP and BIP), 0.8 μM (LF and LB) primer concentrations on different concentrations of a dilution panel of HIV-
1 M:B IIIB virus. The optimum primer volume of 2.5 µL in a total reaction volume of 25 µL (shown in the square box) was achieved for LAMP assay (Test 
2). An increase in the primer concentrations for the inner primers (FIP/BIP) and the loop primers (LF/LB) as shown in the square dotted box, did not yield 
any improved detection compared to when 2.5 µL from the concentration of primer stock solution was used. Indeterminate results (±) shown in the table 
as (+/-) was indicated by a “smear” by  gel electrophoresis and “no Tt value” for real time turbidimeter, Tt value: Time to threshold detection (given in 
minutes), Vis Turb: visual turbidity, NC : Negative control. Positive detections are shown by a plus (+) sign, whereas negative results are shown by a dash 
(-). 
 
 
 
 
 
 
 
 
 
 
   
 
 
 Virus 
concentration 
Test 1 (2 µL primers) 
Test 2 (2.5 µL primers) Test 3 (3 µL primers) Test 4 (2 µM FIP/BIP & 1 µM  LF/LB) 
Primer 
set Tt value 
Vis. 
Turb 
Gel 
results 
Colour 
change Tt value 
Vis. 
Turb 
Gel 
results 
Colour 
change Tt value 
Vis. 
Turb 
Gel 
results 
Colour 
change Tt value 
Vis. 
Turb 
Gel 
results 
Colour 
change 
HiP 2.1x10
5
      -      - (+/-)      - 27.24- 35.42    +    +    + 26.48- 28.48    +    +    + 31.24    +    +    + 
 
2.1x10
4
      -      - (+/-)      - 33.06- 38.12    +    +    + 30.24- 31.24    +    +    + 41.54    +    +    + 
 
2.1x10
3
      -      -      -      - 35.24- 40.54    +    +    +  48    +    +    + 28.36    +    +    + 
 
2.1x10
2
      -      -      -      - 45.54- 49.04    +    +    +      -      -      -      - 55.54- 56.06    +    +    + 
 
2.1x10
1
      -      -      -      -      -      -      -      -      -      -      -      -      -      -      -      - 
 
2.1      -      -      -      -  39    +    +    +      -      -      -      -      -      -      -      - 
 
NC      -      -      -      -      -      -      -      -      -      -      -      -      -      -      -      - 
HiInteg 2.1x10
5
 23.32- 32.06    +    +    + 26.42- 33.36    +    +    +      -      -      -      - 39.30- 41.00    +    +    + 
 
2.1x10
4
 26.06- 32.24    +    +    + 33.12- 39.24    +    +    + 38.14- 48.06    +    +    +   (+/-)    +    +    + 
 
2.1x10
3
 39.54-43.12    +    +    + 39.42- 50.02    +    +    +      -      -      -      - 48.32-50.54    +    +    + 
 
2.1x10
2
 49.06-53.06    +    +    + 41.54    +    +    +      -      -      -      -      -      -      -      - 
 
2.1x10
1
      -      -      -      -      -      -      -      -      -      -      -      -      -      -      -      - 
 
2.1      -      -      -      -      -      -      -      -      -      -      -      -      -      -      -      - 
 
NC      -      -      -      -      -      -      -      -      -      -      -      -      -      -      -      - 
HiLtr 2.1x10
5
 34.12- 52.12    +    +    + 34.06- 39.42    +    +    + 45.02- 49.06        
 2.1x10
4
 47.32- 59.24    +    +    + 40.54- 48.00    +    +    +      -   
      2.1x10
3
      -      -      -      -      -      -      -      -      -   
      2.1x10
2
      -      -      -      -      -      -      -      -      -   
      2.1x10
1
      -      -      -      -      -      -      -      -      -   
      2.1      -      -      -      -      -      -      -      -      -   
      NC      -      -      -      -      -      -      -      -      -   
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Figure 6a. Tubes 1 and 2 show positive 
results by turbidity. Tube 3 shows negative 
non-turbid result  
                       1                2                3          
Figure  6b. Results by visual color detection. 
Tubes 1 purple negative result. Tubes 2 and 
3 pale blue positive results by HNB color 
detection dye.  
Figure 5. Restriction digestion of rt-LAMP amplicons generated by LAMP designed primers. Agerose gel 
photo A shows a single restriction band at 193 bp generated by BsrGI enzyme for amplicons of HiInteg 
set of primers. Agarose gel photo B shows a single restriction band generated by BsmAI enzyme at 205 
bp for amplicons of HiP set of primers. Agarose gel photo A: M - DNA marker VIII, track 1 and 2 – LAMP 
amplicon,  track 3 -restriction band, track 4 and 5 – Negative control. Agarose gel photo B: M – DNA  
molecular weight marker VIII, track 1 – LAMP amplicon, track 2 – restriction band, track 3 – negative 
control. Restriction bands generated at expected fragment lengths (Table 2). 
4.1.2.2 Restriction enzyme digestion of rt-LAMP products 
In order to confirm the specificity of the LAMP products shown by the ladder like bands generated by 
gel electrophoresis, these amplicons which had been generated by HiP and HiInteg sets of primers 
were digested using the set of restriction enzymes described in chapter 3 (Table 2). The aim was to 
generate single bands of the expected sizes. The results obtained showed single bands of the 
calculated sizes for the different enzymes (Figure 5) an indication of specificity of  primer binding to 
their targets. 
 
                                                        
                                         
 
 
 
 
                                                                                                
 
 
 
4.1.2.3 Testing and detection of LAMP products with cell culture supernatants 
Testing of LAMP after optimization was done on cell culture supernatants of IIIB and MVP899-87 
viruses. Figure 6 shows detection methods used for interpreting the results, mainly visual turbidity, 
visual colour change, fluorescence detection, gel electrophoresis and real time turbidimetry. 
 
 
  
 
 
                                             1              2                 3 
A 
B 
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                    1         2        3         4        5 
                 
Figure 6c. Tubes 1 and 2 show positive 
results by SYBR green detection dye. Tube 3 
shows  a negative result.   
Figure 6d. Tracks 1 to 4 show ladder-like 
bands of LAMP amplification on agarose gel. 
Track 5 shows a negative control result.   
Figure 6. Detection methods used during LAMP evaluation. The figure shows various detection methods 
that were used for LAMP. 6a: turbidity due to presence of magnesium pyrophosphate. 6b and 6c: visual 
colour change by hydroxynaphthol blue (HNB) and fluorescent (SYBR green) dyes.  6d:  gel 
electrophoresis showing ladder-like bands which are  typical for LAMP amplificons. 6e:  turbidimetric 
detection using real time  turbidimeter  
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Figure 6e.  Read outs of real time turbidimetry results.  Wells 1 to 3 in 
figure A show blue bars with red origins indicating positive results, while 
wells 4 and 5 remain green indicating negative results. Figure B shows real 
time amplification results. In both figures, vertical line represents the 
threshold value (Abs) generated as a result of optical density (OD) signals 
while in figure B, the horizontal line represents time to threshold detection 
in minutes. The threshold value (optical density) of 0.1 was the value above 
which the positive signals were generated by LAMP turbidimeter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.2.4 Prevention of sample cross contamination 
During the first stages of this study, cross contamination with amplified products was realized, when 
a series of negative samples also tested positive. Source of contamination was traced to some of the 
tube racks which were returned to the lab after opening the LAMP amplification tubes for analysis by 
gel electrophoresis. Apart from changing the rooms and replacing all the racks, pipettes and other 
containers, a series of precautions were introduced for subsequent analysis. These included the 
recommended 3 room strategy: extraction was done in the first room, master-mix was prepared in the 
second room in one clean bench and a second bench was used during sample loading and a third room 
was used for real time amplification. Upon completion of LAMP reaction, all tubes were discarded 
without opening.  
 
 
 
               1                2                       3 
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Figure 7.  Evaluation of analytical sensitivity and rate of detection of LAMP primers for the cell culture 
supernatant dilution panel. Results show the percentage detection rate (n=7) of a dilution panel of the 
MVP899-87 virus for different primer sets detected by real time turbidimetry and confirmed by gel 
electrophoresis. Best performance within this range of virus concentrations is exhibited by  HiInteg and HiP 
sets of primers which detected ≥ 2.9x10
1
 and 2.9x10
2
 copies/mL respectively. Primer sets HiLtr and HiGp 
both showed lower sensitivities for these samples.  
4.1.2.5 Testing  and evaluation of analytical parameters of LAMP primer sets. 
4.1.2.5.1 Sensitivity across a dilution panel 
Different dilutions of MVP899-87 virus ranging from 2.9  to 2.9x108 copies/mL were tested 7 times 
and the results recorded either as positive or negative. Comparisons in primer performance showed 
that the HiInteg set exhibited the highest sensitivity among the panel of HIV-1 M subtype B (Figure 
7). This set of primers detected up to 14% of samples with a concentration of 2.9x101 copies/mL. 
Primer set HiP also exhibited a high sensitivity presenting a detection limit of 2.9x102 copies/mL. All 
primer sets, except for primers HiGp detected all samples ≥2.9x105 copies/mL as quantified by 
Abbott m2000rt system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.2.5.2 Linearity across the primer sets 
Analysis of the linearity of the amplification reaction was performed with decreasing concentrations 
of the MVP899-87 sample. The results in Figure 8 depict an inverse positive linear correlation 
between concentration and time for all primer sets. Samples with higher viral loads tested with the 
HiGp set of primers showed the earliest time to threshold detection at 13 minutes followed by HiInteg 
and HiP both at 20 minutes, while the earliest time to detection realized with HiLtr set of primers was 
30 minutes for the same high viral concentrations. 
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Figure 8. Results of a dilution panel of MVP899-87 virus. Inverse positive correlation between 
the virus concentration and time to detection was observed. Sample dilutions not detected 
were assigned arbitrary 0 (zero) values and appear on the figure as 0. A general increase in time 
is observed from a higher concentration (2.9x10
8
) to a lower virus concentration (2.9x10
1
). A 
sample with 2.9 copies/mL and the negative controls poly A and water were not detected (The 
horizontal axis is labelled from the highest virus concentration to the lowest). 
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4.1.2.5.3 Determination of precision for primers based on time to detection  
Both intra- and inter-assay precisions were tested for all 4 sets of primers. A comparison of real 
time turbidimetry and visual colour detection (HND dye) methods was also performed based 
on time to detection. Statistical analyses were performed and results reported as recommended 
for medical statistics (Lang and Secic, 2006). 
4.1.2.5.3.1 Intra-assay precision 
The highest intra-assay precision was observed with primer sets HiLtr (mean = 38.52; CV = 1.44%) 
and HiGp (mean = 21.49; CV = 2.2%) when tested by turbidimetry (Figure 9). However the two 
exhibited lower precisions, mean = 47.33; CV = 6.5% and mean = 27; CV = 11.6% for HiLtr and 
HiGp respectively, when tested by the HNB dye detection method. HiInteg and HiP exhibited high 
precision for both detection methods. These results showed that HiInteg and HiP were potentially 
more stable and robust compared to HiLtr and HiGp. 
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Real time turbidimetry 
HNB dye detection 
Figure  9.  Results of intra-assay precision for HiInteg , HiP, HiGp and HiLtr sets 
of primers.  The results show mean and standard deviation of time to detection 
for the sets of primers tested. HiLtr and HiGp exhibited the highest precisions by 
real time turbidimetry, but showed a reduced precision for HNB dye detection.  
HiInteg and HiP exhibited stability in precision for both detection methods.  
 
 
 
 
 
 
 
 
 
 
 
 
4.1.2.5.3.2 Inter-assay precision 
Cell culture supernatants of IIIB virus were used to test inter-assay precision and also to compare the 
findings based on the detection method used (real-time turbidimetry versus HNB dye detection). A 
higher precision was observed for real time turbidimetry when compared to the HNB detection 
method. Comparisons in performance between heating block and real time turbidimetry is reported in 
Figure 10. Within each primer set, HiGp recorded the highest precision by real time turbidimetry 
(mean = 21; CV = 2%) but exhibited the lowest precision by HNB dye detection (mean = 26; CV = 
22%). Precisions with accepted ranges were realized for HiInteg (mean = 30; CV = 3%) and HiP 
(mean = 30; CV = 7%) sets of primers by real time turbidimetry and for HNB dye detection (mean = 
33; CV = 9%) for HiInteg and (mean = 33; CV = 0%) for HiP sets of primers. The lowest precision 
was shown for HiLtr by real time detection (mean = 50; CV = 12%) and by HNB dye detection (mean 
= 46; CV = 17%). All CVs calculated for HiLtr were outside the variation range of 10%, which is 
generally established for an acceptable precision (Lang and Secic, 2006). 
4.1.2.5.3.3 Inter-assay precision across subtypes 
Testing was done over a period of 3 days using HIV-1 group M:B and non-B samples of known viral 
loads quantified by the Abbott m2000rt system, using the 4 sets of primers. The highest precision was 
found with HiInteg primers (Table 4) for all subtypes except for subtype F1 which, just like HiLtr 
primer, showed a dismal performance. Viral load estimation for this F1 subtype sample showed a low 
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 Subtype     Viral   
    load 
HiInteg HiP HiLtr HiGp 
  HIV-1  
     M 
  Abbott  
 m2000rt 
 
Mean 
 time  
 SD CV  
(%) 
Mean 
 time 
 SD CV 
(%) 
Mean 
 time 
 
SD 
CV  
(%) 
Mean 
 time 
SD CV 
 (%) 
     A1 6.9x10
5
 32.3 0.9 2.8 27.3 0.9 4.2 29.0 1.4 6.5   ND   -   - 
     B 2.9x10
6
 30.0 0.8 3.2 26.0 1.6 7.6 28.5 1.1 4.6 41.0 3.9 9.5 
     D 2.4x10
6
 32.0 0.8 2.5 29 1.7 7.3 29.0 0.3 1.1   ND   -   - 
     F1 2.5x10
2
 45.1 7.1 19.3 31.0 2.9 1.2 31.0 3.4 13.7   ND   -   - 
     F2 6.5x10
5
 30.0 0.7 2.4 27.0 0.7 2.7 28.5 4.7 1.8   ND   -   - 
     G 1.1x10
5
 33.0 0.6 2.0 27.0 0.5 2.1 28.0 2.7 11.8   ND   -   - 
  HIV-1 O 6.2x10
4
  ND - - 28.2 2.3 10 30.0 1.6 6.7   ND   -   - 
 HIV 2 5.0x10
5
  ND - - 32 1.3 4.9   ND   -    -   ND   -   - 
 Table 4. Inter- assay precision for the 4 sets of primers among HIV-1 M:B and non B subtypes. Overall 
HiInteg primers exhibited higher precision (with the lowest % coefficient of variation (CV)) across all 
subtypes except for HIV-1 M:F1 compared to HiP and HiLtr sets of primers. The lower precision among F1 
subtype by HiInteg was attributed to potentially low viral load. The HiGp set of primers only detected 
subtype B. Samples not detected are indicated as (ND) followed by dashes (-) 
viral load of 250 copies/mL with the Abbott m2000rt assay. Although the detection threshold for 
LAMP assay was not yet determined, it was highly suspected that the low viral load could have been 
responsible for the reduced precision as opposed to its genotype. This observation of non-genetic 
influence was supported by the observation that subtype F2 (which is closely related to F1 in nucleic 
acid sequence pattern), with a higher viral load exhibited a higher precision for all primer sets. 
Observations for the HiP set of primers could not be explained as this set of primers recorded high 
precisions with lower standard deviation for all samples including HIV-1 group O and HIV-2 
samples, despite the fact that all primers were designed to target only HIV-1 group M viruses. The 
HiGp set detected only subtype B virus presenting the lowest precision compared to the other sets of 
primers. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
4.1.2.6 Real time turbidimetry versus HNB dye detection  
An independent T-test was performed to compare the time to threshold (Tt) values obtained by 
turbidimetry and HNB dye detections. No significant difference in the results of turbidimetry 
detection (mean = 33, SD = 11) compared to HNB dye detection (mean = 35, SD = 9); t (22) = -0.49 
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Figure 10. Comparison of 2 detection methods (real time turbidimetry and HNB dye 
detection) for cell culture supernatant from HIV-1 IIIB sample. An earlier detection time by 
real time turbidimetry was observed for all primer sets except for HiLtr compared to HNB dye 
detection.  
was observed.  It was also observed that in each case except for HiLtr, time to threshold detection was 
achieved earlier by turbidimetry compared to HNB dye detection (Figure 10). 
 
 
 
 
 
 
 
 
 
  
 
4.1.2.7 Evaluation of primer mismatches  
Following the discrepancies by the 4 primer sets on analytical sensitivity and inter-assay precision, 
testing for sequence variations within subtypes (using HXB2 as reference strain) was done by 
aligning primer specific targets (F3, B3, FIP, BIP, LF and LB) employing an online  HIV sequence 
alignment tool (http://www.hiv.lanl.gov/content/sequence/QUICK_ALIGN/QuickAlign.html) from 
the Los Alamos National Laboratory.   
HiInteg primer set recorded the minimum average number of mismatches among non-B (A, C, D) 
subtypes, and at the same time showed the highest number (25) of mismatches with HIV-1 group O 
strains (Table 5). Among subtype B strains within which all the primers had been designed to target, 
the number of mismatches was as follows: HiInteg set = 1, HiP = 9, HiLtr and HiGp sets each = 14. 
The highest number of mismatches were mainly observed within the inner primers (FIP and BIP), 
whereas the least number of mismatches were observed within the outer (F3 and B3) and the loop (LF 
and LB) primers. 
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Table 5. Mismatches within primer targets for the 4 LAMP primer sets. Results show the average number 
of mismatches for the target sequences of different primer sets when aligned by an online alignment 
tool obtained from the HIV sequence database from Los Alamos National Library 
(http://www.hiv.lanl.gov/content/sequence/QUICK_ALIGN/QuickAlign.html). The least average 
number of sequence mismatches was shown by HiInteg set, whereas the highest numbers were shown 
by HiLtr and HiGP primer sets. Among HIV-1 M subtype B (in blue dotted boxes) HiInteg recorded a single 
mismatch, whereas HiLtr and HiGp recorded the highest numbers of mismatches of 14. Sequence 
alignments were based on a reference strain (HXB2) of HIV-1 group M subtype B.  
Primer  
Set 
HIV-1 group  
M 
Subtype 
Number of mismatches at targets Total No. 
   F3         B3 
       FIP 
(F1c+F2) 
      BIP 
(B2+B1c)     LF    LB Mismatches 
HiP A 2 3 4 4 3 1 17 
 
B 1 2 1 3 1 1 9 
 
C 1 2 2 3 0 2 10 
 
D 1 2 2 5 0 1 11 
 
O 1 2 5 6 4 2 20 
HiInteg A 3 1 1 1 1 0 7 
 
B 1 0 0 0 0 0 1 
 
C 3 2 0 1      1 0 7 
 
D 1 1 0 0 0 0 2 
 
O 7 3 1 6 3 5 25 
HiLtr A 1 3 5 4 0 3 16 
 
B 1 3 3 4 1 2 14 
 
C 3 4 4 6 1 2 20 
 
D 2 5 4 5 0 3 19 
 
O 3 5 7 6      0 3 24 
HiGp A 5 3 4 7 5 3 27 
 
B 4 1 2 3 3 1 14 
 
C 4 3 4 7 4 3 25 
 
D 4 1 3 2 3 1 14 
 
O 1 2 5 8 4 3 23 
 
  
 
 
 
 
4.1.2.8 Selection of primers for further evaluation 
Based on the results of analytical sensitivity and precision, HiInteg and HiP targeting the integrase 
and the p24 genes respectively were selected for further evaluations and comparisons in the LAMP 
assay. The aim was to select the most appropriate primer set which could later be used for 
quantification of clinical samples by the LAMP assay. 
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4.1.2.9 Evaluation of the sample condition 
4.1.2.9.1 Testing the matrix effect of plasma and aqueous solution 
Plasma samples were spiked with virus from cell culture supernatants and analyzed by real time 
turbidimetry. The means of values for spiked plasma and diluted cell culture supernatants (of 
identical virus concentrations) were compared in order to test whether the type of matrix tested 
influenced the rate of detection by LAMP assay. The rationale for testing matrix was due to the fact 
that under limited logistical conditions, it is sometimes not possible to obtain the required amount of 
plasma for analysis. In such a scenario it would therefore be prudent to dilute the samples in negative 
plasma or diluent in order to obtain the required volume for analysis. The findings on the matrix 
effect would therefore be very instrumental in establishing LAMP under limited logistical conditions.  
An independent T-test was performed to compare the time to threshold (Tt) values for plasma spiked 
samples and RPMI 1640 culture medium samples. There was no significant difference for plasma 
spiked samples (mean = 27, SD = 14) and RPMI 1640 medium samples (mean = 28, SD = 12); t (48) 
= 0.09. The finding thus indicated that there was no significant influence of the matrix when negative 
plasmas were spiked with viruses from cell culture supernatants. Independent testing of the samples 
by the different primer sets also showed no significant difference between HiP primers (mean = 29, 
SD = 7) and HiInteg primers (mean = 26, SD = 17); t (48) = 0.9.  Results therefore confirmed that 
regardless of the primer set used no significant influence of the matrix could be observed for the 
results generated by the LAMP assay.  
4.1.2.9.2 Specificity for HiInteg and HiP primers with negative clinical samples 
HiInteg and HiP primers were tested with HIV negative fresh plasma samples obtained from in-house 
volunteers. 70 µL of whole blood from these volunteers was also used to process DBS before they 
were tested together with their corresponding plasmas. The 5 HIV negative plasmas and their 
corresponding DBS were tested 7 times resulting in a total of 35 tests for each category. 3 HIV 
positive plasmas together with their corresponding DBS were tested 5 times resulting in a total of 15 
tests in each category. The positive controls were samples with low viral loads selected with the aim 
of minimizing the probability of cross contamination. HiInteg primers exhibited 100% specificity 
(Table 6) for each category. HiP exhibited reduced specificities ≥89% for plasma and ≥91% for DBS 
due to false positive detections (Table 7). Although not being the main focus, the lower sensitivity 
realized for HiInteg primers was expected since previous findings on analytical sensitivity and 
precision analysis had shown reduced sensitivity for lower viral loads.  
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Table 6. Specificity analysis of HiInteg and HiP sets of primers for selected clinical samples. HiP set 
showed a reduced specificity and predictive values as a result of false positive detections. The low 
sensitivity by HiInteg set was expected since the 3 positive clinical samples with low viral loads were 
selected to reduce the risk of cross contamination. Specificity results were calculated within 95% 
confidence interval (CI) 
Table 7. False positive results obtained by the HiP primer set for HIV negative plasma and DBS. False 
positive results (in square red boxes) by HiP were realized for 4 samples, while 1 positive sample was not 
detected  in each sample category.  False positive results occurred only with Tt values >30 minutes. In 
the previous analysis HiP showed high sensitivity with a detection time ≤30 minutes for positive samples. 
These results prove that weak positive results by HiP primers with Tt values >30 minutes should be 
interpreted with caution. Tt – time to threshold detection, Tt >60 meant no signal was obtained within 
60 minutes. Viral load (VL) was quantified by Abbott m2000rt system. 
 
                                                       Primer set 
Test parameter   HiInteg                            HiP 
       Plasma    DBS    Plasma DBS 
Sensitivity %  (CI): n =15 40%    (16 - 68) 7%      (1 - 32)  60% (32 - 84) 67% (38 - 88) 
Specificity % (CI) : n =35 100% (90 - 100) 100% (90 - 100)  89%  (73 - 97) 91%  (77 - 98) 
PPV % 100% (54 - 100) 100% (17 - 100)  69% (39 - 91) 77% (46 - 95) 
NPV % 80%   (65 -  90) 71%   (57 -  83)  84%   (68 -  94) 86%   (71 -  95) 
 
 
 
HiP set of primers showed earlier positive results compared to HiInteg set, for all detected samples 
(Table 7), and in 2 cases HiP set detected even samples <1,000 copies/mL. Although previously false 
positive results had been observed due to contamination, contamination was ruled out for these results 
shown by HiP, since not all negative samples including negative controls were falsely detected by the 
set. False negative detections were also random within the 3-day period of analysis. Furthermore 
positive controls of low viral loads had been carefully selected to minimize the risks of 
contamination. The finding of a potential low specificity with HiP primers provided a preference for 
HiInteg primers for the detailed analysis of clinical samples. 
Sample ID Patient details Plasma Dry Blood Spot 
 
VL (Abbott) Sex Time to detection(mins) Time to detection (mins) 
  Copies/mL          HiInteg        HiP      HiInteg          HiP 
N001C      0 Male >60 >60 >60 39 
N002C        0 Male >60 37.06 >60 39 
N003C      0 Male >60 37.24 >60 33.54 
N004C      0 Female >60 43.06 >60 34.24 
N005C      0 Female >60 >60 >60 >60 
W001C      0 Female >60 >60 >60 >60 
P001C   2418 
 
48.18 30.18 50.3 26.12 
P002C     753 
 
>60 >60 >60 36.48 
P003C     612   >60 31 >60 >60 
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4.1.3 Evaluation of HiInteg primers for potential use in analysis of clinical samples 
After pre-analysis of the HiInteg set of primers was selected for eventual use in semi-quantitative 
detection of HIV-1 M:B and non-B subtypes, due to the qualities it showed compared to the other 3 
sets of primers. 
4.1.3.1 Plasma, dry blood spots and dry plasma spots 
Studies have reported potential usability of LAMP technology with non-extracted plasma and whole 
blood samples (Curtis et al., 2008; Curtis et al., 2009). A total of 18 positive plasma samples, 2 
negative samples and their corresponding dried blood spot samples were selected for testing. These 
samples were then categorized as (i) nucleic acid extracted plasma samples (ii) heated non-extracted 
plasma samples (iii) non-extracted plasma samples treated with a lysis buffer and (iv) dry blood spot 
samples, based on their mode of treatment before analysis with LAMP assay. 
i. Nucleic acid extracted plasmas: Samples were treated as described in chapter 3.2.2.2.1.1 
under materials and methods and then used for comparisons during evaluations in steps iii and 
iv. 
ii. Nucleic acid extracted dry DBS: Samples were treated as described in chapter 3.2.2.2.1.2 
under materials and methods and used for comparisons during evaluations in steps iii and iv. 
iii. Heated non-extracted plasma samples: A total of 8 HIV positive plasmas (which included 5 
samples detected by the Abbott m2000rt system and 3 samples below detection threshold) and 
2 negative plasmas were heat-treated and tested by real time turbidimetry together with their 
corresponding extracted plasma and dry blood spot. All (5/5) the samples above detection 
threshold, none (0/3) below detectable threshold and none (0/2) of the negative samples were 
detected by LAMP among extracted plasmas.  Similarly all (5/5) the samples above detection 
threshold, none (0/3) below detectable threshold and none (0/2) of the negative DBS samples 
were detected among the extracted DBS. In contrast none (0/8) of the heat-treated non-
extracted plasmas using either 5.5 µL or 9.5 µL could be detected by LAMP assay. 
iv. non-extracted plasma samples treated with a lysis buffer: A total of 9 HIV positive 
samples and their corresponding extracted plasma and DBS were analyzed. In total, 6/8 
extracted plasmas, 5/8 DBS and none (0/8) of the non-extracted plasmas were detected by 
LAMP assay.  
Although LAMP assay showed the potential for use by both extracted plasma and dry blood spot 
samples, it did not display this ability with non-extracted plasma samples. 
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4.1.3.2 Nucleic acid sequence analysis of primer target regions 
Using different sequences generated in-house and from the HIV database, sequences of various HIV-
1 group M:B and non-B, HIV-1 group O and HIV-2 were selected and aligned with the primer 
binding sites to check for anticipated primer mismatches. Sequences for HIV-1 group O and HIV-2 
were selected purposely for comparisons and due to the fact that these samples had not been detected 
by HiInteg primers. The results show an average of 3 mismatches for HIV-1 M:B and non-B subtypes 
at the outer forward (F3) region, 1 mismatch on outer reverse (B3) and an average of 1 mismatch for 
the inner primers (FIP and BIP) across all the subtypes (Figure 11a and Figure 11b). Loop target 
primers show an average of 1 mismatch. Contrary to findings for HIV-1 group M, group O (Figure 
11c) and HIV-2 (Figure 11d) show in average ≥22 mismatches  indicating that this set of primers is 
not suitable for detecting the RNA of these viruses (see also page 61).  
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Figure 11a. Nucleic acid sequence alignment patterns of HIV-1 M subtypes B and D viruses. HiInteg primers show an average of 1 mismatch per 
subtype within B and D subtypes. Molecular characterization has shown subtypes B and D to be sub-subtypes (Los Alamos, 2008).  Epidemiologically 
subtype D is found in Kenya. This primer set was designed according to the IIIB virus sequence. Incomplete sequences are shown by dashes (non 
dots) at the primer targets. 
10 20 30 40 50 60 70 80 90 100
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....
LAMP primer targets GGTAAGAGATCAGGCTGAACATC------AGACAGCAGTACAAATGGCA-----ATTCATCCACAATTTTAA-----AAGAAAAGGGGGGATTGGGG--
B.FR.83.HXB2_LAI_IIIB_BRU.K034 .......................------....................-----..................-----....................--
B.DE. MVP899-87 .A.....................------....................-----..................-----....................--
B.GA.88-OYI A......................------....................-----...T..............-----....................--
B.NL.00.671_00T36.AY423387 .........G.............------....................-----...T..............-----....................--
B.TH.90.BK132.AY173951 .......................------.A..................-----...T..............-----....................--
B.US.98.1058_11.AY331295 .......................------....................-----..................-----.....G..............--
D.CD.83.ELI.K03454 ............A..........------....................-----..................-----.....G.A............--
D.CM.01.01CM_4412HAL.AY371157 ............A..........------....................-----......T...........-----....................--
D.TZ.01.A280.AY253311 ............A........C.------....................-----...T..............-----....................--
D.CD.85.2226.M ............A.....G....------.......T............-----..................-----....................--
D.UG.94.94UG114.U88824 .........A..A..........------....................-----..................-----....................--
D.ZA.86.R482 .........C..A..........------....................-----..................-----....................--
110 120 130 140 150 160 170 180 190
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....
LAMP primer targets --AGTGCAGGGGAAAGAATAGTAGAC------GCAACAGACATACAAACTAAAG---------------GGGTTTATTACAGGGACAGCAG---
B.FR.83.HXB2_LAI_IIIB_BRU.K034 --........................------......................---------------....................-----
B.DE. MVP899-87 --..................A....T------......................---------------.............A........---
B.GA.88-OYI --.......................T------..T...................---------------......................---
B.NL.00.671_00T36.AY423387 --..................A.....------......................---------------....................-----
B.TH.90.BK132.AY173951 --........................------..............G.......---------------....................-----
B.US.98.1058_11.AY331295 --...........G......A.....------.................C....---------------....C...............-----
D.CD.83.ELI.K03454 --..................A.....------......................---------------.............A......-----
D.CM.01.01CM_4412HAL.AY371157 --..................A.....------......................---------------....................-----
D.TZ.01.A280.AY253311 --........A.........A.....------...T.....T.........C..---------------....................-----
D.CD.85.2226.M --...........G......A.....------......................---------------......................---
D.UG.94.94UG114.U88824 --..................A....T------....................G.---------------....................-----
D.ZA.86.R482 --..................C..C..------T.....................---------------......................---
....|....|....|....|....|..
LAMP primer targets -----CCACTTTGGAAAGGACCAGC  
B.FR.83.HXB2_LAI_IIIB_BRU.K034 -------------------------  
B.DE. MVP899-87 -----..................----
B.GA.88-OYI -----....................  
B.NL.00.671_00T36.AY423387 -------------------------  
B.TH.90.BK132.AY173951 -------------------------  
B.US.98.1058_11.AY331295 -------------------------  
D.CD.83.ELI.K03454 -------------------------  
D.CM.01.01CM_4412HAL.AY371157 -------------------------  
D.TZ.01.A280.AY253311 -------------------------  
D.CD.85.2226.M -----...A................  
D.UG.94.94UG114.U88824 -------------------------  
D.ZA.86.R482 -----...A................  
                                                                         F3 (4721      4743)                            F2 (4747      4766)                    LF  (4769      4786)               F1c  (4787      4806) 
 
 
 
 
 
                                                                            B1c  (4812      4835)                                  LB  (4842      4863)                                                       B2  (4900      4921) 
 
 
 
 
 
                                                                                B3  (4926      4945)  
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10 20 30 40 50 60 70 80 90 100
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....
LAMP primer  targets GGTAAGAGATCAGGCTGAACATC------AGACAGCAGTACAAATGGCA-----ATTCATCCACAATTTTAA-----AAGAAAAGGGGGGATTGGGG--
HXB2 .......................------....................-----..................-----....................--
A1.UG92.037 ......G..G..A..........------....................-----G.....T...........-----....................--
A1.SE.95.UGSE8131 .........G..A........C.------G...................-----......T...........-----....................--
A.CD.97.9 KCC ......G..G..A..G.......------.A..................-----......T...........-----....................--
C.Et.86.E.TH2220 .........A..A.....G..C.------....................-----......T...........-----.....G..............--
C.ES.06.E S. ............A.....G..C.------....................-----......T...........-----....................--
C.ZA.001.176MB ............A.....G..C.------....................-----......T...........-----....................--
F1.BE.93.VI850 ............A..........------....................-----..................-----....................--
F2.CM.95.MP257 A...........A..........------..........G.........-----......T...........-----....................--
G.PT.x.PT2695 ...C..G.....A........C.------.............G......-----......T...........-----....................--
H.CF.90.056 .........C..A..A.....C.------....................-----......T...........-----....................--
J.SE.93.SE7887 .........A..A........C.------....................-----......A...........-----....................--
U.NL.95H10 986 ............A..........------....................-----......T...........-----....................--
AE.JP.DR2594 .........G..A........C.------....................-----......T..T........-----....................--
110 120 130 140 150 160 170 180 190
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|...
LAMP primer  targets --AGTGCAGGGGAAAGAATAGTAGAC------GCAACAGACATACAAACTAAAG-------------GGGTTTATTACAGGGACAGCAG----
HXB2 --........................------......................-------------......................----
A1.UG92.037 --..................A.....------...T.....T............-------------......................----
A1.SE.95.UGSE8131 --..................A.....------......................-------------......................----
A.CD.97.9 KCC --........................------.........T............-------------......................----
C.Et.86.E.TH2220 --..................A....T------...T..........G.......-------------.............A........----
C.ES.06.E S. --..................A.....------........T.............-------------.............A........----
C.ZA.001.176MB --..................A.....------......................-------------.............A........----
F1.BE.93.VI850 --..................A.....------T..................G..-------------......................----
F2.CM.95.MP257 --..................A.....------......................-------------.........T............----
G.PT.x.PT2695 --..................A.....------...T....T.............-------------.........T..........C.----
H.CF.90.056 --..................A.....------......................-------------......................----
J.SE.93.SE7887 --..................A.....------...................G..-------------......................----
U.NL.95H10 986 --..................A.....------...................C..-------------......................----
AE.JP.DR2594 --..................A.....------......................-------------......................----
210 220
....|....|....|....|.
LAMP primer  targets -CCACTTTGGAAAGGACCAGC
HXB2 -....................
A1.UG92.037 -...A................
A1.SE.95.UGSE8131 -...A................
A.CD.97.9 KCC -...A................
C.Et.86.E.TH2220 -..TA................
C.ES.06.E S. -..TA................
C.ZA.001.176MB -..TA................
F1.BE.93.VI850 -...G................
F2.CM.95.MP257 -...G................
G.PT.x.PT2695 -...A................
H.CF.90.056 -...A................
J.SE.93.SE7887 -...A................
U.NL.95H10 986 -...A................
AE.JP.DR2594 -...A................
                                                          F3 (4721      4743)                                    F2  (4747      4766)                 LF  (4769      4786)                       F1c  (4787      4806) 
 
 
 
 
 
                                                           B1c  (4812      4835)                            LB  (4842      4863)                                         B2  (4900      4921) 
 
 
 
 
 
                                                       B3  (4926      4945) 
 
 
 
Figure 11b. Nucleic  acid sequence alignment of selected HIV-1 M: non B, non D isolates with HiInteg LAMP primers. An average of 3 mismatches was 
detected for the F3 forward primer. F3: Forward primer, F2: Forward inner primer, LF: Loop forward, F1c: Forward inner reverse complementary primer, 
B1c: Backward inner reverse complementary primer, LB: Loop backward, B2: Backward inner primer, B3: Backward primer. FIP (F1c+ F2), BIP (B2 + B1c). 
Subtype A and C are prevalent in Kenya. 
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....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
LAMP Primer sets GGTAAGAGATCAGGCTGAACATC-----AGACAGCAGTACAAATGGCA------ATTCATCCACAATTTTAA-------AAGAAAAGGGGGGATTGGGG-
HXB2 .......................-----....................------..................-------....................-
MVP2549-95 A..G..G..C..A..A......T-----GA..................------......T...........-------....................-
MVP5180-91 ...G..G..C..A..A..G...T-----.A..................------C..TG.T...........-------....................-
MVP2171-94 ......G..C..A..A.....CT-----GA..................------...TG.T...........-------....................-
MVP2901-94 ...G..G..C..A..A..G..CT-----.A..................------...TG.T...........-------....................-
MVP5267-95 ...G..G..C..A..A.....CT-----GA..................------...TG.T...........-------....................-
FLI2000-00 ...G..G..C..A..A..G..CT-----....................------...TG.T..T........-------...................A-
FLI5066-03 ...G..G..C..A..A.....CT-----.A..................------...TG.T...........-------....................-
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....
LAMP Primer sets --------AGTGCAGGGGAAAGAATAGTAGAC------GCAACAGACATACAAACTAAAG-----------GGGTTTATTACAGGGACAGCAG------
HXB2 --------........................------......................-----------......................------
MVP2549-95 --------.C......A......T..A.....------...T..C.A........A.C..-----------....C........A........------
MVP5180-91 --------.C.........G...C..A.....------...T..C.A........A.C..-----------....C........A..T.....------
MVP2171-94 --------.C......A..C......A.....------...T..C..........A.C..-----------....C........A........------
MVP2901-94 --------.C......A..G...T..A.....------...T..C.A........A.C..-----------......................------
MVP5267-95 --------.C......A.....G...A.....------...T..C.A........A.C..----------------........A........------
FLI2000-00 --------.C......A......T..A.....------...T..C.A........A.C..-----------.TC.A.TAC.G..AC.GCAG..------
FLI5066-03 --------.C......A..G..G...A.....------...T..C..........A.C..-----------....C........A........------
....|....|....|....|....|...
LAMP Primer sets --------CCACTTTGGAAAGGACCAGC
HXB2 --------....................
MVP2549-95 --------..TA.............G..
MVP5180-91 --------..TA.............G..
MVP2171-94 --------..TA.............G..
MVP2901-94 --------..TA.............G..
MVP5267-95 --------..TA.............G..
FLI2000-00 --------..TA.............G..
FLI5066-03 --------..TA.............G..
                                                      F3 (4721      4743)                                F2  (4747      4766)                   LF  (4769      4786)                  F1c  (4787      4806) 
 
 
 
 
 
                                                              B1c  (4812      4835)                               LB  (4842      4863)                                              B2  (4900      4921 
 
 
 
 
 
                                                                 B3  (4926      4945)  
 
 
 
 
Figure 11c. Nucleic acid sequence alignment of HIV-1 group O sequences with HiInteg primers. The results show mismatches at the outer primers F3 and B3 
and the inner primers (FIP and BIP). Mismatches at these 2 positions were considered as the reasons for insufficient binding of HiInteg primers among 
group O viruses. F3: Forward primer, F2: Forward inner primer, LF: Loop forward, F1c: Forward inner reverse complementary primer, B1c: Backward inner 
reverse complementary primer, LB: Loop backward, B2: Backward inner primer,  B3: Backward primer. FIP (F1c + F2), BIP (B2 + B1c). Until now HIV-1 group 
O has not been detected in Kenya. 
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Figure  11d.  Nucleic acid sequence alignment of HIV-2 with HiInteg set of primers. Results show an average mismatch of ≥5 per primer target.  The 
high number of mismatches shows insufficient primer binding and thus the failure to detect HIV-2 virus RNA. F3: Forward primer, F2: Forward inner 
primer, LF: Loop forward, F1c: Forward inner reverse complement primer, B1c: Backward inner reverse complement primer, LB: Loop backward, B2: 
Backward inner primer,  B3: Backward primer. FIP (F1c + F2), BIP (B2 + B1c). HIV-2 is not prevalent in Kenya 
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . .
LAMP primer  targets GG T A A GA GA T C A GGC T GA A C A T C - - - - - - A GA C A GC A G T A C A A A T GGC A - - - - - A T T C A T C - C A C - A A T T T T A A - - -
B.FR.1983.HXB2_copy_LAI.AF0338 . . . . . . . . . . . . . . . . . . . . . . . - - - - - - . . . . . . . . . . . . . . . . . . . . - - - - - . . . . . . . - . . . - . . . . . . . . - - -
MVP11971 A A . T . . . . . A . . A . . - A . . T . C A - - - - - - . A . . . A T . . . . . T . . . . . . . - - - - - G . . . . . T G . . T G . . . . . . . . - - -
MAC.US.x.239.M33262 A A . C . . G . . A . . A . . - A . . T T C A - - - - - - . A . . C A T . . . . T T . . . . . . . - - - - - G . . . . . T G . . T G . . . . . . . . - - -
H2A.GW.87.CAM2CG.D00835 A A . T . . . . . A . . . . . - A . . T . C A - - - - - - . A . . . A T . . . . . T . . . . . . . - - - - - G . . . . . T G . . T G . . . . . . . . - - -
H2B.GH.86.D205.X61240 A C . C . . . . . C . . A . . - A G T A T C A - - - - - - . . . . . . T T . . . . T . . . . . . . - - - - - . C . . . C T G . . T G . . . . . . . . - - -
H2AB.CI.90.7312A.L36874 . A . C . . . . . . . . . . . - A G T A T C A - - - - - - . A . . . . T T . . G . T . . . . . . . - - - - - GC . . . . T G . . T G . . . . . . . . - - -
H2A.DE.x.PEI2.U22047 A A . T . . . . . G . . . . . - A . . T . C A - - - - - - . A . . . A T . . . . T T . . . . . . . - - - - - G . . . . . T G . . T G . . . . . . . . - - -
H2A.CI.88.UC2.U38293 A A . T . . . . . A . . . . . - T . . T . C A - - - - - - . A . . . A T . . . . . T . . . . . . . - - - - - G . . . . . T G . . T G . . . . . . . . - - -
MAC.US.x.17EC1.AY033233 A A . C . . G . . A . . A . . - A . . T T C A - - - - - - . A . . C A T . . . . T T . . . . . . . - - - - - G . . . . . T G . . T G . . . . . . . . - - -
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
LAMP primer  targets - A A GA A A A GGGGGGA T T GGGG - - - - - A G T GC A GGGGA A A GA A T A G T A GA C - - - - - - GC A A C A GA C A T A C A A A C T A A A G - -
B.FR.1983.HXB2_copy_LAI.AF0338 - . . . . . . . . . . . . . . . . . . . . - - - - - . . . . . . . . . . . . . . . . . . . . . . . . - - - - - - . . . . . . . . . . . . . . . . . . . . . . - -
MVP11971 - . . . . . GG . . A . . A . . A . . . . - - - - - . C C C . . . C A . . . . . . C . . A . C A . T - - - - - - A . C . . . . . A C A . G . . . T A C . . T - -
MAC.US.x.239.M33262 - . . . . . GG . . A . . A . . A . . . . - - - - - . C . C . . . C A . . . . . . T . . A . T A . . - - - - - - A . T . . . . . A C A . G . G . T A C . . T - -
H2A.GW.87.CAM2CG.D00835 - . . . . . GG . . A . . A . . A . . . . - - - - - . C . C . . T C A . . . . . . C . . A . C A . T - - - - - - A . C . . . . . A C A . G . G . T A C . . T - -
H2B.GH.86.D205.X61240 - . . . . . GG . . A . . A . . A . . . . - - - - - . C C C . T . C A . . . . . . C . . . . T A . . - - - - - - A . C . . . . . GC A . G . . . T A C . G T - -
H2AB.CI.90.7312A.L36874 - . . . . . GG . . A . . A . . A . . . . - - - - - . C C C . T . C A . . G . . . C . . . . T A . . - - - - - - A . C . . . . . A C A . G . . . T A C . . T - -
H2A.DE.x.PEI2.U22047 - . . . . . GG . . A . . A . . A . . . . - - - - - . C C C . . . C A . . . . . . C . . A . C A . T - - - - - - A . C . . . . . A C A . G . . . T A C . . T - -
H2A.CI.88.UC2.U38293 - . . . . . GG . . A . . A . . A . . . . - - - - - . C C C . G . C A . . . . . . C . . A . C A . . - - - - - - A . C . . . . . A C A . G . . . T A C . . T - -
MAC.US.x.17EC1.AY033233 - . . . . . GG . . A . . A . . A . . . . - - - - - . C . C . . . C A . . . . . . T . . A . T A . . - - - - - - A . T . . . . . A C A . G . G . T A C . . T - -
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . .
LAMP primer  targets - - - - - - - GGG T T T A T T A C A GGGA C A GC A G - - - - - - - - - - - - - - - - - - C C A C T T T GGA A A GGA C C A GC
B.FR.1983.HXB2_copy_LAI.AF0338 - - - - - - - . . . . . . . . . . . . . . . . . . . . . . - - - - - - - - - - - - - - - - - - . . . . . . . . . . . . . . . . . . . .
MVP11971 - - - - - - - T C C . C C . A A GA . A A A . T T C A . A - - - - - - - - - - - - - - - - - - . T . T . A C A . . G . A . G . A GA G
MAC.US.x.239.M33262 - - - - - - - . . . . C . . . . . . . . A . . A G . . . . - - - - - - - - - - - - - - - - - - . A . . . G . . . . . G . . . . . C . G
H2A.GW.87.CAM2CG.D00835 - - - - - - - . . . . C . . . . T . . . A . . A G . . . . - - - - - - - - - - - - - - - - - - . A G T . G . . . . . . . . . . . T . G
H2B.GH.86.D205.X61240 - - - - - - - A . . . C . . . . . . . . A . . A G . . . . - - - - - - - - - - - - - - - - - - . A . . . C . . . . . G . . . . . T . G
H2AB.CI.90.7312A.L36874 - - - - - - - A . . . C . . . . . . . . A . . A G . . . . - - - - - - - - - - - - - - - - - - . A . . . C . . . . . G . . . . . T . G
H2A.DE.x.PEI2.U22047 - - - - - - - . . . . C . . . . T . . . A . . A G . . . . - - - - - - - - - - - - - - - - - - . A G . . G . . . . . . . . . . . T . G
H2A.CI.88.UC2.U38293 - - - - - - - A . . . C . . . . . . . . A . . A G . . . . - - - - - - - - - - - - - - - - - - . A G . . G . . . . . . . . C . . T . G
MAC.US.x.17EC1.AY033233 - - - - - - - . . . . C . . . . . . . . A . . A G . . . . - - - - - - - - - - - - - - - - - - . A . . . G . . . . . G . . . . . C . G
  F1c (4787    4806)  B1c (4812    4835) LB (4842     4863) 
    B2 (4900    4921) B3 (4926     4945) 
 
 
 
 
 
 
 
                                                                                                     
 
 
  
 
 
 
 
 
F3 (4721    4743)     F2 (4747     4766) LF (4769     4786)   
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4.2 Analytical sensitivity and estimation of lower threshold limits 
4.2.1 Analytical sensitivity 
Analytical sensitivity (ASe) refers to the minimum number of copies in a sample that can be 
measured accurately with an assay. The standard performance parameters of diagnostic quantitative 
assays are the lower limit of detection (LLOD) and the lower limit of quantification (LLOQ). The 
LLOD is the lowest amount of the analyte detectable by an assay in a single reaction with a certain 
degree of certainty, whereas the LLOQ refers to the lowest amount of the analyte which can be 
reproducibly quantified. Methods for determining LLOD and LLOQ in a chemical reaction have 
previously been defined (Haeckel et al., 1998; Mikkelsen and Cortón, 2004), however they have been 
found unsuitable for quantitative assays. Guidelines from the World Organization of Animal Health 
recommend that LLOD be determined as the end point dilution at which 50% of the tested samples 
are positive (World Organization for Animal Health (OIE), 2013). 
Using an in-house software (Ceres) developed by the Virus Diagnostic Department of the Max von 
Pettenkofer-Institute, half maximal effective concentration (EC 50) of viral load panels of (0.2x101 to 
2.9x106 copies/mL) of IIIB and MVP899-87 viruses (tested by Abbott m2000rt system) was 
determined in the LAMP assay. The EC 50 was used as an estimator for LLOD, whereas the LLOQ 
was estimated at a viral load in which ≥95% detection by LAMP was achieved. Samples were tested 
between 10 to 18 times by the LAMP assay and the percentage of positive detections calculated. 
The LLOD was attained at 1.2x103 copies/mL (Figure 12) whereas LLOQ was attained at a 
concentration of 9.8x103 copies/mL. It was also observed that viral loads of above 3x103 copies/mL 
were detected at the rate of more than 70%. These results are consistent with those already obtained 
earlier where samples with low viral loads presented a reduced precision, with only a few detected or 
detection obtained after a repeat test. 
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Figure 12.  Estimation curve for lower limit of detection (LLOD) and lower limit of 
quantification (LLOQ) for LAMP compared to the Abbott m2000rt system.   LAMP response 
rate (vertical axis) was tested using HiInteg set of primers for cell culture supernatants of IIIB 
and MVP899-87 representing HIV-1 M subtype B virus. The figure shows half maximal 
concentration (EC 50) for detection, which estimates LLOD by LAMP, detected at 1,200 
copies/mL. The lower limit of quantification (LLOQ) estimated at 95% detection rate (red 
dotted lines) was reached at 9,800 copies/mL. 
 
 
 
 
  
 
 
 
 
 
 
 
4.2.2 Generation of a mathematical model for estimation of viral load by LAMP assay 
A major feature used in the evaluation of the results by LAMP technology is the generation of large 
amounts of magnesium pyrophosphate deposits as a visible white precipitate (Mori et al., 2001), 
which is produced in proportion to the amount of amplified products. Real time turbidimetry of the 
by-product can be measured and the results estimated based on the time to threshold (Tt) detection.  
Since linearity of the assay based on time had been realized across a dilution panel from HIV cell 
culture supernatant of IIIB sample, the next part of this study was then to test for a linear relationship 
between the known viral load and time to detection. Viral loads for IIIB and MVP899-87 were first 
quantified by the Abbott m2000rt system and 10-fold dilutions for each sample material made from 
higher dilutions of 2.9x106 and 1.2x106 copies/mL. Virus concentrations therefore ranged from 
0.12x101 to 2.9x106 copies/mL. Testing was done 4 times by LAMP turbidimetry and the results 
obtained were used to test for correlation between time and viral load and eventually to generate a 
regression equation for estimation of corresponding viral loads in LAMP. Calculations for estimation 
parameters were done using MS-Excel version 14 (a computer package from Microsoft) 
http://www.microsoft.com/en-us/download/details.aspx?id =5829. 
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Figure 13. Estimation curves for viral load quantification by LAMP assay. Results show a 
linear estimation curve (straight line) and a non-linear estimation curve (dotted line) both 
generated by HiInteg primer sets using HIV cell culture supernatant of IIIB virus.  A high 
regression coefficient of 0.99 was generated for both curves indicating a negligible 
dispersion from the regression line between viral load measured by Abbott m2000rt system 
and time to detection by LAMP assay. An average of 3 minutes was found as the difference 
between a 1log10 difference. Testing was done within a span of 4 days. Tests 1, 2, 3 and 4 
represent the results generated for each day. 
Since the task was to compare and relate an assay for semi-quantitative detection to a purely 
quantitative, two estimation curves, a linear curve y = -2.263 ln(x) + 59.309 and a non-linear curve y 
= 63.526x-0.067 (Figure 13) were generated and used for viral load estimations. From the results it was 
realized that the average time for 1log10 difference was 3 minutes. The 3 minute interval however was 
found to increase as the viral load decreased.  
 
 
 
 
 
 
 
 
 
 
  
 
No significant difference was found for the viral loads estimated from time by the two curves when 
20 different samples with known viral loads were tested by LAMP and the estimated viral loads 
compared with those of the Abbott m2000rt system.  In each case a correlation Rs (20) = 0.8 and a 
linear regression R2 (20) = 0.99 were achieved between Abbott m2000rt and the LAMP assay. These 
results therefore showed that regardless of the estimation model used between the two estimation 
curves no major difference would be realized, and if any, it would be insignificant to alter the results 
by a wider margin of estimation. The linear estimation curve was thus preferred for subsequent 
estimations, mainly due to its ease of use. 
53 
 
Figure 14. Quality control tests for assessment of linearity. Results show a linear 
correlation between LAMP and Abbott m2000rt assay for cell culture 
supernatants of  IIIB, R
2  
(11)= 0.99 and MVP899-87, R
2
 (11) = 0.98 viruses.  
4.2.3 Quality control 
A quality control test was performed to check the linearity of the LAMP viral load values in 
comparison to the viral loads determined by the Abbott m2000rt system using the linear estimation 
curve. Cell culture supernatants of IIIB and MVP899-87 samples with viral loads of approximately 
10 to 2.1x107 copies/mL were used. The results obtained showed again a linear correlation (as had 
previously been shown in Figure 13) between the two groups of LAMP viral loads and the viral loads 
of the Abbott m2000rt system (R2 (11) = 0.99 for IIIB and R2 (11) = 0.98 for MVP899-87) as shown 
in Figure 14. The results further confirmed the reliability of the LAMP assay for samples with high 
viral loads which also showed high concordance between the two assays. 
 
 
 
 
 
 
 
 
 
4.2.3.1 Precision tests based on estimated viral loads generated by linear estimation curve 
4.2.3.1.1 Intra- and inter-assay precision testing based on viral load 
A total of 58 tests of cell culture supernatants of varying viral load measurements by Abbott m2000rt 
were tested in different frequencies during the same runs by LAMP assay, and the viral loads 
obtained used to evaluate the intra-assay precision. Similarly, 21 tests of cell culture supernatants of 
varying viral loads were tested on 3 different days and the LAMP viral loads used to evaluate inter-
assay precision. All the viral load values obtained by LAMP were first transformed into a log scale 
for ease of precision analysis. The precision was evaluated based on standard deviations and not 
based on coefficient of variations as recommended for viral load test assays (Bustin et al., 2009).  
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Table 8.  Inter- and intra-assay precision test results showing log standard deviations between Abbott 
m2000rt system and LAMP assay. Results showed an increase in precision (shown by lower standard 
deviations) with higher viral loads. N/A refers to sample viral loads which were not tested, mainly due to 
viral loads below the threshold of detection established for LAMP assay. 
Apart from 12 samples within the viral load range of 3log10 and 9 samples within the range of 4log10 
which presented 1.3log10 and 1.2log10 deviations for intra-assay and inter-assay respectively, all other 
viral load samples were within the accepted 1log10 standard deviation range. In both cases the lowest 
standard deviations were recorded within viral loads of 5log10 copies/mL indicating a strong 
correlation between LAMP and Abbott m2000rt system within this margin. The results realized for 
samples with 3log10 viral load values were in concordance with those realized during the precision 
analysis where lower viral loads presented lower precision in detection. Further the LLOQ for this 
assay was calculated at 9.8x103 copies/mL whereas the LLOD was calculated at 1.2x103 copies/mL, 
results which could also explain the log difference realized for this group of samples, since detection 
of a sample would not necessarily mean precise quantification.  As shown in Table 8 and Table 9 
there was a general decrease in the variations (hence increased correlation) between Abbott m2000rt 
system and LAMP assay as the viral load increased, suggesting a higher precision and increased rate 
of viral detection at higher viral loads. 
Test Statistic                                                                           Results 
 
Viral load  
log10(cop/mL) 
Frequency  of 
testing 
Mean 
log10 
standard 
deviation x log10 
Coefficient of 
variation (%) 
      
Intra-assay precision 1  N/A   -          -       - 
        (n  = 58) 2     4 2.1        0.5       23 
 
3    12 2.9        1.3       46 
 
4    14 4        1       24 
 
5    16 5.4        0.5         9 
 
6    12 4.73        0.7       15 
Inter-assay precision 
                (n  = 21) 1    N/A    -          -         - 
 
2    N/A    -          -         - 
 
3       3  1.12         1        87 
 
4       9  3.2         1.2        37 
 
5       6   5          0.4         9 
 
6       3   5.4          0.4         7 
 
 
 
4.2.3.1.2 Inter-investigator variation 
A panel of HIV cell culture supernatants of various viral loads was analyzed by 2 independent 
investigators within a duration span of 7 days. Results were analyzed independently by the two 
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Table 9.  Inter-investigator precision between two independent investigators in the same laboratory. The 
results showed a higher precision (lower standard deviation) between the investigators for samples with 
high viral loads, and a reduced precision (standard deviation 1.7log10) for samples in the 3log10 viral load 
category. The findings were consistent with previous findings which have shown that the precision 
increases with higher viral loads. 
investigators and tested for precision and correlation. Samples with high viral loads recorded higher 
precisions and lower standard deviations (Table 9). A strong correlation R2 (11) = 0.75 was also 
calculated for results of both investigators. Lower precisions with low viral loads as observed for the 
3log10 group of samples have already been discussed. The findings show that the accuracy of this 
assay is investigator independent. The results however cannot be interpolated to different 
environmental conditions as the laboratory conditions in which the tests were done were identical for 
both investigators. 
Test Statistic                                                                           Results 
 
Viral load  
Frequency 
Mean      
log10 
standard deviation  
x log10 
Coefficient of 
variation (%) log10(cop/mL) 
Inter-investigator 
Precision 
1         N/A        -                   -              - 
2         N/A        -                   -              - 
 
3 6 1.5 1.7 110 
 
4 6 3.3 0.4 11.6 
 
5 6 4.6 0.3 6.8 
 
6 6       5.0                   0.2 4.8 
 
 
 
4.2.4 Analysis of HIV-1 subtypes from cell culture supernatants 
A total of 166 HIV-1 containing cell culture supernatants were tested by LAMP and Abbott m2000rt 
system and the results of their viral loads compared. The cell culture supernatants included subtypes 
A1 (n = 2), B (n = 144), C (n = 5), D (n = 5), E (n = 2), F1 (n = 2), F2 (n = 3) and G (n = 5). A 
positive linear correlation Rs (166) = 0.7 was obtained with a slope R
2 (166) = 0.6 for the two assay 
platforms (Figure 14). Generally 60% (R2 (166) = 0.6) of the results by LAMP assay were within 
≤1log10 of those results obtained by Abbott m2000rt system. The results also showed that viral load 
values obtained by the LAMP assay were lower compared to those obtained by the Abbott m2000rt 
system. The results also showed that >1log10 difference between the two assays was realized mainly 
by HIV-1 non-B subtypes. As part of the calibration process for the LAMP assay, a standard cell 
culture supernatant sample of MVP899-87 virus with a viral load of 2.1x106 copies/mL was used as 
an internal positive control. The expected time to threshold detection of this internal control by 
LAMP was between 28.30 to 30.0 minutes. 
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Figure 15. Correlation analysis for cell culture supernatant samples of 
various HIV-1 subtypes. A direct linear correlation Rs= 0.7 between LAMP 
assay and Abbott m2000rt was observed. The results showed 60% of the 
viral load measurements within the regression slope (±log10 copies/mL). 
These results also indicated potential challenges with subtype specificity for 
LAMP assay with HiInteg primers.  
 
 
 
 
 
 
 
 
 
4.3 Testing and analysis of clinical patient samples with LAMP assay 
Clinical samples tested in this study were categorized into four main categories namely, 
i. Kenyan plasma samples analyzed in Nairobi 
ii. Kenyan plasma samples analyzed in Munich 
iii. Kenyan Dry Blood Spot samples analyzed in Munich 
iv. Munich plasma samples analyzed in Munich. 
i. Kenyan plasma samples analyzed in Nairobi: This panel consisted of 135 samples (87 HIV 
positive and 48 HIV negative) with viral loads between 0 (undetectable) to 106 copies/mL 
tested by Abbott m2000rt system. HIV negative samples were first tested by rapid diagnostic 
kits (Determine ®) routinely used in Kenya for HIV 1/2 antibody detection. Anti-HIV 
negative plasmas and those undetected by Abbott m2000rt system were used to test the 
specificity of the LAMP assay. 
ii. Kenyan plasma samples analyzed in Munich: This panel included 99 HIV-RNA positive 
plasmas obtained in Nairobi and shipped to Munich within a period of 6 months after 
collection. In Nairobi, the samples were stored at -80°C prior to shipment. Upon arrival in 
Munich, the samples were stored at -20°C and tested within 3 months. Prior to testing by 
LAMP assay, the viral loads of these samples were retested in Munich by Abbott m2000rt 
system which was used as “gold standard” for evaluating LAMP assay. 23 samples from this 
group had undetectable viral load when retested in Munich despite having been positive in 
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Table 10. Sensitivity, specificity and predictive values of LAMP for plasma and dry blood spot (DBS) 
samples. Results show a high sensitivity (82 and 93%) for plasma samples and a reduced sensitivity and 
specificity (76% and 77% respectively)  for DBS samples. The low specificity for DBS samples was 
attributed to a high number of false positive results. The evaluations were carried out at 95% confidence 
interval (CI). PPV – positive predictive value; NPV – Negative predictive value; n – number of samples. 
Nairobi, whereas 77 samples were detected by the Abbott m2000rt system. The 23 undetected 
samples were used to test specificity of the LAMP assay within this category. 
iii. Kenyan Dry Blood Spot samples analyzed in Munich: The panel included 121 dry blood 
spot (DBS) samples which had previously been processed in Kenya and stored at -20°C 
before shipment to Munich. Extracts from these samples were first tested by Abbott m2000rt 
system and afterwards analyzed using the LAMP assay. 
iv. Munich plasma samples analyzed in Munich: This was the last panel and included 112 
samples (92 HIV positive and 20 negative samples) obtained from the local population. 27 
samples of the 92 HIV positive plasmas were dilutions of HIV positive plasma in negative 
plasma. The negative samples were used to estimate the overall specificity of the LAMP 
assay within this category of samples. 
4.3.1 Sensitivity and specificity of LAMP assay with clinical samples 
4.3.1.1 Overall sensitivity and specificity of LAMP assay within sample categories 
Values generated by LAMP assay were used to calculate sensitivity, specificity and predictive values 
for LAMP assay. Sensitivity values realized ranged between 82 and 93% (Table 10) for plasma 
samples while a lower sensitivity of 76% was realized for DBS. A high rate of false positive results 
was also obtained with DBS reducing the specificity of LAMP to 77% within this category. In 
general, a higher specificity (99-100%) was realized for plasma samples compared to DBS. 
Sample category   N Tests 
  
 
Sensitivity (%) Specificity (%)   PPV   NPV 
Kenya in Nairobi     
 
    
       (plasma) n =135 82  (51/62 ) 99 (72/73)     98       87 
                      CI 
 
  70  -  91    93  -  100  90 - 100     78 -  93 
Kenya in Munich  
            (plasma) n =99 86 (66/77) 100 (22/22)     100       67 
                      CI 
 
  76 – 93     84 – 100  95 -  100    48 – 82 
          DBS n =121 76 (45/59)  77 (48/62)       76      77 
                      CI 
 
    63  -  86      65 -  87   63 -  86    65 – 87 
Munich in Munich 
           (plasma) n = 112  93 (86/92) 100 (20/20)     100    77 
                       CI 
 
     86  -  98      83 – 100    96  -  100     56  - 91 
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Table 11. Sensitivity for samples with viral loads ≥ 5000 copies/mL. Results show an increase in 
sensitivity mainly for all plasma samples (red rectangular box). CI- 95% confidence interval, PPV – 
positive predictive value, NPV –Negative predictive value, n – number of samples. 
4.3.1.1.1 Sensitivity and specificity for samples of viral loads above 5,000 copies/mL 
Success for HIV treatment in limited resource settings is indicated by viral loads ≤1,000 copies/mL, 
while treatment failure is considered for viral loads ≥5,000 copies/mL within 3 consecutive tests after 
start of treatment (World Health Organization, 2010a). Results of this study also showed >70% 
detection rate of LAMP for viral loads ≥3,000 copies/mL. Sensitivity analysis was performed 
focusing on samples whose viral loads would indicate treatment failure. This would be important 
mainly to target this group of patients potentially failing treatment. Calculation of the modified results 
showed an improved sensitivity of 95-100% for plasma samples (Table 11). There was also a slight 
improvement in sensitivity for DBS samples. 
Sample category        N            Calculated  at   95% CI 
  
 
Sensitivity (%)       PPV    NPV 
Kenya in Nairobi         
       (plasma)        n =41 100  (41/41)     98       100 
         CI 
 
  91  -  100  90 - 100     95 -  100 
Kenya in Munich  
           (plasma)        n =43 95 (41/43)     100       92 
         CI 
 
  84 – 99  95 -  100    73 – 99 
          DBS        n =20 80 (16/20)       84      76 
          CI 
 
55  -  83   68 -  94   50 – 93 
Munich in Munich 
          (plasma)        n = 61  98 (60/61)     100    96 
         CI 
 
91  -  100 96  -  100 78  - 99 
  
 
4.3.2 Analysis of correlation between Abbott m2000rt and LAMP assay 
Results generated for the different categories of clinical samples by the LAMP assay were further 
subjected to correlation analysis to compare the two quantification assay parameters. The following 
correlation results were obtained; Kenyan plasma samples analyzed in Nairobi Rs (62) = 0.9 (Figure 
16); Kenyan plasma samples analyzed in Munich Rs (77) = 0.84 (Figure 17); Kenyan DBS samples 
analyzed in Munich Rs (59) = 0.2 (Figure 18); Munich samples analyzed in Munich Rs (92) = 0.8 
(Figure 19). One Kenyan sample (NYK73163) analyzed in Munich (Figure 17) could not repeatedly 
be quantified despite showing viral loads of 1x106; while one Munich sample (V1221944) of viral 
load of 1x105 copies/mL (Figure 19) was sub-optimally quantified by the LAMP assay. The 2 
samples were sequenced at the integrase (IN) region to determine their subtypes and evaluate their 
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Figure 17. Correlation analysis for Kenyan plasma samples analyzed in Munich. Results 
showed a direct linear correlation (Rs (77) = 0.84) between the viral loads obtained by Abbott 
m2000rt system and LAMP assays. A regression analysis resulted in R
2
 = 0.63 showing that 
≥63% of the LAMP assay results fitted within the results obtained by the Abbott m2000rt 
system. Sample NYK73163 (shown in red; pointed by an arrow) could not effectively be 
quantified by LAMP despite a viral load ≥1x10
6
 copies/mL by Abbott m2000rt system.  
Figure  16. Correlation analysis for Kenyan plasma samples analyzed in Nairobi. 
Results showed a strong linear correlation (Rs (62) = 0.9) between the viral loads 
obtained by Abbott m2000rt system and LAMP assay. Similarly a regression 
analysis resulted in R
2
 = 0.8 showing that ≥80% of the LAMP assay results fitted 
within the results obtained by the Abbott m2000rt system. 
sequence patterns for any mutations in order to yield parameters for explanation of reduction in 
sensitivity and a possible improvement of the LAMP assay. 
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Figure  18. Correlation analysis for Kenyan dry blood spot (DBS) samples analyzed in 
Munich. Results showed no correlation (Rs (59) = 0.2) between the viral loads 
obtained by Abbott m2000rt and LAMP assays. Similarly a regression analysis resulted 
only in R
2
 = 0.02 showing that only 2% of the LAMP assay results fitted within the 
results obtained by the Abbott m2000rt system. 
Figure 19. Correlation analysis for Munich samples analyzed in Munich. Results 
showed a direct linear correlation (Rs (92) = 0.8) between the viral loads obtained 
by Abbott m2000rt and LAMP assay. A regression analysis resulted in R
2
 = 0.73 
showing that ≥73% of the LAMP assay results fitted within the results obtained by 
the Abbott m2000rt assay. A sub-optimal quantification by LAMP assay (blue 
point shown by an arrow) was realized for sample V1221944. 
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4.3.3 Nucleic acid sequencing and primer modification. 
4.3.3.1 Nucleic acid sequence analysis of primer binding sites of patient samples 
Sequencing of samples with discrepant results between the LAMP and Abbott m2000rt systems was 
performed to check for any mutations or mismatches within the primer regions. A selected number of 
patient samples presenting more than 1log10 deviation between the 2 assays, together with 2 more 
samples (NYK73501 and NYK73461) whose viral loads were within 1log10 were selected and 
sequenced in the integrase gene region. The sequences generated were aligned with primer target 
sequences and analyzed for any base-pair mismatches. Results showed an average of 3 base-pair 
mismatches (Table 12) at the Forward outer primer (F3) target for all these samples. Within this F3 
target, general mismatches of thymine (T) with guanine (G) at position 4730; guanine (G) and 
adenine (A) at position 4733 and thymine with cytosine (C) at position 4742, a second last position at 
the 3’end (Figure 20) were observed. The results further showed that the two samples (NYK73163 
and V1221944), which despite very high viral loads obtained by Abbott m2000rt system assay 
recorded poor sensitivity in quantification by the LAMP assay, showed a high number of mismatches. 
It was further observed that these 2 samples had mismatches at every target of the essential outer and 
inner primers (except for B3 primer target which was not analyzed) which are necessary for the start 
of the amplification process.  A further mismatch was recorded for sample NYK73163 at the last 
position of the 3’end of the inner primer (BIP) (Figure 20).  
Although the sequence pattern for the reverse outer primer (B3) could not be generated due to sub-
optimal amplification in the sequence reaction, a possibility of mismatches also at the B3 target for 
samples NYK73163 and V1221944 was suspected. This finding points towards the fact that 
mismatches in these two specific primers, mainly the F3 and B3 outer targets could be crucial in 
achieving a higher sensitivity for LAMP assay; in fact a mismatch at an outer target followed by 
another at an inner target has a potential to even reduce further the sensitivity of LAMP assay as seen 
with sample NYK73163. On the other hand, mismatches for NYK73501 and NYK73461 were 
located mainly in the middle part (thymine (T) and guanine (G) at position 4730 and guanine (G) and 
adenine (A) at position 4733). The only extra mismatch for sample NYK73501 was at the first 
position in the 5’end. Although sample V1221944 belonged to subtype C virus, there was a variation 
in its sequence patterns at B2 and B3 primer targets, where it showed several mismatches compared 
to other C subtypes sequenced. Sample NYK73163 on the other hand belonged to HIV-1 group M 
subtype A1. Although useful in speeding up the amplification process, the loop target primers, have 
not been found (by design) to be very important in the amplification of LAMP products. However, for 
the sake of a quantitative detection which estimates the viral load based on time, the importance of 
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Table 12. Number of mismatches for clinical samples showing >1log10 discrepant results between  Abbott 
m2000rt and LAMP assays. Results showed samples NYK73163 and V1221944 (outliers shown in figure 
17 and 19) to have the highest number of mismatches both for outer (B3) and inner (FIP and (or) BIP) 
primers. Samples NYK73528 and KEM6507 which had shown sub-optimal amplification also recorded a 
high number of mismatches at F3 outer region. The number of mismatches at outer B3 primer was not 
included in the analysis due to sub-optimal amplification at the B3 region. It was however suspected that 
the mismatches at B3 would not significantly alter the results obtained in the table.  
these primers cannot be underestimated. In this study however, only a single mismatch was found for 
one LF target. Based on the position within LF, this single mismatch was deemed not to have any 
major effect on the sensitivity of LAMP, and as such may not have contributed much to the poor 
sensitivity shown for sample NYK73163. Based on the 10 samples analyzed, these results did not 
show a single pattern of mismatches among subtypes A1 and C identified (Table 12). 
Sample Number Subtype 
Outer 
primer          Inner primers 
    Loop      
Primers 
Total number 
of mismatches  
  
    F3  
     FIP 
(F1c+F2) 
    BIP 
(B2+B1c)     LF 
     
LB 
NYK73163     A1 3 3 4 1 0 11 
NYK73528     A1 4 0 1 1 0 6 
NYK73575     A1 3 1 1 1 0 6 
NYK73621     A1 3 0            2 1 0 6 
KEM6507     A1 4 1            2 1 0 8 
RT2225     A1 3 1 3 1 0 8 
NYK73501     C 3 1 2 1 0 7 
NYK73461     C 2 1            2 1 0 6 
KEM 6444     C 3 0            2 1 0 6 
V1221944     C  3 0 15 1 0 19 
 
 
  
 
4.3.3.2 Design of modified primers 
Primer target F3 was modified to remove mismatches at positions 4730, 4733 and 4742 (Figure 20; 
F3 shown in red). The modified and the standard sets of primers were then used in re-analysis of 
samples and the results compared. Samples IIIB and MVP899-87 which had been used as standard 
subtype B samples, together with single samples each representing subtypes D, F and G were 
included in the analysis. The results obtained for the modified set showed a drastic reduction in the 
viral load quantification for the two subtype B viruses (Table 13), with sample MVP899-87 recording 
approximately 9.8x104 copies/mL by standard primer set against 1.3x101 copies/mL for modified 
primer set, while sample IIIB recorded approximately 8.8x104 copies/mL by the standard primer set 
against 1.3x102 copies/mL by the modified primer set. On the other hand, an improved sensitivity 
with the modified primers on samples NYK73528 and KEM6507, which had shown poor sensitivity 
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Table 13.  Comparison of viral load results for LAMP obtained by the standard and the F3-
modified sets of primers. Results showed a drastic reduction in viral loads for subtype B samples 
(IIIB and MVP899-87) by the F3-modified primers compared to standard primers (red square 
box). A  trend of improved sensitivity by F3-modified primers among 3 samples representing 
non-B viruses is also shown (blue square boxes). 
 
with the standard primer set, was obtained.  Sample NYK73501 was still within the 1log10 range 
between the two primer sets which was a reproducible result from the initial analysis during the viral 
load quantification (Table 13). In general, the modified primer set showed an improved sensitivity 
among some HIV-1 M non-B subtypes as compared to the B subtypes where it had poor sensitivity. 
The drastic reduction in the viral loads of the two B subtypes with the modified primers points 
towards the effects of mismatches at the target primers on the sensitivity of LAMP assay. 
With the modification of F3 outer primer target additional mismatches were introduced into the 
primer sequence of subtype B at the 3 positions (Figure 20). Since F3 target is important for initiating 
amplification, there was a possibility of non-optimal amplification initiation which may have been 
reproduced in the subsequent reactions. This observation is also supported by an improvement in the 
sensitivity of the assay for the 3 non-B subtype samples, albeit with a small margin. Since only the F3 
outer target was modified, poor sensitivity still shown with sample NYK73163 may be as well 
attributed to further mismatches in other targets, namely the FIP and the B3. It is worth noting that 
FIP target had a similar number of mismatches as the F3 and the BIP targets, with BIP even having a 
mismatch at the last position on the 3’end, which could influence the efficiency of amplification. 
Although the nucleic acid sequence of B3 target was not completely achieved, it is possible that this 
target too had a similar number of mismatches as F3 for this sample. The increased number of 
mismatches at these sites among other factors is deemed to have influenced the sensitivity of LAMP 
assay on this sample, even with the modified set of primers. 
 
 
 
 
 
 
 
 
Sample number 
Viral load (copies/mL) 
- Abbott (m2000rt) 
     Viral load (copies/mL) 
LAMP 
 
                 Viral Load      Standard primers       Modified primers 
NYK 73163 1,300,000 0 0 
NYK 73528 300,000 0 560 
NYK 73501 60,000 21,000 9,000 
KEM 6507 11,000 40 900 
V1116227 22,000 25,000 800 
V1216136B  110,000 50 2,600 
V0634505  2,500 150 140 
MVP899 - 87  2,900,000 98,000 10 
HTLV-IIIB 2,100,000 88,000 130 
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F3 (4721       4743) F3 – Modified  (4721       4743)       F2 (4747       4766) 
    LF  (4769       4786)    B1c (4812       4835) 
     LB (4842       4863) 
   F1c (4787       4806) 
    B2 (4900       4921)     B3 (4926       4945) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Nucleic acid sequence alignments of sequenced samples with HiInteg standard and F-3 modified primers. Results show the sequence 
patterns of both standard and F3-modified (red title) primers with modifications at positions; 4721, 4730 and 4742. A high number of mismatches is 
shown for samples NYK73163 and V1221944 which had shown poor sensitivity during amplification. The primers were re-tested with sequenced 
Kenyan samples including sample NYK73163 which had shown sup-optimal amplification by LAMP assay. F3: Forward primer, F2: Forward inner 
primer 2, LF: Loop forward, F1c: Forward inner reverse complement primer, B1c: Backward inner reverse complement primer, LB: Loop backward, 
B2: Backward inner primer, B3: Backward primer. FIP (F1c+ F2), BIP (B2 + B1c). Partial or no sequences at the outer prime B3 were obtained for 
some samples. 
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Chapter 5 
5 Discussion 
With the rising HIV drug resistance due to ART treatment in Sub-Saharan Africa and the possible 
transmission of ART resistant strains, a global threat to the success already achieved in HIV/AIDS 
control is eminent. Measures to curb this spread of resistant strains including an improvement in 
laboratory capacities and introduction of simple, affordable and rapid viral load measurement 
technologies should be put in place within these countries with limited resources. This study showed 
that using integrase primers, LAMP assay exhibits a potential for semi-quantitative detection of viral 
load of HIV-1 group M viruses in blood and plasma for treatment monitoring of HIV infected 
patients. The results in this study are considered not sufficient to allow quantitative measurement of 
viral load as recently reported using p24 primers (Zeng et al., 2014). Semi-quantitative detection has 
also been recently reported for microfilaria detection by LAMP (Drame et al., 2014) used to prevent 
serious adverse events before exposure to treatment. 
5.1 Evaluation and testing of primers and assay conditions 
5.1.1 Preliminary assessment of primers and assay conditions 
In the first part of this study it was shown that the first four (outer and inner) primers designed for 
LAMP amplification to amplify HIV-1 templates in normal rt-PCR using Taq polymerase enzyme 
effectively worked for HIV-1 subtype B. Taq polymerase enzyme is important in PCR reaction due to 
its ability to withstand high temperatures in thermo-cyclic reactions. On the other hand Bst 
polymerase enzyme is important in isothermal reaction due to its ability to displace DNA strands 
under a thermo-stable condition. For this reason Bst polymerase remains an important enzyme to 
initiate amplifications in isothermal reactions such as LAMP. The specificity of these primers was 
ascertained by restriction digestion of LAMP amplicons which yielded the expected restriction 
products from the specific endonucleases. The finding that the selected primers were able to amplify 
cDNA templates at defined laboratory conditions for rt-PCR showed the possibility of using these 
primers not only for LAMP amplification, but also in rt-PCR. The findings thus depict rt-PCR as an 
alternative quality control assay for LAMP primers and would therefore be important as a 
troubleshooting tool in the event of challenges experienced during LAMP analysis. 
As described and shown in previous studies (Mori et al., 2001; Parida et al., 2008; Tomita et al., 
2008) this study revealed that all detection methods including, real time monitoring of turbidity, 
visualization of fluorescence under UV light and gel electrophoresis of LAMP amplification products 
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were equally reproducible. Additionally use of a HNB colour detection dye that neither requires real 
time monitoring nor UV lamp for detection was also effective and reproducible in qualitatively 
detecting the LAMP products (Figure 6). Use of HNB dye not only guarantees simplicity of the assay 
thereby reducing costs but also eliminates post amplification procedures which are time consuming 
and a risk to laboratory contamination by amplified products. Although T-test results comparing real 
time detection to HNB dye detection showed no significant differences in the means, results however 
showed a general lateness in time to threshold detection by visual colour change compared to real 
time detection by a turbidimeter. In their study Bista and colleagues (Bista et al., 2007) observed that 
the colour change for samples with high viral loads (>107 copies/ml) were detected earlier (i.e. <30 
minutes), whereas those samples with viral loads between 104 and 105 copies/mL were detected after 
long (i.e. >60 minutes) incubation periods. The finding of late detections by visual colour change 
presents a negative implication if the visual detection method is to be used for a quantitative 
detection.. Indeed it was realized during this study that the colour change at the visual level indicated 
an all-or-none phenomenon implying a “yes” or “no” result and as such did not exhibit a quality for 
quantitative analysis. This finding thus presents a limitation of this assay, if visual detection is to be 
used as a quantification method since the HNB colour intensities between different viral loads would 
not be discriminated. 
5.1.2 Stringency of primer binding 
The second part of this study evaluated the primers designed for targets of 4 major conserved regions 
in the HIV genome: LTR (HiLtr), p24 (HiP) in the gag, integrase (HiInteg) in the pol and gp41 
(HiGp) in the env gene. Selection of the most suitable primer set was important if it was to be used in 
testing samples from different HIV-1 group M subtypes. Indeed various studies have demonstrated 
that HIV genetic diversity pose a major problem in PCR quantification, especially among the non-B 
subtypes (Damond et al., 1999; Gueudin et al., 2007; Scott et al., 2009; Wirden et al., 2009). The first 
finding in this study demonstrated that the 4 sets of LAMP primers ably amplified HIV-RNA from 
cell culture supernatants samples belonging to subtype B. This finding offered the possibility of 
having a variety of options in the conserved regions of the HIV genome for selection and designing 
LAMP primers (Figure 7). Previous studies have also demonstrated that improved quantification 
results were achieved by use of dual-target assays (Pas et al., 2010), nevertheless in this study only 
one target was used.  
5.1.3 Influence of mismatches 
Even with the ability of the 4 primer sets to detect samples of subtype B virus, there was a variation 
in analytical sensitivity among them. HiInteg and HiP primers, targeting the integrase in the pol and 
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p24 in the gag gene respectively, showed higher analytical sensitivities compared to the remaining 2 
primer sets, as was shown in Figure 7. The discrepancies among these primers could mainly be 
attributed to the number of mismatches within these primer sets with the subtype B virus upon which 
they were tested during quantification (Table 5). During the mismatch analysis of the various group 
M subtypes, the least average number of mismatches was realized with HiInteg primers followed by 
HiP primers. The two previously published primer sets had recorded the highest analytical 
sensitivities, detecting a virus concentration as low as 2.1x101 and 2.9x102 copies/mL respectively 
within a subtype B virus sample panel.  
Detrimental effects of mismatches on nucleic acid amplification by PCR assays have been well 
elucidated (Klein et al., 2001; Whiley and Sloots, 2005) and although scarce, available publications 
have also shown that these mismatches have the potential to affect quantification of amplification 
products in real time PCR (Stadhouders et al., 2010; Whiley and Sloots, 2005). However it is worth 
noting that even with the high number of mismatches two sets of primers, HiP and HiLtr, not only 
detected all HIV-1 group M subtypes, but also group O while HiInteg detected only HIV-1 group M 
subtypes (Table 4). On the other hand HiGp only detected group M subtype B. The finding of 
detection of group O viruses by HiP and HiLtr despite the high number of mismatches may not be 
explained conclusively in this study. However it can be hypothesized that there is a probability that 
the detrimental effect of mismatches in LAMP primers are dependent on the 8 arbitrary regions (F3, 
B3, F2, F1c, B1c, B2, LF, LB) within the 6 targets and the positions of the mismatches within these 
regions (5’end or 3’end). Indeed several studies (Bru et al., 2008; Christopherson et al., 1997; Klein 
et al., 2001; Kwok et al., 1990; Stadhouders et al., 2010; Whiley and Sloots, 2005) have shown that 
mismatches at the 3’ end region of a primer are known to exceptionally be detrimental to the 
efficiency of PCR amplification, which may not only lead to underestimation of the initial copy 
numbers but even to a complete abolishment of the amplification (Stadhouders et al., 2010). This 
assertion of position dependence was well elucidated in this study, when different nucleic acid 
sequences of subtypes of HIV-1 group M, O and HIV-2 were aligned with HiInteg primers.  
As shown in Figure 11 (a and b) mismatches were realized at different positions of different targets 
within B and non-B subtypes. Mismatches within MVP899-87 which was a standard sample were 
realized at the second base from the 5’end within F3 with no mismatch at the B3 outer primer 
sequence targets. On the same sample, another mismatch was observed at the last base at the 3’end of 
B1c target and no mismatch at the B2 and the 2 FIP sequence targets of the primers. MVP899-87 had 
been quantified and was demonstrated to have the highest analytical sensitivity with HiInteg primer 
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set. The HiInteg primer set showed an average of 7 mismatches (Figure 11c) within the F3 target at 
different positions including the last position at the 3’end among the group O viruses, which it failed 
to detect. This finding is possibly a predictor of the importance of F3 and B3 sequence targets in the 
initiation of amplification and any mismatches at the 3’end of these targets are likely to affect the 
amplification process.  
Detrimental effect of mismatches at F3 and B3 sequence targets could be supported by the 
observation that despite a mismatch at the 3’end of the B1c sequence target, the amplification and 
quantification was not affected for the MVP899-87 sample. Indeed F3 and B3 are also known as 
strand displacement primers and as such have their major role during strand displacement at the 
initiation of the isothermal reaction, whereas FIP and BIP have their major role in loop formation 
(Parida et al., 2008). It therefore means that a mismatch at the 3’ end of F3 or B3 and also a mismatch 
at the 3’end of F2 and B2 are likely to be detrimental by lowering sensitivity and even leading to non-
amplification in the LAMP assay.  
The results obtained by other sets of primers as well show the possibility that mismatches at the 5’ 
end and the internal region of LAMP primers at F3, B3, F2 and B2 may not have a major influence in 
LAMP amplification process, since all these primers were still able to amplify the templates. Results 
by these primers also showed that mismatches at the 3’end of F1c and B1c seemed not to have 
detrimental effects on the amplification process of the tested samples. Apart from the outer and the 
inner primers, studies have shown that loop primers although not very necessary in the initial LAMP 
amplification process, accelerate the reaction process by one third to one half of the reaction time 
(Nagamine et al., 2002; Parida et al., 2008). This added benefit of acceleration of the LAMP process 
by these primers underscores the need to ensure that only limited or no mismatches exist within the 
LF and LB primer sequences and if present they should be avoided at the 3’end. For the purposes of 
this study, loop primers are particularly essential since the estimation of viral load for HIV positive 
samples was based on the time to threshold detection. 
Two primer sets HiInteg and HiP were therefore selected for further evaluation and refinement for 
analysis of clinical samples. Within these two sets of primers it was realized that HiP set of primers 
was very sensitive among the clinical samples but was associated with a low specificity.   
5.1.4 False positive reactions in LAMP assay 
The low specificity due to false positive results realized for the selected HIV negative plasma by HiP 
set of primers was an important finding in this study. Furthermore this primer set not only amplified 
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HIV-1 group O viruses but also HIV-2 viruses, despite the fact that HIV-1 and HIV-2 viruses have a 
restricted sequence homology in the p24 region. For a long time this sequence diversity has hindered 
the development of a viral load assay able to reliably quantify all subtypes of both viruses (Pas et al., 
2010). Since false positive results were obtained for 4 HIV negative samples during analysis of 
plasma and dry blood spot, there was a high possibility that the results obtained for HIV-2 by the HiP 
set of primers were false positive. Some of the possible major reasons for false positive results would 
include sample contamination, cross-reactivity, mis-priming and primer dimerization. .  
5.1.4.1 Sample contamination 
One of the major draw backs in LAMP, just as in PCR, is the problem of carry over contamination 
which is mainly contributed to by the high sensitivity of the assay. Previous publications (Bai et al., 
2011) have suggested that the products of LAMP amplification are very stable and as such not easily 
degraded, posing a risk of carry over contamination. In this study however, although at the initial 
stages contamination was a major setback, precautions were put in place which included not opening 
the tubes after amplification, apart from using different rooms, clean benches and gloves. In some 
experiments viral load samples (<5,000 copies/mL) were used to minimize the possibility of carry 
over contamination. During the analysis negative controls were used which comprised of water, Tris-
buffer, poly A or 0.9% NaCl.  The negative controls continuously tested negative. Therefore the false 
positive results realized by HiP primers during the study could not fairly be attributed to sample 
contamination. 1 
5.1.4.2 Cross-reactivity 
The positive amplification of HIV-2 by HiP primers could alternatively have resulted from cross-
reactivity, which in such a case in patient care would lead to misdiagnosis and inappropriate patient 
management. Cross-reactivity has previously been reported (Pas et al., 2010) for some viral load 
commercial assays. During this analysis, HiP primers were designed only for single targets within the 
HIV-1 M:B genome. Many commercial assays have currently introduced the concept of dual targets 
in an attempt to reduce the possibility of cross-reactivity with primers (Damond et al., 2010; Pas et 
al., 2010). The fact that only single target for HiP primers were available could be hypothesized for 
the false positive results, a matter that invites further evaluation.  
                                                          
1
 To further rule out sample contamination, repeat tests were performed with HiP primers after 6 months using 
fresh aliquots of cell culture supernatant samples. False positive results were still generated. HIV-1 group O and 
HIV-2 showed false positive results in the presence or absence of reverse transcriptase enzyme. With these latest 
results a possibility of master-mix or carry over contamination was ruled out.  
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Further reasons for false positive results in nucleic acid amplification systems include the presence of 
primer-dimer formations as a result of extensions of self-annealed primers. Not many publications 
have dwelt on the effect of primer-dimer formation on LAMP and since the subject was not part of 
the study, it was not possible to elaborate the effects of primer-dimer formation. Although at the 
primer level, a possibility of primer-primer binding within FIP and BIP primers of HiInteg (Table 1) 
leading to primer-dimer formation would have been anticipated, the results generated by HiInteg set 
did not, however, show the challenge of false positive results.  
5.1.4.3 Mis-priming 
Mis-priming is another possible reason for false positive results in PCR amplification. Since within 
the human genome also exist retroviral elements, these elements have the potential to bind to     
primers designed to detect retroviruses. Briefly, as already mentioned in the literature review, HIV 
belongs to the family Retroviridae and during co-evolution between viruses and humans, many 
retroviruses tend to “capture” bits of the human genome and likewise “deposit” bits of their genomes 
in the human genome. Therefore primers designed to detect HIV could in some cases share 
significant homology within the human genome structure and lead to false positive results. The 
argument of existing homology between the human and HIV genomes would thus seem plausible in 
respect to the results obtained in this study where false positive results mainly occurred after 30 
minutes and were only seen with negative plasma samples and not in saline used as negative controls. 
The argument may further be strengthened by the high number of primers used during LAMP 
amplification assay which increases the risk of binding to non specific targets as opposed to normal or 
quantitative PCR. Furthermore, HIV-1 group O and HIV-2 detected by HiP set of primers had been 
cultivated in the human H9 cell line and as such the potential of traces of human DNA within the cell 
line supernatant can not be ruled out.  
The finding in this study of false positive results for HiP primers occurring after 30 minutes, would 
point towards a possibility of specific binding of LAMP primers to unspecific target sequences in the 
sample. One reason may be due to the complex cycling process of LAMP (Figure 2b), since 
amplification mainly depends on loop formation and amplification of these loops leading to rapid 
formation of pyrophosphate deposits. The latter observation would therefore imply that an extension 
of reaction time would potentially lead to unspecific amplifications. As was also realized in this 
study, analysis of LAMP products by gel electrophoresis was shown to be highly sensitive and 
specific and as such could be used to clarify the reason for unspecific amplification. However this 
study also realized occasional atypical banding patterns for HIV negative samples following 
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amplification (Figure not shown). These banding patterns in the absence of nucleic acids have 
previously been reported in different studies (Inacio et al., 2008; Kuboki et al., 2003; Teng et al., 
2007; Yeh et al., 2005). The challenges of atypical banding as well as potential high risk of 
contamination pose a significant hurdle in using gel electrophoresis. Furthermore gel electrophoresis 
would increase the amount of time for LAMP by an extra 1½ hours and requires highly sophisticated 
equipment in laboratories.   
In their study, Curtis and colleagues (Curtis et al., 2009) also showed the presence of false positive 
results by a similar set of p24 target primers in a LAMP reaction. Zeng and colleagues, however, in 
their recent publication showed quantitative detection of HIV-1 virus by LAMP assay using the p24 
target primers (Zeng et al., 2014) without reporting any false positive results in their evaluation. The 
primers used by Zeng´s group and those used in this study mainly differed in their positions within 
the gag-p24 target of HXB2 genome (1224 – 1441 for Zeng´ versus 1311 – 1515 used in this study). 
Alignment of the two sets of primers with HIV-1 group M (A to F) subtypes (Appendix 1 and 2) 
however showed that the p24 (HiP) target primers used in this study (Appendix 2) exhibited a high 
specificity among the different non B subtypes compared to those of  Zeng´s group (Appendix 1). It is 
however worth noting that the primers designed by Zeng´s group mainly targeted HIV-1 group M 
subtypes B, C and BC circulating in China. 
5.1.5 Visual detection of LAMP amplification products 
One of the advantages cited for LAMP assay is the ability to visually detect amplification products by 
colour change due to the presence of intercalating dyes and by turbidity due to accumulation of 
magnesium pyrophosphate deposits. The dyes however are not sequence-specific and as such bind to 
DNA indiscriminately including non-specific amplifications. On the other hand, use of turbidity may 
not be reliable as magnesium pyrophosphate will also accumulate during non-target specific 
amplifications. This challenge would possibly be overcome by including fluorescence labeled primers 
and quencher probes into the reactions. Fluorescence labeled primers would then incorporate only 
into target specific amplicons and the quencher probes quench any unincorporated labeled primer 
allowing the detection of only specific amplification products. The final result would therefore lead to 
visual distinction between target specific and non-specific amplifications, since fluorescent signals 
would only be generated for the specific targets. Replacement of turbidity as the final amplification 
signal by using fluorescence labelled primers has successfully been used in sequence specific 
detection by LAMP assay (Curtis et al., 2009). In a recent publication for real time detection of a 
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HIV-2 integrase target by LAMP, a Hex fluorescent label and Black Hole Quencher were effectively 
used to quantify HIV-2 group A and B virus (Curtis et al., 2014).   
5.1.6 Sensitivity of LAMP assay and establishment of detection limits 
5.1.6.1 Sensitivity of LAMP using HIV cell culture supernatants 
Analysis of HIV cell culture supernatants of various subtypes showed a general lower sensitivity of 
LAMP assay compared to the Abbott m2000rt system, since only 60% of the samples fitted within 
1log10 difference (Figure 15). Some of the samples presenting ≥1log10 were dilutions obtained from 
samples with higher viral loads measured by the Abbott m2000rt system. These samples were 
measured in triplicate in the LAMP assay. There is thus a theoretical possibility that inconsistencies 
could have occurred during the dilutions. In general it has been established that errors including 
pipetting errors, freeze thawing cycles and handling steps could detrimentally affect a test thus 
leading to lower quantifications. It is therefore possible that diluting samples before testing on LAMP 
assay could lower the analytical sensitivity of this assay. However the fact that a correlation of 70% 
was realized between LAMP assays (established as semi-quantitative) and Abbott m2000rt system 
(purely quantitative assay) presented a promising potential use of the LAMP assay in the estimation 
of viral load for undiluted clinical samples. 
5.1.6.2 Establishment of LAMP detection limits 
Two fundamental achievements of this study were the establishment of lower threshold limits and the 
generation of a mathematical model for estimation of the viral load by LAMP assay. The achievement 
of LLOQ 9.8x103 (approximately 10,000) copies/mL basically means that the LAMP assay should 
detect all HIV-1 group M positive samples ≥10,000 copies/mL within the first run. LAMP assay was 
further able to detect >70% of samples with viral loads >3,000 copies/mL, apart from the LLOD 
which was established at a 50% detection rate at a viral load of 1.2x103 copies/mL.  
Although samples >1,000 copies/mL were theoretically meant to be detected within the first 45 
minutes within the first run, the majority of samples with viral loads <2,500 copies/mL were only 
detected within 2 runs, especially as the viral loads approached 1,000 copies/mL. This finding was a 
useful indication of a potential limitation of LAMP assay in testing viral load especially in patients on 
treatment with viral load levels close to or below 1,000 copies/mL. 
The current WHO guidelines (World Health Organization, 2013a) recommend the detection of viral 
load ≥1,000 copies/mL after 2 consecutive tests in order to identify a treatment success or failure. 
This new recommendation is a lower threshold compared to the recommendation made in 2010 which 
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had put the treatment failure at viral load measurement ≥5,000 copies/mL (World Health 
Organization, 2010a; World Health Organization, 2010b). Therefore when using an optimized LAMP 
assay to meet the new WHO threshold, samples without a signal (undetected) within the first 45 
minutes in the first run should be retested and in case of discordant results a 3rd test would be 
necessary. Some studies (Curtis et al., 2008) have also realized that doubling the reaction mix and the 
template volume increases the sensitivity of the LAMP assay within samples of low viral loads. This 
assertion however needs further investigation for HIV clinical samples between 1,000 and 10,000 
copies/mL for non-B subtypes. An earlier attempt during this study to improve the sensitivity of the 
assay by increasing the buffer concentration of the master mix did not yield any improvement.  
During this study it was also realized that LAMP would cost approximately € 8.00 (US $ 11) per test 
as compared to € 38.00 (US $ 52) per test for Abbott Real Time HIV-1 assay. This calculated cost 
would therefore mean that any 2 extra tests performed by LAMP assay would still be cost effective 
compared to the price of commercial viral load assays currently available. 
5.2 Analysis of clinical samples 
5.2.1 Optimization of sample material for LAMP analysis 
Another objective of this study was to analyze various categories of samples by the LAMP assay to 
identify the most appropriate sample material that would be simple, cost effective and stable for viral 
load quantification by the LAMP assay. As revealed in this study, extracted nucleic acid provided the 
most reliable results, with extracted whole blood and plasma providing optimal results. Results with 
dry blood spot extracts could not reliably be interpreted quantitatively as the results obtained with 
these extracts showed overestimations and underestimations compared to established viral load 
measurements by the Abbott m2000rt system (Figure 18). 
5.2.1.1 Dried blood spot samples  
Dried blood spots have currently been used for HIV-1 RNA quantification, DNA genotyping and 
other diagnostic assays. They have particularly been used as an alternative to peripheral blood plasma 
for periodic viral load testing (Alvarez-Munoz et al., 2005; Bertagnolio et al., 2010; Bertagnolio et 
al., 2007; Garrido et al., 2009)  especially in resource limited countries where they have been found to 
perform equally well as plasma (Johannessen et al., 2009). The advantages of using DBS are: (i) easy 
collection and storage as they neither require special collection equipment nor refrigeration (ii) 
requirement of a small volume of blood thus have been used in infants (iii) ease of transportation 
since they can be shipped as non-dangerous goods and (iv) the possibility of having extra samples for 
future analysis as each card takes about 5 to 6 spots (Bertagnolio et al., 2007; Brambilla et al., 2003; 
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Johannessen et al., 2009). All these qualities make DBS ideal for resource limited countries, and if 
used together with the LAMP assay the cost of viral load testing would significantly be reduced. 
Indeed some studies have estimated a cost reduction of U.S $ 2.67 per test (Neogi et al., 2012) when 
DBS are used instead of direct plasma for viral load testing. The results in this study however showed 
that there is a further need for improvement and optimization of LAMP assay if DBS samples are to 
be used.   
5.2.1.1.1 Viral load analysis for LAMP using DBS samples 
5.2.1.1.1.1 Sensitivity, specificity and correlation analysis 
Although lower compared to those generated for plasma samples, the sensitivity of 76% and 
specificity of 77% reached for DBS samples offered a potential for improvement of LAMP for use 
with such samples. Even with promising results on sensitivity and specificity, no correlation between 
LAMP and Abbott m2000rt systems was achieved for DBS samples analyzed. The Spearman’s 
correlation coefficient of 0.2 achieved within this group of samples was considered far too low to be 
reliable (Figure 18). This finding has the implication that LAMP as it is designed in this study cannot 
be used with DBS samples for determination of viral load. 
5.2.1.1.1.2 False negative results 
A closer look at the false negative results showed that although the majority of samples had viral 
loads <5,000 copies/mL by Abbott m2000rt system, 3 samples were >10,000 copies/mL. The 
corresponding plasmas for the 3 latter samples had been detected by the LAMP assay. This study had 
established a LLOQ of approximately 10,000 copies/mL and as such it was expected that the 3 
samples would easily be detected by LAMP assay. The reason for failing to detect the 3 samples 
cannot conclusively be explained. One prominent reason might be insuffient extraction of HIV-RNA. 
Viral loads for the remaining LAMP assay negative samples were <3,000 copies/mL, which points 
towards the need to optimize the extraction criteria for DBS samples. During extraction of these 
samples, one spot (70 µL), compared to 200 µL for plasma, was diluted in 1,000 µL extraction buffer, 
from which only 200 µL was used for extraction of the nucleic acid giving a reduction in the amount 
of viral load by >75%. The nucleic acid was eluted in 50 µL of elution buffer from which only 5 µL 
of the extract was finally used in LAMP analysis. Therefore only about 2% of the original sample 
viral load in the DBS was recovered for quantification by the LAMP assay. Other studies have also 
shown low sensitivity of DBS samples among patients with viral loads <5,000 copies/mL (Barin et 
al., 2005; Hamers et al., 2009; Scott et al., 2009; Uttayamakul et al., 2005). Perhaps evaluating the 
performance of LAMP assay by extracting DBS in 500 µL or 200 µL would yield better results.  
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5.2.1.1.1.3 False positive results 
Specificity of LAMP for DBS samples was reduced (Table 10) by the presence of false positive 
detections.  Furthermore some samples showed unreliably high viral load estimations compared to the 
results obtained by the Abbott m2000rt system. Even with the advantages of DBS cross- 
contamination is still a potential risk mainly during punching of the spots. Extraction of the DBS to 
generate maximum possible DNA or RNA material is also laborious and time consuming, potentially 
increasing the risk of contamination. Despite the precautions put in place, this study as well cannot 
rule out contamination as one possible contribution towards false positive results generated, since 
extraction and processing of these samples was performed manually. Even with avoidance of 
contamination, the presence of proviral DNA among DBS samples might be a major hindrance in 
correctly quantifying viral load values (Johannessen et al., 2009) and as such could have contributed 
to extremely high values as well as some false positive results. DBS consists of whole blood and cell 
associated HIV-1 DNA, which is present in the peripheral blood mononuclear cells. As a result, the 
cell associated HIV-1 DNA is frequently found in the extracted nucleic acid (Bruisten et al., 1993). 
Other studies have also reported abnormally high viral load measurements and false positive results 
attributed to the possible influence of proviral DNA (Johannessen et al., 2009; Waters et al., 2007). 
Although the presence of proviral DNA is beneficial in routine qualitative diagnosis (Curtis et al., 
2008), its presence might become detrimental in viral load quantification.  
Proviral DNA has been found to remain stable even with the fluctuation and reduction of plasma 
RNA below the detection limit (Lillo et al., 2004). This stability of proviral DNA would not be 
beneficial to the viral load quantification of patients, since constant detection of proviral DNA would 
mean that recovering patients would unnecessarily be switched to second line treatment thereby 
putting pressure on the available drug regimen. Further evaluation of DBS and their possible use with 
the LAMP assay should therefore be undertaken to address the challenges of unreliable results. In 
evaluating DBS for use in the LAMP assay, it would also be prudent to evaluate the performance of 
LAMP on DPS as well as dry serum spots since other groups have found these to be efficient in 
quantitative analysis and genotyping (Dachraoui et al., 2008; Plantier et al., 2005)..  
5.2.1.2 Unprocessed whole blood and plasma 
Although some studies have reported success with LAMP assay for unprocessed samples simply by 
heating plasma or whole blood (Bista et al., 2007; Curtis et al., 2008) or by directly using lysis buffer 
hence avoiding the heating step (Curtis et al., 2009), experiments in this study did not succeed in 
generating plausible results for samples treated by any of the two methods. However when the same 
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samples were processed and nucleic acid extracted from them, positive detections were made by the 
LAMP assay.  
5.2.2 Performance characteristics of LAMP assay for HIV-1 virus positive plasmas 
5.2.2.1 Sensitivity and specificity 
This study depicts LAMP as a potential tool for use in quantifying viral load among patients of HIV-1 
group M subtype B and non-B subtype infections circulating in Kenya. Analysis among German 
samples showed a sensitivity of 93% and specificity of 100%, whereas sensitivity between 82% and 
86%, with specificity between 99% and 100% was achieved for Kenyan samples. The high 
sensitivities and specificities depict this assay to have a high property of detecting HIV-1 in clinical 
plasma samples, with low false positive results. Increased sensitivity of 95% and 100% which were 
achieved by this assay for samples with viral loads >5,000 copies/mL (Table 11) showed an increased 
chance of using LAMP to detect patients either failing treatment or those with putative HIV 
resistance during ART treatment. This would be in line with the earlier WHO recommendation (for 
resource limited countries) that continuous detection of values ≥5,000 after 3 consecutive tests 
following treatment initiation would indicate treatment failure  (World Health Organization, 2010a).  
Upon improvement, LAMP assay would be able to identify patients with continuous viral load 
measurements >1,000 copies/mL as currently recommended by WHO for confirming treatment 
failure (World Health Organization, 2013a). 
5.2.2.2 Correlation analysis 
High correlation ≥0.8 achieved for all plasma sample categories between LAMP and Abbott m2000rt 
systems are an indication that the LAMP assay could potentially be optimized and used for estimation 
of viral loads in resource limited settings with limited deviations from the current commercial assays 
in use. Indeed average differences in viral load quantifications were calculated at 0.4log10 for samples 
from Kenya and 0.3log10 for samples from Germany (Table 8). In most cases the Abbott m2000rt 
system recorded higher viral load values compared to LAMP assay. The difference in log10 values 
was however within 1log10 range hence indicating a higher correlation between the two assays. The 
findings thus show that although there is a wide difference in the limits of detection (≥50 copies/mL 
versus ≥10,000) owing to the differences in their test sensitivities, the two assays would potentially 
show minimal differences in detecting samples with higher viral loads. A closer look at individual 
log10 differences showed that samples with lower viral loads and those samples of non-B subtypes 
showed higher log differences between the Abbott m2000rt system and the LAMP assay, indicating 
that the sensitivity of LAMP, apart from viral load, is also subtype dependent  (Figure 15). The 
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assertion of subtype dependence was also exhibited by a Kenyan sample (NYK73163) which could 
not be quantified by LAMP assay, despite the fact that a viral titer of >106 copies/mL was detected 
with the Abbott m2000rt system (Figure 17) and additionally a German sample (V1221944) which 
showed sub-optimal quantification (Figure 19). 
5.2.2.3 Subtype specificity of RNA quantification by LAMP 
Subtype dependence on the sensitivity of quantitative assays has been described previously and is not 
only restricted to the LAMP assay. Reported failures by commercial assays to monitor viral loads in 
patients infected by non-B subtypes have been documented (Alaeus et al., 1997; Damond et al., 1999; 
Gueudin et al., 2007), yet even others have reported under-quantification of viral loads among 
different commercial assays (Foulongne et al., 2006; Sloma et al., 2009; Wolff and Gerritzen, 2007). 
In their evaluation of three commercial assays Katsoulidou and colleagues (Katsoulidou et al., 2011) 
showed that log10 differences in viral loads were dependent on a specific HIV-1 group M subtype. 
Their observation could be partly attributed to the fact that the current commercial assays are 
predominantly designed based on highly specific primers targeting selected regions of the HIV-1 M:B 
genome and hence any mismatches within primer or probe binding sites would potentially have a 
significant influence on detection and accuracy of the particular test system.  
The two samples that were under-quantified (Figure 17 (in red) and Figure 19 (in blue, pointed to by 
an arrow)) originated from Kenya and Germany. Contrary to expectation of a subtype B virus, the 
German sample was identified to belong to subtype C, whereas the Kenyan sample belonged to 
subtype A1. As already discussed on primer-target mismatches, a number of mismatches were found 
for these samples mainly at the primer 3’end. The Kenyan sample (NYK73163) for example, was 
found to have mismatches at or around the 3’end on the outer and the inner LAMP primers (Figure 
20) an indication that mismatches at these positions within these primer regions would drastically 
affect efficiency of LAMP quantification. These samples were however amplified by the Abbott 
m2000rt system, probably due to the fact that the reagents, cycling conditions and primer/probe 
design have been optimized for mismatch tolerance (Scott et al., 2009; Swanson et al., 2006; Tang et 
al., 2007) even though the primers for the Abbott system (Tang et al., 2007) just like for LAMP assay 
were designed from the highly conserved integrase (IN) region. However, even with the high 
optimization, the Abbott m2000rt system has been reported even to miss a non-B sample from Greece 
(Katsoulidou et al., 2011). 
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5.2.2.4 Optimization of primers for improvement in LAMP quantification 
With the finding of a possible detrimental effect of mismatches, designing primers for HIV-1 group 
M non-B subtypes remains crucial if LAMP assay is to be used for monitoring patients in Africa and 
other resource limited settings. Due to genomic strain variability of different subtypes of HIV-1 
(Foley B. et al., 2013; Wain-Hobson, 1992) it is still not possible to develop universal primers and 
probes. Further, most of the available sequences in the sequence banks for primer and probe selection 
have mainly been for subtype B with non-B representing a minority, hence the risk of mismatches at 
the primer target sites are higher with non-B subtypes (Katsoulidou et al., 2011). In order to reduce 
the risks and effects of mismatches if LAMP assay is to be used for quantification, knowledge of all 
circulating subtypes would therefore be necessary, and perhaps designing a mixture of LAMP primers 
from consensus sequences of the circulating non-B subtypes would improve sensitivity of the assay. 
5.3 Conclusion 
The benefits of viral load testing for monitoring efficacy of HIV treatment, adherence of patients or 
early detection of resistance have been well documented in various studies. The high costs and 
limited use of the currently available commercial viral load tests expose the global community to a 
potential threat of circulation and spread of HIV resistant strains. If this potential threat is not 
controlled, a complete reversal of the gains realized so far in the fight against HIV/AIDS, especially 
in Africa is eminent. This study has managed to evaluate and establish a LAMP assay as a semi-
quantitative procedure to measure HIV-1 group M viral load. The assay is thus shown as a potential 
alternative to monitor success of ART treatment especially in resource limited settings where low 
costs and short time to provide results are a necessity. Patients showing viral loads >5,000 copies/mL 
would easily be detected within 3 consecutive tests. With improved sensitivity detection of a majority 
of samples within the recommended >1,000 copies/mL range would be achieved. Present challenges 
realized in this assay which include potential primer mismatch, the problem of false positive results, 
sub-optimal analytical sensitivity for viral loads <5,000 copies/mL, insufficient detection from DBS 
and low subtype specificity need further improvement and evaluation. 
5.4 Recommendations for improvement 
Apart from the recently published studies for HIV-1 subtype quantification within a Chinese 
population (Zeng et al., 2014) and HIV-2 (Curtis et al., 2014), this is the first study attempting to 
establish LAMP for semi-quantification of HIV-1 in a limited resource country, where challenges of 
circulation of several HIV-1 non-B subtypes are expected.  In order to address the challenges 
identified during the investigations, it is recommended designing LAMP primers from consensus 
sequences of most of the circulating subtypes, use of fluorescent labeled primers and quencher probes 
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to improve the specificity of LAMP detection, and parallel testing of samples or doubling the reaction 
mix to capture low viral load samples (<3,000 copies/mL).  Further research is needed on the possible 
use of dry blood spots, plasma spots or serum spots. There is also need for future adaptation of the 
LAMP assay for detection of HIV-1 group O virus. 
Finally, for the past decade African and other resource limited countries have focused their attention 
exclusively on scaling up HIV treatment and on prevention strategies. Little attention has been paid to 
monitor the success of treatment which in some cases has led to unnecessary switch to a second line 
treatment, drastically increasing the cost of treatment. Currently, the risk of exposure to resistant HIV 
strains is eminent due to a possibility of spread of resistant strains within these regions. Both factors 
strengthen the need to introduce a viral load monitoring tool which would be effective and efficient in 
HIV quantification as well as cost effective. LAMP assay upon improvement presents an opportunity 
as a cost-effective, rapid to run and user friendly viral load monitoring tool and thereby supporting 
optimal treatment of HIV patients in resource limited countries. 
5.5 Summary 
 The study established loop-mediated isothermal amplification (LAMP) assay for semi-
quantitative detection of HIV-1 group M viruses using integrase gene target primers. There is 
need for further optimization among HIV-1 group M non-B subtypes. 
 The assay as established is not able to detect HIV-1 group O or HIV-2 virus. 
 Reliable quantification of LAMP assay is reduced for HIV-1 samples of viral loads <5,000 
copies/mL 
 Refinement of the assay is needed for dry blood spots in order to avoid a high rate of false 
positive and false negative results. 
 Advantages of LAMP include, isothermal amplification hence it can be used in the field, short 
time to get results and cost-effectiveness making it suitable for resource limited settings. 
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Appendix 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Zeng modif ied rev GC C C A T A T C A C C T A GA A C T T ~ ~ ~ ~ ~ ~ ~ C A T GGG T A A A A G T A G T A GA A GA GA ~ ~ ~ ~ ~ ~ GC T T T T A GC C C A GA A G T A A T A ~ ~
B.FR.1983.IIIB_LAI.A04321 . G . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . C . . . . . . . . . . . G . . . ~ ~
A.UG.1992.92UG031.AY187680 A G T . . C G . . . . . . . . G . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . G . . . . . . A . . . . . . . A . ~ ~ ~ ~ ~ ~ . . . . . C . . . . . C . . . . . . . . T ~ ~
A.KE.1997.M21_ps2.AY772969 . T . . T . G . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . A . . . . . . . A . ~ ~ ~ ~ ~ ~ . . . . . C . . . . . . . . . . . . . . . ~ ~
A1.SE.1995.SE8891.AF069673 A T . . T . . . . . . . . . . G . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . G . . . . . . A . . . . . . . A . ~ ~ ~ ~ ~ ~ . G . . . C . . . . . . . . . . . . . . . ~ ~
A1.KE.2000.KSM4024.AF457077 . T . . T . G . . . . . . . . G . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . A . . . . . . . A . ~ ~ ~ ~ ~ ~ . . . . . C . . . . . . . . . . . . . . . ~ ~
A2.CY.1994.94CY017_41.AF286237 . G . T . . . . . . . . . . . G . . G . ~ ~ ~ ~ ~ ~ ~ . C . . . . . C . . . . . . . . . . . . . . A . ~ ~ ~ ~ ~ ~ . . . . . C . . . . . . . . . . . . . . . ~ ~
A2.KE.1999.KNH1234.DQ367261 . A G . T . G . . . . . . . . G . . . . ~ ~ ~ ~ ~ ~ ~ . . . A . . . . . . . . . . A . . . . . . . A . ~ ~ ~ ~ ~ ~ . G . . . C . . . . . . . . . . . . . . . ~ ~
B.CN.2001.DH002.AB078704 . . . . . . T . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . C . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . ~ ~
B.CN.2001.DH001.AB078703 . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . ~ ~
C.MM.1999.mIDU101_3.AB097871 . G . . . . . . . . . . C . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . A . . . . G . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . G . . . . . . ~ ~
C.BW.1996.96BW1104.AF110969 . G . . . . . . . G . . . . . G . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . A . . . . G . . . . ~ ~ ~ ~ ~ ~ . . . . . C . . T . . . . . G . . . . . . ~ ~
D.KE.2001.NKU3006.AF457090 . G . . T . . . . . . . . . . . . . C . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . A . . . . G . . . . ~ ~ ~ ~ ~ ~ . . . . . C . . . . . . . . . . . . . . . ~ ~
D.BR.2004.patient_04BRSAP19.DQ . G . . . . . . . . . . . . . G . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . A . . . . . . . A . ~ ~ ~ ~ ~ ~ . . C . . C . . . . . . . . . . . . . . . ~ ~
F1.FI.1993.FIN9363.AF075703 . G . T . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . G . . GA . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . T . . . ~ ~
F1.AR.2002.ARE933.DQ189088 . T . . T . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . G . . G . . G . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . ~ ~
F2.JP.-.KG1270.AB453729 . . . T C . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . A . . . . . . . . . ~ ~ ~ ~ ~ ~ K . . . . C . . Y . . . . . . . . . . . . ~ ~
F2.CM.2002.4463_13.EU619278 . A A T . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . A . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . C . . . . . . . . . . . G . . . ~ ~
G.GH.2003.GHNJ175.AB231893 A . . . . . . . . . . . . . . . . . C . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . A . ~ ~ ~ ~ ~ ~ . . C . . C . . T . . . . . . . . . . . . ~ ~
G.CN.2002.02CNLN35.EF122523 . G . . T . G . . . . . . . . G . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . A . . . . . . . A . ~ ~ ~ ~ ~ ~ . . C . . C . . T . . . . . . . . . . . . ~ ~
O.US.2010.LTNP.JN571034 A . . . C . C . . C . . C . . G . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . G . C . . . . . . . . . A . ~ ~ ~ ~ ~ ~ . . C . . . . A . . . T . . . A . T . . T ~ ~
O.CM.1991.MVP5180.L20571 A G . . . . C . . C . . C . . G . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . G . C . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . C . . . . A . . . T . . . A . T . . T ~ ~
F3 (1224 – 1243) F 2   (1250 – 1273) LF (1293 – 1276) 
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Zeng modif ied rev ~ C C C A T G T T T T C A GC A T T A T C A G ~ ~ ~ ~ T T A A A C A C C A T GC T A A A C A C A G T GG ~ ~ ~ ~ ~ T C A A GC A GC C A T GC A A A T G T T ~ ~
B.FR.1983.IIIB_LAI.A04321 ~ . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . ~ ~
A.UG.1992.92UG031.AY187680 ~ . . . . . . . . C . . . . . . . . . . . . . ~ ~ ~ ~ . . . . . T . T G . . . . . . . . . . T . . . . . ~ ~ ~ ~ ~ C . . G . . . . . T . . . G . . . . . . . ~ ~
A.KE.1997.M21_ps2.AY772969 ~ . . T . . . . . C . . . . . . . . . . . . . ~ ~ ~ ~ . . . . . T . T G . . . . . G . . . . T . . . . . ~ ~ ~ ~ ~ C . . G . . . . . T . . . . . . . . . . . ~ ~
A1.SE.1995.SE8891.AF069673 ~ . . . . . . . . C . . . . . . . . . . . . . ~ ~ ~ ~ . . . . . T . T G . . . . . G . . . . T . . . . . ~ ~ ~ ~ ~ C . . G . . . . . T . . . . . . . . . . . ~ ~
A1.KE.2000.KSM4024.AF457077 ~ . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ . . . . . T . T G . . . . . . . . . . T . . . . . ~ ~ ~ ~ ~ C . . G . . . . . T . . . . . . . . . . . ~ ~
A2.CY.1994.94CY017_41.AF286237 ~ . . T . . . . . . A . . . . . . . . . . . . ~ ~ ~ ~ . . . . . T . . T . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ . . . . . . . . . T . . . . . . . . . . . ~ ~
A2.KE.1999.KNH1234.DQ367261 ~ . . . . . . . . C A . . . . . . . . . . . . ~ ~ ~ ~ . . . . . T . . G . . . . . G . . . . T . . . A . ~ ~ ~ ~ ~ C . . G . . . . . . . . . . . . . . . . . ~ ~
B.CN.2001.DH002.AB078704 ~ . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ . . . . . . . . . A . . . . . . . . . . . ~ ~
B.CN.2001.DH001.AB078703 ~ . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . ~ ~
C.MM.1999.mIDU101_3.AB097871 ~ . . . . . . . . . A . . . . . . . . . . . . ~ ~ ~ ~ . . . . . . . . . . . . T . . . . T . . . . . A . ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . ~ ~
C.BW.1996.96BW1104.AF110969 ~ . . . . . . . . . A . . . . . C . . . . . . ~ ~ ~ ~ C . G . . . . . . . . . T . . . C T . . . . . . . ~ ~ ~ ~ ~ C . . . . . . . . . . . . . . . . . . . . ~ ~
D.KE.2001.NKU3006.AF457090 ~ . . . . . . . . . A . . . . . . . . . . . . ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . ~ ~
D.BR.2004.patient_04BRSAP19.DQ ~ . . . . . . . . C . . . . . . . . . . . . . ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . C . ~ ~
F1.FI.1993.FIN9363.AF075703 ~ . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ . . . . . . . . . . . . . . . . . T . . . . . . . ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . ~ ~
F1.AR.2002.ARE933.DQ189088 ~ . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ . . . . . . . . . . . . T . . . . T . . . . . . . ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . ~ ~
F2.JP.-.KG1270.AB453729 ~ . . . . . . . . . A . . . . . . . . . . R . ~ ~ ~ ~ . . . . . . . . . . . . Y . . . . . . . . . . R . ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . ~ ~
F2.CM.2002.4463_13.EU619278 ~ . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . ~ ~
G.GH.2003.GHNJ175.AB231893 ~ . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ . . . . . T . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . ~ ~
G.CN.2002.02CNLN35.EF122523 ~ . . . . . . . . . A . . . . . . . . . . . . ~ ~ ~ ~ . . G . . T . . . . . . . . . . . . . . T . . . . ~ ~ ~ ~ ~ . . . . . . . . . T . . . . . . . . . C . ~ ~
O.US.2010.LTNP.JN571034 ~ . . T . . . . . C A T G . . . . . G . . . . ~ ~ ~ ~ A . T . . T . . T . . . . . . . . T G . C A . A . ~ ~ ~ ~ ~ . . . . . G . . . T T . A . . . G . . C . ~ ~
O.CM.1991.MVP5180.L20571 ~ . . T . . . . . . A T G . . . . . . . . . . ~ ~ ~ ~ A . C . . T . . . . . . . . G . . T G . C A . A . ~ ~ ~ ~ ~ C . . . . GG . . T T . A . . . G . . . . ~ ~
F1c (1318 – 1294) B1c   (1339 – 1363) LB   (1371 – 1391) 
cii 
 
 
 
 
 
 
 
 
 
 
Appendix 1: Primer alignment of sequences for the p24 target primers used in the Chinese study ( Zeng et. al., 2014). Sequence alignment shows an 
average of 4 and 3mismatches at the F3 and F2 targets respectively for the non-B subtypes. This primer set is potentially specific for HIV-1 group M 
subtype B virus. 
 
 
 
 
 
 
 
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | .
Zeng modif ied rev ~ ~ ~ ~ C C A T C A A T GA A GA A GC T GC ~ ~ ~ ~ ~ ~ GA A T GGGA T A GA T T A C A T C C A G
B.FR.1983.IIIB_LAI.A04321 ~ ~ ~ ~ . . . . . . . . . . G . . . . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . G . G . . . . . . .
A.UG.1992.92UG031.AY187680 ~ ~ ~ ~ . . . . . . . . . . G . . . . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . C . . GA C . . . . . . . A
A.KE.1997.M21_ps2.AY772969 ~ ~ ~ ~ . . . . . . . . . . G . . . . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . C . . G . . . . . . . . . .
A1.SE.1995.SE8891.AF069673 ~ ~ ~ ~ . . . . . . . . . . G . . . . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . C . . G . . . . . . . . . .
A1.KE.2000.KSM4024.AF457077 ~ ~ ~ ~ . . . . . . . . . . G . . G . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . C . . GG . . . . . . . . .
A2.CY.1994.94CY017_41.AF286237 ~ ~ ~ ~ . . . . . . . . . . G . . . . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . C . . GG . . . . . . . . .
A2.KE.1999.KNH1234.DQ367261 ~ ~ ~ ~ . . . . . . . C . . G . . . . . . . - ~ ~ ~ ~ ~ ~ . . . . A . . . C . . . . . . . . . . . . .
B.CN.2001.DH002.AB078704 ~ ~ ~ ~ . . . . . . . . . . G . . . . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . G . . . . . . .
B.CN.2001.DH001.AB078703 ~ ~ ~ ~ . . . . . . . . . . G . . G . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . G . . . . . . .
C.MM.1999.mIDU101_3.AB097871 ~ ~ ~ ~ . . . . . . . . . . . . . G . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . .
C.BW.1996.96BW1104.AF110969 ~ ~ ~ ~ . . . . . . . . . . G . . G . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . . . . G . . . . . . . . . .
D.KE.2001.NKU3006.AF457090 ~ ~ ~ ~ . . . . . . . . . . G . . . . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . . . . GC . . . . . . . . A
D.BR.2004.patient_04BRSAP19.DQ ~ ~ ~ ~ . . . . . . . . . . G . . . . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . . . . GC . . . . . . . . .
F1.FI.1993.FIN9363.AF075703 ~ ~ ~ ~ . . . . T . . . . . G . . . . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . C . . . . . . . . . . . . .
F1.AR.2002.ARE933.DQ189088 ~ ~ ~ ~ . . . . . . . . . . G . . . . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . C . . . . . . . . . . . . .
F2.JP.-.KG1270.AB453729 ~ ~ ~ ~ . . . . . . . . . . G . . . . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . C . . G . . . . . . . . . .
F2.CM.2002.4463_13.EU619278 ~ ~ ~ ~ . . . . . . . . . . G . . . . . . . - ~ ~ ~ ~ ~ ~ . . . . . . . . C . . G . . . . . . . . . .
G.GH.2003.GHNJ175.AB231893 ~ ~ ~ ~ . T . . . . . . . . G . . . . . . . - ~ ~ ~ ~ ~ ~ . . G . . . . . C . . G . . . . . . . . . C
G.CN.2002.02CNLN35.EF122523 ~ ~ ~ ~ . T . . . . . . . . . . . . . . . . - ~ ~ ~ ~ ~ ~ . . G . . . . . . . . GC . . . . . . . . C
O.US.2010.LTNP.JN571034 ~ ~ ~ ~ T A . . . . . . . . . . . . . . A . - ~ ~ ~ ~ ~ ~ . . C . . . . . . . . . A C T . . C . . . C
O.CM.1991.MVP5180.L20571 ~ ~ ~ ~ T A . . . . . . . . G . . . . . A . - ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . A C T . . . . . . C
B2  (1418 – 1400) B3 (1441 – 1420) 
ciii 
 
10 20 30 40 50 60 70
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . .
Odari et al p24 primers A T T A T C A GA A GGA GC C A C C ~ ~ ~ ~ ~ ~ ~ A A C A C C A T GC T A A A C A C A G T ~ ~ ~ ~ ~ ~ C A A GC A GC C A T GC A A A T G T T A A A ~ ~ ~
B.US.1985.BAL_85US_Ba_L.AY7134 . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~
B.FR.1983.IIIB_LAI.A04321 . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~
A.UG.1992.92UG031.AY187680 . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . T . T G . . . . . . . . . . T . . . ~ ~ ~ ~ ~ ~ . . G . . . . . T . . . G . . . . . . . . . . ~ ~ ~
A.KE.1997.M21_ps2.AY772969 . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . T . T G . . . . . G . . . . T . . . ~ ~ ~ ~ ~ ~ . . G . . . . . T . . . . . . . . . . . . . . ~ ~ ~
A1.SE.1995.SE8891.AF069673 . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . T . T G . . . . . G . . . . T . . . ~ ~ ~ ~ ~ ~ . . G . . . . . T . . . . . . . . . . . . . . ~ ~ ~
A1.KE.2000.KSM4024.AF457077 . . . . . . . . . . . . . . . T . . . ~ ~ ~ ~ ~ ~ ~ . . T . T G . . . . . . . . . . T . . . ~ ~ ~ ~ ~ ~ . . G . . . . . T . . . . . . . . . . . . . . ~ ~ ~
A2.CY.1994.94CY017_41.AF286237 . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . T . . T . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . T . . . . . . . . . . . . . . ~ ~ ~
A2.KE.1999.KNH1234.DQ367261 . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . T . . G . . . . . G . . . . T . . . ~ ~ ~ ~ ~ ~ . . G . . . . . . . . . . . . . . . . . . . . ~ ~ ~
B.CN.2001.DH002.AB078704 . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . A . . . . . . . . . . . . . . ~ ~ ~
C.MM.1999.mIDU101_3.AB097871 . . . . . . . . . . . . . . . . . . T ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . T . . . . T . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~
C.BW.1996.96BW1104.AF110969 . C . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . T . . . C T . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~
D.KE.2001.NKU3006.AF457090 . . . . . . . . . . . . . . . . . . T ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~
D.BR.2004.patient_04BRSAP19.DQ . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . C . . . . ~ ~ ~
F1.FI.1993.FIN9363.AF075703 . . . . . . . . . . . . G . . . . . T ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . T . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~
F1.AR.2002.ARE933.DQ189088 . . . . . . . . . . . . G . . . . . T ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . T . . . . T . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~
F2.JP.-.KG1270.AB453729 . . . . . . R . . . . . R . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . Y . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~
F2.CM.2002.4463_13.EU619278 . . . . . . . . . . . . G . . . . . . ~ ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~
G.GH.2003.GHNJ175.AB231893 . . . . . . . . . G . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . T . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~
G.CN.2002.02CNLN35.EF122523 . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ ~ . . T . . . . . . . . . . . . . . T . . ~ ~ ~ ~ ~ ~ . . . . . . . . T . . . . . . . . . C . . . . ~ ~ ~
O.US.2010.LTNP.JN571034 . . . G . . . . . G . . . . . A G T . ~ ~ ~ ~ ~ ~ ~ . . T . . T . . . . . . . . T G . C A . ~ ~ ~ ~ ~ ~ . . . . G . . . T T . A . . . G . . C . . . . ~ ~ ~
O.CM.1991.MVP5180.L20571 . . . . . . . . . . . . G . . T G T . ~ ~ ~ ~ ~ ~ ~ . . T . . . . . . . . G . . T G . C A . ~ ~ ~ ~ ~ ~ . . . . GG . . T T . A . . . G . . . . G . . ~ ~ ~
F3 (1311 – 1329) F2   (1393 – 11 17) LF  (1394 – 1370) 
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | .
Odari et al p24 primers ~ A GA A A C C A T C A A T GA GGA A GC T G ~ ~ ~ ~ ~ ~ T G T T GC A C C A GGC C A GA T A A ~ ~ ~ ~ ~ GA GA T C C A A GGGGA A G T GA ~ ~
B.US.1985.BAL_85US_Ba_L.AY7134 ~ . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . ~ ~
B.FR.1983.IIIB_LAI.A04321 ~ . . . G . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . A . . . . . . . . . . . . . . . . G . ~ ~ ~ ~ ~ . . . . A . . . . . . . . . . . . . . ~ ~
A.UG.1992.92UG031.AY187680 ~ . . . T . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . G . ~ ~ ~ ~ ~ . . . . A . . . . . . . . . . . . . . ~ ~
A.KE.1997.M21_ps2.AY772969 ~ . . . T . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . A . . C . . . . . . . . . . . . . G . ~ ~ ~ ~ ~ . . . . A . . . . . . . . . . . . . . ~ ~
A1.SE.1995.SE8891.AF069673 ~ . . . T . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . A . . C . . . . . . . . . . . . . G . ~ ~ ~ ~ ~ . . . . A . . C . . . . . . . . . . . ~ ~
A1.KE.2000.KSM4024.AF457077 ~ . . . T . . . . . . . . . . . . . . G . . . . ~ ~ ~ ~ ~ ~ . A . C C . . . . . . . . . . . . . G . ~ ~ ~ ~ ~ . . . . G . . . . . . . . . . . . . . ~ ~
A2.CY.1994.94CY017_41.AF286237 ~ . . . T . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . A . . C . . . . . . . . . . . . . G . ~ ~ ~ ~ ~ . . . . A . . . . . . . . . . . . . . ~ ~
A2.KE.1999.KNH1234.DQ367261 ~ . . . T . . . . . . . . C . . . . . . . . . . ~ ~ ~ ~ ~ ~ . A . . C . . . . . . . . . . . C . G . ~ ~ ~ ~ ~ . . . . A . . . . . . . . . . . . . . ~ ~
B.CN.2001.DH002.AB078704 ~ . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ A A . . . . . . . . . . . . . . . . G . ~ ~ ~ ~ ~ . . . . G . . . . C . . . . . . . . . ~ ~
C.MM.1999.mIDU101_3.AB097871 ~ . . . T . . . . . . . . . . . A . . G . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . A . . G . ~ ~ ~ ~ ~ . . . . A . . . . . . . . . . . . . . ~ ~
C.BW.1996.96BW1104.AF110969 ~ G . . T . . . . . . . . . . . . . . G . . . . ~ ~ ~ ~ ~ ~ . . . . . . . . . . . . . . . A . . G . ~ ~ ~ ~ ~ . . . . A . . . . . . . . . . . . . . ~ ~
D.KE.2001.NKU3006.AF457090 ~ . . . G . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . A A . . . . . . . . . . . . A . . G . ~ ~ ~ ~ ~ . . . . A . . . . . . . . . . . . . . ~ ~
D.BR.2004.patient_04BRSAP19.DQ ~ . . . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . A . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ . . . . A . . . . . . . . . . . . . . ~ ~
F1.FI.1993.FIN9363.AF075703 ~ . . . C . . . . . T . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . A . . C . . . . . . . . . . . . . G . ~ ~ ~ ~ ~ . G . . A . . T . . . . . . . . C . . ~ ~
F1.AR.2002.ARE933.DQ189088 ~ . . . C . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . A . C C . . . . C . . . . . . . . G . ~ ~ ~ ~ ~ . G . . A . . T . . . . . . . . . . . ~ ~
F2.JP.-.KG1270.AB453729 ~ . . . T . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . A . . C . . G . . . . T . . . . . G . ~ ~ ~ ~ ~ . . . . A . . T . . A . . . . . . . . ~ ~
F2.CM.2002.4463_13.EU619278 ~ . . . T . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . A . . C . . . . . . . T . . . . . . . ~ ~ ~ ~ ~ . . . . A . . . . . . . . . . . . . . ~ ~
G.GH.2003.GHNJ175.AB231893 ~ G . . T . . T . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ ~ . A . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ . . . . . . . . . C A . . . . . . . . ~ ~
G.CN.2002.02CNLN35.EF122523 ~ G . . T . . T . . . . . . . . A . . . . . . . ~ ~ ~ ~ ~ ~ . A . . C . . . . . . . . . . . . . . . ~ ~ ~ ~ ~ . . . . A . . . . . . . . . . . . . . ~ ~
O.US.2010.LTNP.JN571034 ~ G . . . G T A . . . . . . . . A . . . . . A . ~ ~ ~ ~ ~ ~ G T . GC . . . . . . . G . . . . . . . ~ ~ ~ ~ ~ . G . . A . . . . C A . . . . . . . . ~ ~
O.CM.1991.MVP5180.L20571 ~ G . . . G T A . . . . . . . . . . . . . . A . ~ ~ ~ ~ ~ ~ G T . A C . . . . . . . G . . . . . . . ~ ~ ~ ~ ~ . G . . A . . . . C A . . . . . . . . ~ ~
F1c  (1361 – 1340) B1c   (1455 – 1417) LB   (1475 – 1493) 
Appendix 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
civ 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2: Primer alignment of sequences for the p24 target primers used in the current study (Curtis et al., 2008). Sequence alignment shows an 
average of 1 and 3 mismatches at the F3 and F2 targets respectively for all HIV-1 group M subtypes aligned. Although this primer set would 
potentially amplify all the subtypes aligned and potentially amplify some HIV-1 group O viruses, there is a possibility of sub-optimal amplification of 
some C and D subtypes due to the position of the mismatches. 
 
 
 
 
B2 (1514 – 1494) 
170 180 190 200
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . .
~ ~ C A T A GC A GGA A C T A C C A G T A C ~ ~ ~ ~ C C T T C A GGA A C A A A T A GGA T G
B.US.1985.BAL_85US_Ba_L.AY7134 ~ ~ . . . . . . . . . . . . . . . . . . . . . ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . .
~ ~ . . . . . . . . . . . . . . . T . . . . . ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . . . .
~ ~ T . . . . . . . . . . . . . . T . . . . . ~ ~ ~ ~ . . . . . . A . . . . . . . . . . C . . .
~ ~ . . . . . . . . . . . . . . . T . . . . . ~ ~ ~ ~ . . C . . . A . . . . . . . . . . . . . .
~ ~ . . . . . . . . . . . . . . . T . . . . . ~ ~ ~ ~ . . C . . . A . . . . . . . . . . . . . .
~ ~ . . . . . . . . . . . . . . . T . . . . . ~ ~ ~ ~ . A . . . . A . . . . . . . . . . . . . .
A2.CY.1994.94CY017_41.AF286237 ~ ~ . . . . . . . . . . . . . . . T . . . . . ~ ~ ~ ~ . . . . . . . . . . . . . . . . . . T . .
~ ~ . . . . . . . . . . . . . . . T . . . . . ~ ~ ~ ~ . . C . . . A . . . . . . G . . . . . . A
~ ~ . . . . . . . . . . . . . . . T . . . . . ~ ~ ~ ~ T . . . . . . . . G . . . . . . . . . . .
~ ~ . . . . . . . . . . . . . . . T . . . . G ~ ~ ~ ~ . . . . . . . . . . . . . . . . . C . . .
~ ~ . . . . . . . . . . . . . . . T . . . . . ~ ~ ~ ~ . . . . . . . . . . . . . . . . . C . . .
~ ~ T . . . . . . . . . . . . . . T . . . . . ~ ~ ~ ~ . . . . . . . . . . . . . . . . . C . . .
~ ~ T . . . . . . . . . . . . . . T . . . . . ~ ~ ~ ~ . . . G . . A . . . . . . . . . A C . . .
~ ~ T . . . . . T . . . . . . . . T . . . . . ~ ~ ~ ~ . . . . . . . . . . . . . . . . C A . . .
~ ~ T . . . . . T . . . . . . . . T . . . . . ~ ~ ~ ~ T . C . . . . . . . . . . . . . C A . . .
~ ~ T . . . . . . . . . . . . . . T . . . . A ~ ~ ~ ~ T . . . . . . . . . . . . . . . . C . . .
~ ~ T . . . . . . . . . . . . . . T . . . . . ~ ~ ~ ~ . . . . . . . . . . . . . . . . . C . . .
~ ~ T . . . . . . . . . . . . . . T . . . . . ~ ~ ~ ~ A . . G . . . . . G . . . . . . A . . . .
~ ~ T . . . . . . . . . . . . . . T . . . . A ~ ~ ~ ~ . T . G . . . . . . . . . . . . . C . . .
~ ~ . . . T . . T . . . . . A . . T . . C . . ~ ~ ~ ~ . . A G . . A . . G . . . G . T C A C . .
~ ~ . . . T . . T . . . . . A . . T . . C . . ~ ~ ~ ~ A . A G . . A . . G . . . . . T A T . . .
Odari et al p24 primers
B.US.1985.BAL_85US_Ba_L.AY7134
B.FR.1983.IIIB_LAI.A04321
A.UG.1992.92UG031.AY187680
A.KE.1997.M21_ps2.AY772969
A1.SE.1995.SE8891.AF069673
A1.KE.2000.KSM4024.AF457077
A2.CY.1994.94CY017_41.AF286237
A2.KE.1999.KNH1234.DQ367261 
B.CN.2001.DH002.AB078704
C.MM.1999.mIDU101_3.AB097871
C.BW.1996.96BW1104.AF110969 
D.KE.2001.NKU3006.AF457090 
D.BR.2004.patient_04BRSAP19.DQ
F1.FI.1993.FIN9363.AF075703 
F1.AR.2002.ARE933.DQ189088
F2.JP.-.KG1270.AB453729
F2.CM.2002.4463_13.EU619278
G.GH.2003.GHNJ175.AB231893
G.CN.2002.02CNLN35.EF122523
O.US.2010.LTNP.JN571034
O.CM.1991.MVP5180.L20571
B3 (1535 – 1515) 
